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ABSTRACT 
 
 The tumor suppressor p53 plays a central role in the protection against DNA 
damage and other forms of stress, primarily by inducing cell cycle arrest or apoptosis. 
Mutation of p53, which is one of the most frequent genetic alterations detected in 
human cancers, inactivates these growth regulatory functions; in addition, very often 
mutant p53 acquires tumor-promoting activities (gain-of-function). A complete and 
thorough understanding of the signaling circuitry that regulates wild-type and mutant 
p53 functions is therefore a primary objective for basic cancer research, since it may 
lead to development of important tools for diagnosis and therapy of tumors. One 
crucial component of such knowledge is the protein interaction profile of p53. 
 To gain novel insights on p53 interactions, we used a phylogenetic approach. We 
reasoned that a comprehensive map of the protein interaction profile of Drosophila 
p53 might reveal conserved interactions of the entire p53 family in man. Using a 
genome-scale in vitro expression cloning approach, we identified 91 previously 
unreported Dmp53 interactors. Next, we studied and characterized the interaction of 
human orthologs of newly identified Dmp53 interactors with all p53-family proteins, 
and it resulted in the identification of several novel interactants of this family of 
tumor suppressors (Part 1 of this Thesis). 
 In parallel, we verified that many of the mammalian orthologs of Dmp53 
interactors could also bind to an oncogenic p53 mutant (R175H), and therefore are 
potential novel targets or effectors of mut-p53 gain of function activities. Among 
those proteins we focused our attention on DAB2IP, a tumor-suppressor gene that 
functions by counteracting the activation of multiple oncogenic pathways. There are 
evidences that mutant p53 has a stimulatory role in all the signaling pathways that are 
normally inhibited by DAB2IP; therefore, we propose that mutant p53 may bind and 
functionally inactivate DAB2IP as one of the mechanisms of its gain-of-function. 
Given the crucial role of DAB2IP in modulating cellular responses to TNF, we focus 
on the potential relevance of this interaction in the connection between inflammation 
and cancer (Part 2 of this Thesis). 
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FOREWORD 
 
During my PhD I have been involved in two different projects. Although both 
concern the analysis of proteins that interact with the p53 family of tumor 
suppressors, they are markedly distinct; for this reason I discuss them as separate 
parts in this Thesis. 
 
The first project is focused on the identification and characterization of novel 
evolutionarily conserved interactors of p53 family proteins, and involved screening of 
a genome-wide Drosophila cDNA library for proteins that would bind to Drosophila 
p53 (Dmp53) in vitro. The project also included the study of the interaction of human 
orthologs of newly identified Dmp53 interactors with all p53-family proteins, and 
resulted in the identification of several novel interactants of this family of tumor 
suppressors. This work was recently published, and is included in this Thesis as a 
journal reprint in PART 1. 
 
The second project derives from the precedent work, and is focused on the study of 
the functional link between one of the newly identified p53 family interactors, the 
signaling protein DAB2IP, and mutant forms of p53. In particular, this project deals 
with the potential relevance of this interaction in the well established connection 
between inflammation and cancer. This work is still in progress, and is described in 
PART 2. 
 
The introduction section has been written essentially for PART2 of the Thesis, and 
therefore is mainly focused on mutant p53, inflammatory pathways in cancer, and the 
novel p53 interactor DAB2IP.  
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INTRODUCTION 
 
According to the 2008 World Cancer Report of the IARC, in the next years cancer 
will become the first cause of death worldwide (www.iarc.if). It is now clear that 
cancer is a disease involving dynamic changes in the genome characterized by defects 
in regulatory circuits (cellular checkpoints), which finely modulate normal cell 
proliferation and homeostasis. All human tumors share six common features: self-
sufficiency in growth signals, insensitivity to growth inhibitors, evasion of 
programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis (Hanahan and Weinberg, 2000). In 
addition to these six hallmarks, tumor formation may benefit also from the 
inflammatory microenvironment (Mantovani, 2009) and from changes in cell 
metabolism to sustain deregulated cell proliferation (Hanahan and Weinberg, 2011). 
Tumorigenesis is a multistep process, and these steps reflect genetic alterations that 
drive the progressive transformation of normal cells into highly malignant derivatives. 
In general, these mutations occur in proto-oncogenes, thus promoting growth and 
survival of cancer cells, and in tumor suppressor genes, allowing cancer cells to 
escape from their physiological anti-proliferative control (Hanahan and Weinberg, 
2000). 
One of the most important signalling pathways against tumor formation and 
progression is the p53 tumor suppressor pathway. p53 was discovered in 1979 by 
three independent groups as an interacting partner of the viral SV40 T-antigen (Kress 
et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979). For almost a 
decade, p53 was believed to be a tumor antigen with transforming capabilities. Only 
during the late 1980s, it was understood that p53 is indeed a tumor suppressor and 
that the evidence for its supposed oncogenic functions had been erroneously collected 
from tumor-derived mutant clones (Weisz et al., 2007b). 
After more than thirty years of research, extensive knowledge has been more and 
more achieved regarding the complexity of the p53 pathway. 
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p53-family proteins in cancer 
p53 is mainly  a transcription factor whose activation is promoted by a wide range of 
stress signals such as NTP depletion, DNA damage, hypoxia, oncogenes activation, 
nucleolar stress, and differentiation cues. Once activated, p53 is capable of 
coordinating a complex cellular response that leads to cell-cycle arrest, DNA repair, 
senescence, or programmed cell death. Given its pleiotropic functions, p53 was 
suitably dubbed the “guardian of the genome” (Levine and Oren, 2009; Muller et al., 
2001). 
Beside p53, two p53-related genes were identified: p63 and p73 (Mills et al., 1999; 
Yang and McKeon, 2000; Yang et al., 1999). These proteins are structurally similar 
and functionally related to p53, and hence the entire p53 family may be considered as 
a unique signaling network able to affect cell proliferation, differentiation, and death. 
Figure 1. The p53 family as a network. The p53-family pathway is activated by a wide array of 
signals, including potentially oncogenic stresses, as well as physiological cues. Once activated, the 
pathway induces diverse cellular outcomes, ranging from cell-cycle arrest, to senescence, to 
programmed cell death (apoptosis). A web of upstream regulators control covalent modifications, 
protein levels, and cellular localization of p53-family proteins, and can either activate or inhibit the 
pathway in response to specific signals. Downstream, protein cofactors modulate promoter selection 
and transcriptional functions of p53-family proteins, fine-tuning the cellular response to any given 
signal (Collavin et al., 2010). 
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All three p53-family proteins are structurally related with a very similar domain 
organization, present a similar set of alternative isoforms, and similar post-
translational modifications affect their functions (Figure 2). However mouse models 
revealed important differences in their biological role underlying that p53-family 
paralogs have acquired a high degree of functional specificity since their duplication 
and divergence during evolution (Lu et al., 2009; Yang et al., 2002). No effects in 
viability and in embryonic development was detected in p53-null mice, which die of 
cancer at young age supporting the fundamental role of p53 in preventing formation 
of spontaneous tumors (Donehower et al., 1992). On the contrary, p73-null mice are 
born viable but have nervous system abnormalities, hydrocephalus, and 
immunological problems with chronic inflammation. p73-null mice generally die 
within the first 2 months (Yang and McKeon, 2000). p63-null mice are born alive, but 
die immediately after birth. They show a severe phenotype, lacking limbs and a wide 
range of epithelial structures including skin, prostate, breast, and urothelia, (Mills et 
Figure 2. Structure of p53-family proteins and their principal isoforms, together with some 
regulatory post-translational modifications (Collavin et al., 2010). 
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al., 1999; Yang et al., 1999) indicating that p63 is required to maintain the pool of 
proliferating stem cells during development of epithelia (Senoo et al., 2007; Su et al., 
2009). 
A wealth of data show that both p63 and p73 have a role in tumor suppression beside 
their unique functions. Analysis of the tumor predisposition of p63 and p73 
heterozygous mice revealed a consistent connection with cancer: p63+/- and p73+/- 
mice develop spontaneous tumors and survive similarly to p53+/- mice (Flores et al., 
2005). Moreover p63 and p73 can induce cell-cycle arrest, senescence, DNA repair, 
and apoptosis in response to chemotherapic drugs like p53 (Lang et al., 2004; Lin et 
al., 2009). The silencing of p73 and p63 increases the transforming potential of p53-
null mouse embryonic fibroblast (Lang et al., 2004). Even if there are not evidence of 
mutations that compromise their functions in cancer, p63 and p73 are aberrantly  
expressed in tumors. In particular, ΔN- p63 and p73 isoforms are frequently over-
expressed in cancer and it has been hypothesized that they act as dominant-negative in 
respect to the oncosuppressive isforms (Deyoung and Ellisen, 2007). 
The emerging picture is that of an intricated pathway, in which all p53 family proteins 
are involved in the response to oncogenic stress and physiological inputs and in which 
all the p53 family members share many oncosuppressive functions. 
 
Relevance of protein-protein interactions in the regulation and function of p53 
and p53-related proteins 
Currently more than 150 p53-binding proteins have been described (source: BioGrid 
and Mint databases). p53 interactors can be classified into two large groups: 
regulators or effectors (Levine et al., 2006). Regulatory proteins act upstream of p53 
and, essentially, directly modify p53 structure. As mentioned, several upstream 
kinases phosphorylate p53 upon cellular stress, and induce its stabilization and 
activation (Bode and Dong, 2004). Ubiquitin ligases such as Mdm2, Cop1 and PirH2 
are also of fundamental importance in p53 modulation, because they warrant a rapid 
turnover of this proapoptotic transcription factor in the absence of cellular stress 
(Brooks and Gu, 2006). Another important class of p53 interacting proteins is 
represented by enzymes that control its acetylation: HATs and HADACs. These 
proteins modulate the transcriptional activity of p53 downstream of activator kinases 
(Bode and Dong, 2004). Other p53 interacting proteins can act as transcriptional 
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cofactors to target p53 on selected promoters, for instance Smad proteins (Cordenonsi 
et al., 2003). Finally, p53 interaction with the peptidyl-prolyl isomerase Pin1 affects 
conformation, other post-translational modifications, and its transcriptional activity 
(Zacchi et al., 2002). 
Effectors of p53 activities are a class of molecules responsible for transcription-
independent p53 functions. In particular BclX and Bcl2 are two important 
mitochondrial-associated proteins with which p53 makes contact to induce apoptosis 
(Moll et al., 2005). p53 functions also as a scaffolding protein able to constitute multi-
protein complexes. SWI/SNF chromatin remodeling complexes mediate histone 
acetylation and contribute to p53 dependent transcription (Oh et al., 2008); methyl-
transferases mediate p53-dependent transcriptional repression (Esteve et al., 2007). 
Proteins that localize to DNA-damage foci are another important class of p53 
interactors. These proteins, such as RAD51, accumulate on sites of DNA damage, and 
bind p53 during DNA repair process (Buchhop et al., 1997).  
When compared to the large number of studies on p53 interactions, much fewer 
studies were conducted to isolate p73 or p63 binding proteins. Among various p73 
interactors it has been identified the protein Itch as an important p73 ubiquitin ligase 
(Rossi et al., 2005). An important upstream regulator of p73 is the protein kinase c-
Abl, that phosphorylates p73 and promotes its binding with p300, which in turn 
acetylates p73 thus promoting transcription (Mantovani et al., 2004). YAP-1  interacts 
with p73 and it is necessary to recruit p73 and p300 on promoters of pro-apoptotic 
genes (Levy et al., 2007). 
At the moment, even fewer proteins have been described that interact with p63. 
In some cases, protein partners are shared among all p53-related proteins (i.e Daxx); 
but most of the numerous identified p53 interactors have not been specifically tested 
for binding to p63 or p73 (Collavin et al., 2010). 
Given the current data on the protein interaction profile of p53, it is conceivable that 
many more p63 and p73 (and p53) binding proteins exist, that can be involved in 
regulating specific functions of these important transcription factors, under different 
conditions.  
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Mutant p53 
Mutation or functional inactivation of the tumor suppressor p53 is an almost universal 
feature of human cancer. The frequencies of reported TP53 mutations vary 
considerably between cancer types, ranging from 10% in haematopoietic 
malignancies (Peller et al., 2003) to 50–70% in ovarian (Schuijer and Berns, 2003), 
colorectal (Iacopetta, 2003), and head and neck (Blons and Laurent-Puig, 2003) 
cancers. Whereas somatic TP53 mutations contribute to sporadic cancer, germline 
TP53 mutations cause Li-Fraumeni Syndrome (LFS), a rare type of cancer 
predisposition which is not associated with site-specific tumors, but rather with a 
variety of tumor types occurring at a relatively early age (Varley, 2003). 
Unlike most tumor-suppressor genes, which usually undergo gene-expression 
inactivation in carcinogenesis by deletions or truncating mutations, TP53 is frequently 
inactivated (74%) by missense mutations (IARC TP53 Database). As a consequence, 
in the vast majority of tumors, cells express a full-length mutant form of p53, which 
differs from the wild-type counterpart in a single amino acid substitution. 
Both germline mutations and sporadic somatic mutations show the same distribution 
in the TP53 gene (Varley, 2003). Indeed, they are not randomly dispersed along the 
whole sequence, but are generally found in the region corresponding to the DBD of 
the protein. As shown in figure 3, almost a third of all missense mutations arise in six 
“hotspot” codons (Hollstein et al., 1991; Petitjean et al., 2007). Most TP53 mutations 
can be classified into two main categories according to their effect on the 
thermodynamic stability of the p53 protein (Bullock and Fersht, 2001). These two 
Figure 3. The distribution of reported missense mutations along the p53 sequence. The six most 
common hotspot mutations are highlighted in yellow for DNA-contact mutations, green for locally 
distorted mutants and blue for globally denatured mutants. The domain architecture of p53 is aligned 
below. TA, transactivation domain; PR, proline-rich domain; DBD, DNA binding domain; Tet, 
tetramerization domain; Reg, carboxy-terminal regulatory domain. Data derived from the IARC TP53 
Database. 
 
  13 
mutation categories are commonly referred to as “DNA‑contact” and 
“conformational” mutations. The first group includes mutations in residues directly 
involved in DNA binding, such as R248Q and R273H. The second group comprises 
mutations that cause local (such as R249S and G245S) or global (such as R175H and 
R282W) conformational distortions. 
p53 mutations are involved in the process of carcinogenesis by three non-mutually 
exclusive mechanisms (Brosh and Rotter, 2009): 
1. Loss of functions (LOF): mutation abrogates the tumour suppressor functions 
of the affected allele. This loss of function is due to reduction of p53 binding 
to its consensus DNA sequence and, consequently, hampered transcriptional 
activation of p53 target genes (Kato et al., 2003). Besides missense mutants, 
LOF is achieved by gene deletions and truncations, splicing and nonsense 
mutations. Truncations and deletions also affect non transcriptional functions 
of p53. 
2. Dominant-negative effect: most missense mutations produce a full-length 
mutant p53 capable of inhibiting, to varying degrees, the function of the wild-
type protein encoded by the second allele. This dominant-negative effect is 
achieved by oligomerization of mutant and wild-type proteins, forming a 
heterotetramer defective in sequence-specific DNA binding (Milner and 
Medcalf, 1991; Milner et al., 1991). Hence, even if the wild-type allele is 
retained, the cell may be rendered devoid of wild-type p53 functions through 
such a mechanism. Remarkably, though, a mutant p53 heterozygous state is 
often transient and TP53 mutations are frequently followed by loss of 
heterozygosity (LOH) during cancer progression. 
3. Gain of functions (GOF): mutant p53 acquires new functions not present in 
the wild-type p53 protein. These new functions can actively contribute to 
various aspects of tumor progression.  
 
Mechanism of the Gain-of function of mutant p53 
As the field of p53 research evolves, it is increasingly evident that many mutant p53 
forms not only lose their tumour suppressive functions and acquire 
dominant‐negative activities, but also gain new oncogenic properties that are 
independent of wild‐type p53. The demonstration of the GOF of mutant p53 is 
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supported by numerous evidences which include cell culture studies that 
demonstrated the capability of mutant p53 to impinge on pivotal cellular regulatory 
networks, mouse models that established the ability of mutant p53 to increase tumour 
aggressiveness and metastatic potential, as well as clinical studies that revealed 
associations between TP53 mutations and poor clinical outcome in a variety of 
malignancies (Oren and Rotter, 2010). 
 
 
Figure 4. Selected oncogenic properties of mutant p53 and their underlying mechanisms. The 
inner circle (shaded blue) represents oncogenic phenotypes associated with the activities of mutant p53 
proteins. The outer circle depicts key mechanistic properties of p53 mutants that underlie the 
phenotypes listed in the inner circle. Each of the phenotypic effects can be attributed to almost each of 
the mechanistic properties; hence the inner blue circle can be freely rotated. (Brosh and Rotter, 2009) 
 
 
The mechanisms of the Gain-of-functions of mutant p53 can be subdivided in three 
main categories: 
 
Interaction with p63 and p73 
A central point in gain‐of‐function mechanism is the ability of p53 mutants to bind 
and inactivate p53 family members, p63 and p73 (Di Como et al., 1999; Gaiddon et 
al., 2001). Evidence supporting this notion, besides numerously experiment in cells, 
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has come from the recently developed knock‐in mouse model in which p53R172H 
was shown to bind p63 and p73, consequently inhibiting their abilities to induce 
cell‐cycle arrest and suppress tumor formation (Lang et al., 2004). Mut-p53 proteins 
can engage in direct protein–protein interactions with p73 and p63, rendering them 
transcriptionally inactive (Marin et al., 2000; Strano et al., 2002). Consequently, 
genes that are normally controlled by p63 or p73 will become deregulated. Depending 
on whether p63/p73 regulate a particular gene positively or negatively, mut-p53 
overexpression will result in repression or induction of that gene, respectively. 
The capacity of different p53 mutants to bind p73 was shown to be significantly 
influenced by the site of mutation as well as by the single nucleotide polymorphism at 
codon 72 (Bergamaschi et al., 2003). Moreover, the p73‐binding capacity is 
correlated with the ability of p53 mutants to protect cells from chemotherapeutic 
agents, and, accordingly, with less favorable response to chemo‐radiotherapy in 
patients with head and neck cancer (Li and Prives, 2007). 
The interaction between mut-p53 and p63/ p73 can be regulated by cell-intrinsic and 
extrinsic signals and by additional partner proteins, as illustrated by the formation of a 
ternary complex between mut-p53, p63, and Smad proteins, which is induced by 
TGF-b and oncogenic Ras (Adorno et al., 2009). Conceivably, many other factors 
may modulate the association between mut-p53 and p63/p73, determining the efficacy 
of this mechanism of mut-p53 GOF. 
 
Alteration of gene expression 
Despite that mutant p53 proteins are unable to recognize wt-p53 consensus (Kato et 
al., 2003), modulation of gene transcription by mutant p53 is well documented and 
the list of mutant p53 target genes is constantly growing (Brosh and Rotter, 2010). 
Mut-p53 proteins typically retain an intact transactivation domain (TAD), which may 
still operate exactly as it does within the wt-p53 protein, but can now be targeted to 
different sites on the chromatin. Two distinct mechanisms have been proposed to 
explain the re-indirection of mutant p53 in novel transcription star-sites. The first one 
is based on the evidence that several p53 mutants, although defective in sequence-
specific DNA binding, retain the ability to bind specific non-B DNA structures with 
high affinity (Gohler et al., 2005). Therefore, the specificity of mutant p53 to certain 
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regulatory sequences is perhaps mediated by preferential binding to structural DNA 
motifs and not consensus sequences. 
In a second scenario mutant p53 interacts with sequence-specific transcription factors, 
specific co-activators, histone-acetyltransferase, or histone deacyetilases augmenting 
or repressing the expression of genes that are targeted directly by the partner factors 
(Oren and Rotter, 2010). Besides p63 and p73, the first two transcription factors 
shown to interact with mutant p53 were SP1 and ETS1 (Chicas et al., 2000; Sampath 
et al., 2001). The transcriptional complex modulated by mut-p53 and directed by this 
transcriptional factors promotes pro-survival signals; also wild-type p53 binds to SP1 
and ETS1 but the result of their modulation is opposite to that one of mut-p53 (Kim 
and Deppert, 2004). Similarly, the transcription factor NF-Y, which also interacts 
with wild-type p53, was demonstrated to bind to mutant p53. Conversely to wild-type 
p53, which recruits HDAC1 on the promoters of NF-Y target genes, mutant p53/NF-
Y complex is associated to p300, thus inducing their transcription. This complex was 
proposed to support the growth promoting properties of mutant p53 as well as the 
chemoresistance of some mutant p53 bearing tumours (Aas et al., 1996; Bergh et al., 
1995; Lu and El-Deiry, 2009). Mutant p53 interacts also with the transcription factor 
vitamin D receptor (VDR). Mutant p53 is indeed recruited on VDR-regulated genes 
and modulates their expression, thus converting vitamin D receptor into an anti-
apoptotic factor (Stambolsky et al., 2010). Finally, recent data implicate mutant p53 
in activating genes involved in inflammation such as those encoding cytokines, 
chemokines and extracellular matrix modulators. Mutant p53 was shown to enhance 
the NF‐κB response to tumour necrosis factor α (TNFα) in cancer cells (Weisz et al., 
2007a), and to transcriptionally activate NFKB2 (Scian et al., 2005).  
 
Interaction with other proteins 
Additional protein–protein interactions most certainly also play a role in mut-p53 
GOF not through recruitment of DNA binding proteins, but rather through modulation 
of non‐transcriptional factors. It emerges that the core domain of mutant p53 is not 
only the major site of missense mutations, but it might gain additional functions 
serving as protein–protein interaction module that sequesters and inactivates proteins 
with oncosuppressor activities. Moreover, given the high concentration of mut-p53 
protein in tumor cells, relatively weak molecular interactions, which are marginal 
within the wt-p53 protein, may now be amplified by mass action and reach a 
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threshold that allows them to exert a measurable impact on biochemical processes 
within the cell (Strano et al., 2007). Thus, it was found that mut-p53 can disrupt 
ATM-mediated cellular responses to double-stranded DNA breaks (Song et al., 2007; 
Song and Xu, 2007). Mut-p53 can bind MRe11, an upstream component of 
ATM‐dependent DNA‐damage response pathway and, consequently, inhibit the 
cellular response to DNA double‐stranded breaks. Another case in point is the 
interaction between p53 and topoisomerase I (Topo I); this interaction leads to an 
increase in aberrant homologous DNA recombination events and mutagenic DNA 
rearrangements, spawning an additional type of genomic instability (Restle et al., 
2008). Mut-p53 was identified to interact with promyelocytic leukemia (PML) protein 
a known tumor suppressor (Haupt et al., 2009). Yet, when it binds to mut-p53, it can 
augment the latter’s transcriptional activity, thereby enhancing the ability of mut-p53 
to stimulate cell proliferation and colony formation. As p53 mutant was shown to 
interact with several RNA-binding proteins, it was suggested that it might participate 
in the spatial organization of transcription/processing factories providing a growth 
and survival advantage to tumor cells (Heinlein et al., 2008). 
 
Regulation of mutant p53 stability and activity 
In contrast to the plethora of information available in the case of wild-type p53, the 
regulation of mutant p53 stability and activity and the status of its post-translational 
modifications are much less characterized (Brosh and Rotter, 2009). 
Mutant p53 proteins often accumulate at extremely high levels in tumors (Bartek et 
al., 1991). In fact, immunohistochemical (IHC) detection of p53 in tumors usually 
indicates TP53 missense mutation and can provide prognostic and predictive 
informations (Soussi and Beroud, 2001). 
Nonetheless mutation by itself is not sufficient to explain the greater stability of 
mutant p53 compared to its wild-type counterpart. Indeed in several murine and 
zebrafish models caring mutant p53, no stabilization of the protein was detected in 
normal tissues but mut-p53 is instead expressed at high levels in tumours (Lang et al., 
2004; Lee et al., 2008; Olive et al., 2004). Similarly, mutant p53 does not accumulate 
in normal tissues from patients with Li-Fraumeni syndrome, but only in derived 
tumours.  
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A clue to the nature of the additional mutant p53-stabilizing mechanism may be 
provided by the fact that, in primary cells derived from mut-p53 knockin mice, the 
intrinsically unstable mut-p53 can be stabilized by genotoxic stress, very much like 
wt-p53 (Lang et al., 2004). Because many tumor cells experience chronic DNA 
damage, it is conceivable that the resultant signaling events, normally aimed at 
stabilizing and activating the endogenous wt-p53, do the same also to the resident 
mut-p53, except that rather than curbing cancer, this now results in cancer promotion. 
Other ubiquitin ligases that target wild-type p53 regulate mutant p53 stability such as 
C-terminus of HSP70-interacting protein (CHIP) (Esser et al., 2005; Lukashchuk and 
Vousden, 2007). CHIP-mediated ubiquitylation of mutant p53 is counteracted by the 
chaperone HSP90, which binds to mutant p53 increasing its stability (Esser et al., 
2005). Since HSP90 is frequently over-activated in tumours (Kamal et al., 2003), the 
dependency of mutant p53 on HSP90 may partly account for its specific accumulation 
in tumours and underlie the therapeutic potential of HSP90 inhibitors (Solit and 
Rosen, 2006). 
The subcellular localization of mutant p53 is another parameter that affects its 
oncogenic properties. Although mutant p53 usually accumulates in the nucleus of 
cancer cells, it localizes also to the cytoplasm, depending on the type of mutant, the 
cellular context and a variety of stress signals that modulate p53 localization 
(Lukashchuk and Vousden, 2007; Sepehrnia et al., 1996). It has been demonstrated 
that cytoplasmic p53 mutants can inhibit autophagy in cancer cells (Morselli et al., 
2008). For each of 22 mutant p53 forms analyzed, a unique localization pattern was 
observed, from almost exclusively nuclear (for example, p53 R282W) to almost 
exclusively cytosolic (for example, p53R 273H). Chronic suppression of autophagy 
was demonstrated to facilitate tumorigenesis, and several proteins that promote 
autophagy are considered tumour suppressors (Maiuri et al., 2009). Hence, inhibition 
of autophagy may constitute yet another oncogenic property of p53 mutants, 
highlighting the importance of subcellular localization of p53 mutants in tumours. 
Mutant p53 oncogenic properties: Cell transformation and inhibition of 
apoptosis 
Mutant p53 plays a fundamental role in cellular transformation as demonstrated in 
both human and mouse models: introduction of mut-p53 forms can transform p53-null 
cells and endow them with an increased ability to form colonies in soft agar and 
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tumours in mice (Dittmer et al., 1993). On the other side, down-regulation of 
endogenous mutant p53 rendered those cells less tumorigenic (Bossi et al., 2006; 
Bossi et al., 2008). Mutant p53 was shown to cooperate with activated oncogenic Ras 
in transformation of primary mouse embryo fibroblasts (MEFs) (Lang et al., 2004). 
This property is due to the ability of different p53 mutants to bind and inactivate p53 
family members, p63 and p73. The axis between mut-p53 and Ras has been 
confirmed also in vivo by using mouse models of skin (Caulin et al., 2007), lung 
(Jackson et al., 2005) and pancreatic cancers (Hingorani et al., 2005). Such mice 
exhibited increased tumor formation, accelerated tumor progression and elevated rates 
of metastasis relative to their p53-null counterparts. 
Pioneer studies related many p53 mutants to the ability to confer an elevated 
resistance to cells towards a variety of pro-apoptotic signals such as cMyc-induced 
apoptosis in leukemic cells (Lotem and Sachs, 1995). Interestingly, overexpression of 
various tumour-associated p53 mutants can render cells more resistant to killing by 
anticancer agents (Blandino et al., 1999; Li et al., 1998; Matas et al., 2001), whereas 
knockdown of endogenous mutant p53 sensitizes cancer cells to killing by such 
molecules (Bossi et al., 2006; Wong et al., 2007). The antiapoptotic activities of mut-
p53 may thus not only accelerate tumor progression but also hinder the response of 
cancer patients to anticancer therapy. 
Mutant p53 oncogenic properties: Genomic instability 
Several p53 mutations were reported to disrupt the DNA damage response, leading to 
genomic instability, manifested by inter-chromosomal translocations (Gualberto et al., 
1998). Mutant p53 can inhibit ATM-mediated cellular responses to double-stranded 
DNA breaks (Song et al., 2007). In addition to this, mutant p53 can interfere with 
DNA repair by attenuating base excision repair (Offer et al., 1999) and by binding 
topoisomerase I, thus leading to aberrant homologous DNA recombination events and 
mutagenic DNA rearrangements (Albor et al., 1998; Restle et al., 2008). 
Additional manifestations of the enhanced genomic instability due to mutant p53 have 
been reported: higher mutation rates in the T-cell receptor of cells exposed to X-
irradiation (Iwamoto et al., 1996), increased frequency of centrosome amplification 
and aberrant mitoses in mouse mammary epithelial cells (Murphy et al., 2000), as 
well as increased gene amplification in Saos2 cells (El-Hizawi et al., 2002). The 
existence of this connection was established also in vivo: in a mouse model for breast 
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cancer, following carcinogen administration, mutant p53 expressing cells showed a 
defect in G2/M check point control, large nuclei, and aberrant ploidy (Caulin et al., 
2007; Hingorani et al., 2005). 
Mutant p53 oncogenic properties: Cell migration and invasion 
Although p53 knockout mice are highly tumour prone, these lesions do not 
metastasize frequently nor generally display invasive pathology (Attardi and Jacks, 
1999). On the contrary, presence of mutant p53 leads to a marked increase in the 
incidence of highly metastatic carcinomas in various mouse models (Doyle et al., 
2010; Heinlein et al., 2008; Lang et al., 2004; Morton et al., 2010; Olive et al., 2004). 
Indeed, mutant p53 was found to enhance the activation of EGFR/integrin signaling 
and modulating TGFβ pathway thus facilitating cell migration and invasion (Adorno 
et al., 2009; Dhar et al., 2008; Muller et al., 2009). This is achieved by two non-
mutually exclusive mechanisms of inhibition of p63 anti-metastatic functions. 
Furthermore, mutant p53 can induce EMT in several cancer models, including 
prostate, lung and breast cancer thus allowing invasivness: EMT transition is 
supported by mutant p53 modulating Slug or Twist activity (Kogan-Sakin et al., 2011; 
Wang et al., 2009), or by suppressing the anti-invasive gene CCN-5/WISP2 (Dhar et 
al., 2008). Recently, it has been also demonstrated a role of mutant p53 in 
coordinating three-dimensional growth: mut-p53 depletion in aggressive breast 
cancer-derived cells reverts malignant-appearing cells into more benign cells, which 
form acinus-like structures (Freed-Pastor et al., 2012). 
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Figure 5. Mutant p53 regulates cell migration and invasion by inhibiting p63. (A) Upon TGF-β 
induction, SMAD2 is phosphorylated and promotes binding of mutant p53 to p63, alleviating p63-
mediated suppression of Sharp-1 and Cyclin G2 to allow for cell migration and invasion. (Adorno et 
al., 2009) (B) p63 inhibits activation of RCP (through transcriptional targets that are currently 
unknown) to prevent α5β1 integrin and EGFR recycling to the plasma membrane. When mutant p53 is 
present, p63 activity is suppressed, resulting in enhanced RCP-driven recycling of α5β1 integrin and 
EGFR. This activates Rho and PKB/Akt to promote cell migration and invasion (Muller et al., 2009). 
(Muller et al., 2011) 
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Inflammation and cancer 
It was in 1863 that Rudolf Virchow noted leucocytes in neoplastic tissues and made a 
connection between inflammation and cancer (Virchow, 1863). He suggested that the 
“lymphoreticular infiltrate” reflected the origin of cancer at sites of chronic 
inflammation. Over the past 150 years our understanding of the inflammatory 
microenvironment of malignant tissues has amply supported Virchow’s hypothesis; 
nevertheless, our knowledge of the implication of the inflammatory process in cancer 
are far from being totally understood; indeed, both drugs that block and stimulate the 
inflammatory process are currently being explored in cancer therapy (Mantovani and 
Pierotti, 2008). 
Inflammation is the physiological response to injury caused by wounding, chemical 
irritation/damage, or infection. Acute inflammation starts a cascade of cytokines and 
chemokines that attract immune and non-immune cells, mainly neutrophilis, to 
infiltrate disrupted and damaged tissue. The process of acute inflammation is usually 
self-limiting because the production of pro-inflammatory cytokines gives way to anti-
inflammatory cytokines as healing progresses. Chronic inflammation is more difficult 
to define, but mononuclear cells, macrophages, lymphocytes, and plasma cells are 
found in addition to neutrophilis, and active tissue destruction and repair proceed 
simultaneously. Chief components of this healing process are angiogenesis and 
fibrosis.  
Innate immune cells, such as dendritic cells (DCs), natural killer (NK) cells, 
macrophages, neutrophils, basophils, eosinophils and mast cells, are the first line of 
defense against foreign pathogens. When tissue homeostasis is perturbed, they release 
soluble mediators, such as cytokines, chemokines, matrix remodelling proteases and 
reactive oxygen species (ROS), and bioactive mediators such as histamine, that 
induce mobilization and infiltration of additional leukocytes into damaged tissue. 
Macrophages and mast cells can also activate vascular and fibroblast responses in 
order to orchestrate the elimination of invading organisms and initiate local tissue 
repair. DCs, on the other hand, take up foreign antigens and migrate to lymphoid 
organs where they present their antigens to adaptive immune cells. They are, 
therefore, key players in the interface between innate and adaptive immunity. 
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Induction of efficient adaptive immune responses requires direct interactions with 
mature antigen-presenting cells and a pro-inflammatory milieu. Adaptive immune 
cells, such as B and T lymphocytes, express diverse antigen-specific receptors and are 
committed to a specific unique 
antigen. Therefore, clonal 
expansion is required to obtain 
sufficient antigen-specific B and/or 
T lymphocytes to counteract 
infection. Hence, the kinetics of 
adaptive responses are slower than 
innate responses. 
Whether an inflammatory immune 
response may become pro- or anti- 
tumorigenic is a delicate balance 
between adaptive and innate 
immune system: a healthy and 
regulated adaptive immune 
response is regarded as anti-
tumorigenic, whereas an 
unrestrained innate or inappropriate 
adaptive response may lead to 
chronic inflammation and a pro-
tumorigenic environment. At the 
risk of oversimplifying, for the sake 
of clarity, it can be said that acute 
inflammation counteracts, while 
chronic inflammation promotes 
cancer development. 
 
 
 
Figure 6. Pathways that connect inflammation and 
cancer. Cancer and inflammation are connected by an 
intrinsic pathway and an extrinsic pathway. The two 
pathways converge, resulting in the activation of 
transcription factors, mainly nuclear factor-κB (NF-κB), 
signal transducer and activator of transcription 3 
(STAT3) and hypoxia-inducible factor 1α (HIF1α), in 
tumour cells. These transcription factors coordinate the 
production of inflammatory mediators. The cytokines 
activate the same key transcription factors in 
inflammatory cells, stromal cells and tumour cells, 
resulting in more inflammatory mediators being 
produced and a cancer-related inflammatory 
microenvironment being generated. (Mantovani et al., 
2008) 
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Epidemiology of the association of cancer with inflammation 
Epidemiological data support the strong correlation between endogenous (such as 
inherited disease and obesity) and exogenous (acquired infections and noxius insults) 
inducers of chronic inflammation and cancer (Medzhitov, 2008). 
Several chronic inflammatory diseases lead to increased risk of cancer. Inflammatory 
bowel disease, Crohn’s pathologies and ulcerative colitis are associated with 
increased rates of colon adenocarcinoma (Gillen et al., 1994). In chronic pancreatitis, 
there is an increased rate of pancreatic cancer. Heavy alcohol consumption is involved 
in this inflammatory process and contributes with a 50-fold increased risk of 
pancreatic and liver cancers (Andren-Sandberg et al., 1997). 
Environmental and chemical exposures can cause chronic inflammation, such as 
bronchitis and emphysema, and contribute to carcinogenesis. Tobacco smoke is a key 
example: inhalation of >60 chemical carcinogenes and irritants can cause mutations in 
cancer-related genes, and also contributes to chronic inflammation of the lungs, 
plausibly being responsible for the majority of lung cancer cases (Boffetta, 2006; 
Grozio et al., 2007). 
Chronic infections are also a linked to cancer. Viral hepatitis B and C lead to chronic 
inflammation of the liver and are likely responsible for the majority of heapatocellular 
carcinomas worldwide (Tsukuma et al., 1993). Bacterial infection and colonization of 
the stomach by Helicobacter pylori causes chronic gastritis and is associated with the 
majority of gastric cancers (Parsonnet et al., 1991).  
The connection between inflammation and cancer is also supported by the evidence 
that certain anti-inflammatory drugs (such as aspirin or COX-2 inhibitors) reduce the 
risk of various tumors (Cuzick et al., 2009).  
On the other hand, the adaptive immune response is fundamental to prevent tumor 
formation by detecting and eliminating transformed cells: immunocompromised 
individuals have an increased risk of several types of cancers and patients taking 
immunosuppressive drugs have three times greater risk of developing various 
malignancies (de Visser et al., 2006). Indeed, immunological therapies and even 
vaccination are actively being explored as promising potential approaches for cancer 
treatment and prevention. 
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A specific case: Inflammatory breast cancer (IBC) 
Inflammatory breast cancer (IBC) is a rare but aggressive subtype of breast cancer, 
refractory to local therapy, surgery, and radiation, which accounts for about 1-5% of 
all cases of breast cancer (Dawood and Cristofanilli, 2011). In general, women with 
IBC are younger, are more likely to have metastatic disease at the time of diagnosis, 
and have shorter survival than women with non-inflammatory breast cancer. 
Clinically, IBC is characterized by the rapid onset of breast warmth, erythema, and 
edema (peau d’orange) often without a well-defined tumor mass. Along with 
extensive breast involvement, women with inflammatory carcinoma often have early 
involvement of axillary lymph nodes. The characteristic pathologic finding is dermal 
lymphatic invasion by carcinoma, which can lead to obstruction of the lymphatic 
drainage causing the clinical picture of erythema and edema. 
IBC tumors are frequently estrogen- and progesterone- receptor negative (Dawood 
and Cristofanilli, 2011; Paradiso et al., 1989). 
The presence of tumor-associated macrophages (TAM) is a characteristic of this type 
of tumors (Mantovani et al., 2007) and different studies provided the evidence that the 
NF-κB pathway is hyperactivated in IBC compared with non-inflammatory breast 
cancer (Van Laere et al., 2007; Van Laere et al., 2006). Characteristic of IBC tumors 
are also over-expression of various chemokines and their receptors (Cabioglu et al., 
2007; Muller et al., 2001), which are transcriptional targets of NF-κB. In addition, 
inflammatory carcinomas are more likely to have mutations in p53 (Aziz et al., 2001). 
The normal function of p53 can be altered by two distinct mechanisms in IBC: direct 
mutation of the gene (30%), or cytoplasmic sequestration of the protein (37%) (Moll 
et al., 1992). Moreover, different mechanisms can lead to high expression levels of 
VEGF, its receptor (VEGFR), and angiopoietins (Colpaert et al., 2003; Van der 
Auwera et al., 2004), inducing the formation of new vessels and lymph-vessels 
networks involved in metastatic spread of IBC tumors. Surprisingly, the epithelial 
marker E-cadherin has been found to be over-expressed in IBC, and may contribute to 
the unique IBC phenotype (Colpaert et al., 2003). It has been hypothesized that loss of 
E-cadherin occurs transiently in the early phase of IBC, to induce EMT process and 
allow metastasis, but at the time of diagnosis tumor cells have reinstated its 
expression. 
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In summary, IBC displays unique molecular changes that support tumorigenesis, 
angiogenesis and metastasis, uncovering the link between inflammation, NF-κB, 
mutant p53, and EMT. The current scarcity of effective treatments makes IBC an 
important model for the clinical investigation of targeted therapy. 
 
Mechanisms of chronic inflammation that lead to cancer 
Carcinogenesis is a multi-step process with sequential stages of initiation, promotion 
and progression. During normal life humans and mice accumulate somatic mutations 
in various cell types. These “initiated cells” accumulate during life and inflammation 
may act as a promoter to: a) cause those cells to acquire additional mutations 
(possibly by increasing the formation of ROS and by preventing apoptosis of 
damaged cells); b) drive those mutant cells to proliferate; c) confer a growth 
advantage (Darwinian “selection”) to pre-neoplastic and neoplastic cells. 
Both extrinsic and intrinsic inflammation pathways may be carcinogenic (Mantovani 
and Pierotti, 2008). In the extrinsic pathway, chronic inflammation and/or infection is 
the driving force that causes the increase in cancer risk. Alternatively, in the intrinsic 
pathway up-regulation of oncogenes (i.e. Ras) or inactivation of tumor suppressor 
genes (i.e. p53) affects the expression of various inflammatory genes and leads to 
recruitment of inflammatory cells (Allavena et al., 2008). Indeed, inflammatory cells 
are present in the microenvironment of nearly all tumors regardless of the underlying 
etiology. So in the intrinsic pathway, genetic mutations stimulate the tumor cells to 
produce inflammatory cytokines and free radicals, which in turn can create a feedback 
loop with recruited inflammatory cells favoring carcinogenesis. A prolonged 
inflammatory response can contribute to increased mutation rates and overall genetic 
instability (Colotta et al., 2009). Inflammation can reduce expression and activity of 
DNA mismatch repair genes, and increase expression of DNA methyltransferases, 
leading to a global hypermethylation of the genome; hypermethylation of tumor 
suppressor genes contributes to carcinogenesis (Colotta et al., 2009). Finally, chronic 
inflammation causes elevated levels of reactive oxygen species (ROS) and reactive 
nitrogen species (NO), that in “physiological” inflammation have an important 
microbicidal activity (Hussain et al., 2003). In the tumor microenvironment ROS and 
nitric oxide lead to DNA strand breaks, point mutations, and aberrant DNA cross-
linking, thereby causing genomic instability (Hussain et al., 2003). Moreover ROS 
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and NO promote angiogenesis and transcriptional activation of proto-oncogenes, 
increasing the metastatic potential of tumors (Ishikawa et al., 2008; Wink et al., 
2008). 
 
The role of pro-inflammatory cytokines 
Inflammatory cytokines (such as TNFα, IL1 and IL6) and chemokines (such as IL8), 
produced by the tumor cells and/or tumor associated leucocytes and platelets, may 
contribute directly to malignant progression (Aggarwal et al., 2006). 
An inflammatory cytokine network may influence survival, growth, mutation, 
proliferation, differentiation, and movement of both tumor and stromal cells. 
Moreover these cytokines can regulate communication between tumor and stromal 
cells, and tumor interactions with the extracellular matrix (Barrientos et al., 2008). 
Inflammatory cytokines induce DNA damage up-regulating levels of ROS and NO, as 
discussed earlier. Moreover they can also affect genome integrity via inhibition of 
cytochrome p450 or gluthatione S-transferase (Bubici et al., 2006). Cytokines and 
chemokines have the potential to stimulate tumor-cell proliferation and survival and 
some of them act as autocrine growth and survival factors for malignant cells: 
hematological malignancies growth is stimulated by IL6 (Tricot, 2000; Voorzanger et 
al., 1996), while for gastric carcinoma it has been found an involvement of IL1 (El-
Omar et al., 2000); moreover IL8 and other related chemokines are involved in 
growth of melanoma and other type of cancers (Haghnegahdar et al., 2000; Kollmar et 
al., 2007). Inflammatory cytokines can affect the extracellular matrix through up-
regulation of metalloproteinases and adhesion molecules (Opdenakker and Van 
Damme, 1992). Certain tumor cells have receptors for adhesion molecules and use 
these molecular tools, typical of migrating leucocytes, to seed at distant anatomical 
sites (Martin-Padura et al., 1991). Thus, inflammatory cytokines stimulate invasion 
and metastasis of cancer cells through a plethora of mechanisms. 
 
Tumor Necrosis Factor Alpha (TNFα) 
TNFα is a major mediator of inflammation, through actions directed to both tissue 
destruction and recovery. While inducing death of diseased cells at the site of 
inflammation, TNFα stimulates fibroblast growth. It can destroy blood vessels but 
also induce angiogenic factors (Wang and Lin, 2008). TNFα was identified in the late 
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1970s as a cytokine having a capacity to suppress tumor cell proliferation and induce 
tumor regression (Sidhu and Bollon, 1993). However, emerging evidences have 
shown that TNFα is one of the major mediators of cancer related inflammation and 
acts as a tumor-promoting factor (Balkwill, 2009). These controversial effects of 
TNFα underlie the differences between acute vs chronic TNFα administration: high 
concentration of local TNFα can induce hemorrhagic tumor necrosis while low dose, 
chronic TNFα promotes tumor progression (Wang and Lin, 2008). 
Although initially it was identified as a specific macrophage product, TNFα has now 
been shown to be produced by a wide variety of tumor cells: TNFα can be detected in 
malignant and/or stromal cells in human ovarian (Wu et al., 1993), breast (Montesano 
et al., 2005), prostate, bladder, and colorectal cancer (Schmiegel et al., 1993), 
lymphomas (Digel et al., 1989) and leukaemias (Au et al., 2006). In human tumors the 
presence of TNF is associated with a poor prognosis, loss of hormone responsiveness 
and cachexia/asthenia. 
There is also evidence for pro-cancer actions of TNFα in animal models; TNFα 
administration confers invasive properties on some tumor cell lines and induced 
metastasis in an experimental model of fibrosarcoma (Orosz et al., 1993). In line with 
this pro-tumoral action, TNFα-/- and TNFR1-/- mice were shown to be resistant to 
chemically induced carcinogenesis, and to development of liver metastasis in an 
experimental model of colon cancer (Arnott et al., 2004). 
Tumors develop mechanisms to subvert the equilibrium of the organism; they 
manipulate the cells homeostasis and uncover the “dark side” of many positive 
processes. Given this, we can understand the apparent “paradox” of a protein named 
tumor necrosis factor that can act as efficient tumor promoter. 
 
Structure and function of TNFα  and its receptors 
TNFα is synthesized as a 26kDa membrane bound pro-peptide (pro-TNF) and is 
released after cleavage by the TNF-converting enzyme (TACE). In its soluble form, 
TNFα is able to recognize its receptors acting as a homotrimer with a subunit 
molecular mass of 17kDa. TACE can also realese TNF-receptors from the cell 
surface: these circulating cytokine-binding proteins represent an important 
mechanism of negative regulation for the biological activity of soluble TNFα 
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(Bemelmans et al., 1996). TNF-receptors don’t have any enzymatic activity: the 
signals are transmitted through the recruitment of different protein complexes leading 
to the activation of effector proteins and protein kinases (Aggarwal, 2003). 
TNF family receptors can be classified into three major groups: 
1. TNFR1 containing a death domain (DD) in the cytoplasmatic tail. The 
activation of these receptors leads to the recruitment through DD of 
intracellular DD–containing adaptors such as FADD (Fas-associated DD) and 
TRADD (TNF-R associated DD) which are involved together in the activation 
of caspase cascade and induction of apoptosis through the formation of death 
inducing signaling complex (DISC). 
On the other side, TNFR1 is involved in the recruitment of TRAF (TNFR 
associated factor) family member. 
2. TNFR2 containing TRAF-interacting domain (TIM) in the cytoplasmatic tail. 
Activation of these receptor leads to the direct recruitment of TRAF proteins 
involved in signal trasduction pathways activation such as MAPK (mitogen–
activated protein kinases: JNK, p38MAPK, ERK), inhibitor of NF-κB (such as 
IKK), and PI3K (phosphatidyl-inositol 3-kinase) pathways. 
3. TNFR without functional intracellular signaling domains. This class of 
receptors acts like a decoy efficiently competing with the other two receptor 
groups for their ligands. 
TNFR1 (also called TNFRp55/p60) is ubiquitously expressed in all cells while 
TNFR2 (TNFRp75/p80) is specifically expressed in immune and endothelial cells. 
Given that TNFR1 coordinates the majority of TNF biological activities, it is the most 
relevant for TNF-induced carcinogenesis. 
 
 
Signaling pathways downstream of TNF-R1  
The initial step in TNFR1 signaling involves the binding of the TNFα trimer to the 
extracellular domain of TNF-R1 and the release of the inhibitory protein SODD 
(silencer of death domains) from TNF-R1’s intracellular domain. The resulting 
aggregated TNF-R1 is recognized by TRADD, which recruits additional adaptor 
proteins like the kinase RIP (receptor interacting protein), TRAF2, and FADD. These 
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latter proteins recruit key enzymes to TNFR1 that are responsible for initiating 
signaling events. 
 
The DISC complex (or TNFR complex II) 
 TNFα can induce two main forms of ‘‘extrinsic’’ (or death receptor-mediated) 
programmed cell death (PCD): (a) classical apoptosis, characterized by caspase-
dependent chromatin condensation and fragmentation, membrane blebbing and 
formation of apoptotic bodies; (b) necrosis-like caspase-independent PCD, 
characterized by absent or marginal chromatin condensation, lack of nuclear 
fragmentation and disruption of membrane integrity (Leist and Jaattela, 2001). The 
former is the best characterized type of cell death triggered by TNFα. This pathway is 
initiated by formation of a death inducing 
signaling complex (DISC) on the 
intracellular domain of TNFR1. This 
complex, also called TNFR signaling 
complex II, consists of TRADD, FADD and 
caspase-8. Activation of caspase-8 by FADD 
starts the caspase cascade, resulting in 
destruction of cell components, 
fragmentation of DNA, and apoptosis. 
Moreover caspase-8 can also initiate the 
mitochondrial apoptotic pathway (or 
‘‘intrinsic’’ death pathway) leading to the 
release of several mediators (e.g. 
cytochrome-C) that further amplify the 
caspase cascade (Du et al., 2000) 
 
The RIP complexes (or TNFR complex I) 
Although TNFα can directly induce cell death under certain conditions (e.g. when 
protein synthesis is blocked), most often it induces transcription and activation of 
inflammatory genes. This indicates that TNFR1 signaling can also provide a 
mechanism to suppress the apoptotic stimulus (Locksley et al., 2001). 
Figure 7. Intracellular tumor necrosis factor 
signaling (Balkwill, 2009) 
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This pathway is initiated by recruitment of RIP1 and TRAF2 to the intracellular 
domain of activated TNFR1, forming the so-called “TNFR complex I” at the plasma 
membrane. This leads to rapid activation of NF-κB with subsequent induction of 
several anti-apoptotic proteins such as cIAP family and cFILP. Formation of active 
complex I can also lead to formation of a cytoplasmic complex constituted by TRAF2 
and RIP1, promoting activation of MAPKs pathway (Varfolomeev and Ashkenazi, 
2004). 
TNFR complex II, involved in PCD, is assembled following receptor endocytosis; 
ubiquitylation of RIP1 and TRAF2 promotes their dissociation from the receptor, 
leading to the loading of FADD and TRADD, thus initiating apoptosis. Concomitant 
with the induction of apoptosis, NF-κB signaling is blocked through caspase-8-
mediated degradation of RIP1. 
TNF-induced apoptosis is therefore under the control of complex I: complex II 
initiates apoptosis only when NF-κB activity cannot sustain sufficient levels of 
antiapoptotic proteins (Varfolomeev and Ashkenazi, 2004). 
 
TNF-mediated MAPKs pathway activation  
TNF-signaling cascade is the result of distinct pathways with opposite behaviors 
highly interconnected. Consequently it can be justified the difficult to understand at 
the molecular levels the specific steps of TNFα signal transduction. 
Even if TRAF2 and RIP1 are the characterizing proteins of complex I formation, it 
has been demonstrated that RIP1 kinase activity and TRAF2 are not requested for NF-
κB activation (Wajant et al., 2003). Instead TRAF2 is necessary for MAPKs pathway 
activation leading the formation of an alternative complex I. 
The steps that lead to the formation of this alternative cytopalsmic complex I are not 
fully understood even if recently it has been indentified DAB2IP as a mediator of this 
transition (as subsequently will be discussed). 
The mitogen-activated protein kinase (MAPK) cascades are among such signaling 
systems, which are evolutionary conserved in all eukaryotic cells. MAPKs are 
activated by a well-recognized mechanism of dual phosphorylation that derives by a 
cascade of protein kinases: MAP3K phosphorylates and thereby activates MAP2K, 
and activated MAP2K in turn phosphorylates and activates MAPK. 
  32 
TNFα, like other stress, can activate JNK and p38MAPK signaling cascades. The 
MAP3K that diverts TNFα signaling to JNK and p38MAPK activation is ASK1 
(apoptosis signal regulating kinase 1) (Nishitoh et al., 1998). 
ASK1 is a serine/threonine kinase 
tightly regulated by phosphorylation 
process: it has been reported that 
phosphorylations in Ser83 and Ser967 
have an inhibitory role, while 
phsphorylation in Thr838 is involved 
in activation of this protein. Moreover 
thioredoxin (Trx) inhibits ASK1 
through direct binding linking its 
activation to ROS: Trx has a redox 
active site, ROS can affect its redox 
status leading to ASK1 release and 
activation. Its kinase activity is also 
affected by the binding with 14-3-3 
protein that recognized phosphorylated 
Ser967 (Takeda et al., 2008). 
Over-expression of ASK1 induces 
apoptosis in various cells through 
mitochondria-dependent caspase 
activation, and ASK1 is required for 
apoptosis induced by oxidative stress, 
TNFα, and endoplasmic recticulum 
stress (Matsukawa et al., 2004). The 
TRAF2-RIP1 complex interacts with 
ASK1 and stimulates its activation 
inducing the release of 14-3-3 and de-
phosphorylation of Ser967 (Takeda et al., 2008). Therefore, inflammation can induce 
ASK-1 activation both by ROS formation and by TNF-induced TRAF2-RIP1-ASK1 
complex formation. Activated ASK-1 induces the MAP2Ks upstream to JNK (MKK4 
Figure 8. Mitogen-activated protein kinase 
(MAPK) pathways. MAPK pathways are activated by 
environmental stresses, such as inflammatory cytokine 
stimulation. The different upstream activators of Jun 
N-terminal kinases (JNKs) and p38 MAPKs, such as 
MAP2K and MAP3K family members, are depicted. 
In addition, downstream targets, including 
transcription factors and other effectors, which 
determine a range of biological responses from cell 
proliferation, survival, differentiation and migration to 
inflammation and cancer, are shown. (Wagner et 
al.,2009) 
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and MKK7) and to p38MAPK (MKK3 and MKK6) thus activating these two 
pathways (Matsukawa et al., 2004). 
 
p38MAPK pathway 
p38 is a 38kDa protein and it is rapidly tyrosine phosphorylated in response to LPS 
(Han et al., 1994). Different stimuli converge to p38 such as UV, heat, osmotic shock, 
inflammatory cytokines and growth factors. The complexity of this pathway is 
increased by the observation that p38 activation is not only dependent to the stimulus 
but also to the cell type (Zarubin and Han, 2005). 
Many transcription factors encompassing a broad range of actions have been shown to 
be phosphorylated, and so activated, by p38. After TNFα stimulation, p38 plays an 
essential role in production of pro-inflammatory cytokines (such as IL1β, IL6 and 
TNFα) (Perregaux et al., 1995), induction of enzymes such as COX2 and iNOS, 
effectors of the inflammatory process (Zarubin and Han, 2005). Moreover p38 is 
involved directly in the regulation of caspase activity (Juo et al., 1997); nevertheless, 
the involvement of p38 in apoptosis looks to be cell type- and stimulus- dependent. 
 
JNK pathway 
The c-Jun N-terminal kinase (JNK) group of MAP kinases, also known as stress-
activated protein kinases (SAPK), represent a group of enzymes that are activated by 
exposure of cells to cytokines and environmental stress (Gupta et al., 2010; 
Whitmarsh and Davis, 1996). JNK is activated by dual phosphorylation of Thr and 
Tyr residues. The JNK protein kinases are a group of MAP kinases that are encoded 
by three genes: jnkl; ink2; and jnk3 (Gupta et al., 2010; Whitmarsh and Davis, 1996). 
The jnkl and ink2 genes are ubiquitously expressed. In contrast, the jnk3 gene is 
selectively expressed in the brain, heart, and testis. Transcripts derived from these 
genes are alternatively spliced: all three jnk genes are expressed as 46kDa and 55 kDa 
protein kinases due to differential processing of the 3' coding region of the 
corresponding mRNA (Gupta et al., 2010). 
Besides the phosporylation dependent regulation of upstream MKK4 and MKK7 
kinases, the JNK proteins are inhibited by interaction with the cytoplasmic JNK-
interacting protein 1 (JIP1) (Dickens et al., 1997). The protein GPS2 (G-protein 
pathway suppressor-2) has been identified as another suppressor of JNK under TNFα 
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stimulation (Jin et al., 1997). JNK is able to stimulate the activity of AP-1 
transcription factor in response to specific stress signals, such as TNFα. JNK can 
recruit AP-1 through the direct phosphorylation of AP-1 components (c-Jun and 
ATF2) (Whitmarsh and Davis, 1996). AP-1 is an important trans-activator of a 
number of stress responsive genes including the genes for IL-1 and -2, CD40, CD30, 
TNFα, and c-Jun itself. In addition, AP-1 participates in the transcriptional induction 
of proteases and cell adhesion proteins (e.g., E-selectin) important to inflammation 
(Karin et al., 1997). 
JNK phosphorylates and regulates the activity of many other transcription factors 
including Elk-1, p53 and c-Myc and non-transcription factors, such as members of the 
Bcl-2 family (Bcl-2, Bcl-xL, Bim and BAD), in response to a variety of extracellular 
stimuli (Kyriakis and Avruch, 2001). There are many evidences that indicate the JNK 
pro-apoptotic function in response to pro-inflammatory cytokines. The pro-apoptotic 
role of JNK is evident from analyses of JNK knock-out mice: MEFs (mouse 
embryonic fibroblast) lacking both JNK1 and JNK2 are resistant to PCD induced by 
stress stimuli like TNFα (Davis, 2000); mice without TRAF2 are not able to activate 
JNK and are resistant to TNF-induced apoptosis (Wajant et al., 2003). 
Notably, JNK activation by TNFα is controlled by NF-κB, and block of NF-κB 
activity prolongs JNK signaling after TNFα (Tang et al., 2001). Interestingly, it is a 
persistent JNK activation that is ultimately responsible for triggering cell death, and 
NF-κB counteracts this activity by promoting shut-down of activated JNK. Indeed, 
JNK plays an obligatory role in efficient apoptosis triggered by TNF-R stimulation: in 
fact, inhibition of JNK signaling by pharmacological agents effectively protects NF-
κB-deficient cells from TNF-mediated cytotoxicity (Tang et al., 2001). 
JNK activation may contribute to apoptosis only if the apoptotic process has already 
been activated. JNK-mediated pro-apoptotic signaling induced by TNFα appears to 
rely on factors already present in cells instead that need to be transcribed: JNK might 
induce apoptosis via modulating the proapoptotic Bcl-2 family protein: prolonged 
JNK activation resulted in the production of jBID, which is a novel proteolytic 
fragment of BID (Deng et al., 2003). It has been shown that jBID specifically induces 
the release of Smac from mitochondria and subsequently Smac displaces caspase-8 
inhibitor c-IAP1 from TNF-receptor 1 complex, thereby allowing the initiation of 
apoptosis. 
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The importance of JNK in TNF-mediated cytotoxicity is further underscored by its 
conservation throughout evolution. The Drosophila TNF homolog, Eiger, depends on 
JNK to induce death rather than on the caspase-8 like protein, Dredd (Moreno et al., 
2002). Moreover JNK-induced apoptosis signaling in flies is mediated by Hid, Reaper 
and Grim, the functional equivalents of mammalian Smac/Diablo. Thus, the pro-
apoptotic activity of JNK appears to be a remnant of a primordial death-inducing 
mechanism engaged by TNFR. 
 
TNF and the NF-κB pathway 
Nuclear factor-κB (NF-κB) is a nuclear transcription factor that was first identified in 
1986; this name derives from its initial identification as a nuclear protein bound to an 
enhancer element of the Ig kappa light chain gene in B cells (Aggarwal, 2004). 
NF-κB is a family of seven structurally related 
vertebrate transcription factor subunits that 
function in various combinations as an inducible 
transcription factor. In humans, this family 
includes the proteolytically processed DNA 
binding subunits termed NF-κB1 (50 and 105 
kDa), NF-κB2 (50 and 100 kDa), and the 
transcriptional activators termed Rel A, C-Rel, 
and Rel B (Siebenlist et al., 1994). These proteins 
can form homodimers or heterodimers, which in 
turn bind to DNA target sites known as κB sites. 
The different Rel/NF-κB proteins show a distinct 
ability to form dimers, distinct preferences for 
different κB sites, and distinct abilities to bind to 
inhibitory subunits (Gilmore, 2006). 
Frequently referred as a “central regulator of 
inflammation,” NF-κB controls the expression of 
inducible chemokines, cell adhesion molecules, 
and vasoactive and anti-apoptotic proteins important in the cellular stress response 
(Pahl, 1999). NF-κB responds to a diverse series of inflammatory activators, 
Figure 9. Model of NF-κB canonical 
pathway activation 
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including ultraviolet light, dsRNA, cytokines, vasoactive peptides, and viral 
oncogenes, which allow it to function as a signaling integrator. 
NF-κB activation is controlled by two distinct pathways, termed the “canonical” 
(Karin, 1999) and the “non canonical” pathways (Senftleben et al., 2001). 
In the “canonical” pathway, there is the translocation from the cytoplasm to the 
nucleus of a heterodimer composed by the transactivating subunit, 65-kDa Rel A, and 
a DNA-binding subunit, NF-κB1. In contrast, the more recently described 
noncanonical pathway controls processing and translocation of the NF-κB2–Rel B 
complexes. 
Under normal conditions, Rel A-NF-κB1 is sequestered in the cytoplasm by IκBα, an 
ankyrin repeat (AR) domain-containing inhibitory protein which binds Rel A, 
inactivating its DNA binding and nuclear translocation ability (Beg and Baldwin, 
1993). The hallmark of NF-κB activation via the canonical pathway involves the 
proteolysis of the IκB inhibitor (Karin, 1999). Upon receiving a signal, IκB is 
phosphorylated at two conserved serine residues in its N-terminal regulatory domain 
by activation of the multi-protein cytoplasmic IKK (the “signalsome” (Maniatis, 
1997)). Once phosphorylated and while still bound to NF-κB, IκBs almost 
immediately undergo polyubiquitination and degradation by 26S proteosomes (Karin, 
1999). As a result, liberated NF-κB rapidly enters the nucleus to activate target gene 
expression. 
The cytoplasmic IκB kinase (IKK) is a multi-protein complex of approx 700 kDa 
composed of at least 10–14 discrete proteins (Maniatis, 1997). The IKK “core” 
consists of two catalytic kinases IKK-α and -β, and a noncatalytic signal 
recognition/scaffolding protein referred to as IKKγ (the NF-κB essential modulator 
[NEMO]); IKKβ activation is thought to be the major regulatory step in the canonical 
pathway. IKKβ activation involves serine phosphorylation of two activation loop 
serine phosphoacceptors. IKKγ is required for IKK activation through its ability to 
organize the assembly of IKKs into the activated high-molecular-weight complex. It 
recruits the IκBα inhibitor into the activated IKK complex where it becomes 
phosphorylated and consequently degradated. IKKγ serves also as an adapter 
molecule to recruit upstream kinases that phosphorylate the catalytic subunits (Sethi 
et al., 2008). 
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In response to cytokines, such as TNFα, IKKγ recruits inactive cytosolic IKK to a 
complex formed on the cytoplasmic effector domains of the liganded TNF receptor 
associated to TRADD, TRAF2 and RIP1. Here, an ordered activation process is 
initiated by the upstream mitogen activated protein kinase kinase kinases (MAP3Ks). 
The MAP3Ks that activate IKK include the NF-κB inducing kinase (NIK), and the 
transforming growth factor (TGF)-β associated kinase-1 (TAK1) (Malinin et al., 
1997). 
NF-κB affects the regulation of a huge amount of genes involved in distinct metabolic 
processes; among them, it is possible to identify three different clusters, depending on 
the timeframe of their transactivation after NF-κB activation: 
1. Early genes: primarily encoding for cytokines that mediate TNFα’s ability to 
amplify local cytokine cascades in inflamed tissue (i.e. IL1, IL6, TNF, IL8 and 
others chemiokines) and regulatory components of NF-κB pathway cascade 
(such as IκBα, A20…) 
2. Middle genes: encoding for anti-apoptotic proteins (such as cIAP 1-2, cFLIP, 
BID…) and enzymes involved in metabolic process (i.e. SOD2) 
3. Late genes: encoding for a more promiscuous class of genes. Among them 
there are receptor/cell surface proteins (i.e. ICAM1) and proteins involved in 
remodeling of extracellular-matrices (such as MMP9) 
Because genes regulated by the canonical NF-κB activation include also inhibitors of 
the pathway, the system is under negative feedback control and the pathway is only 
transiently activated. 
Among its direct targets, NF-κB induces the re-synthesis of IκBα that serves to 
recapture and inactivate NF-κB, restoring the cell to homeostasis. A second level of 
negative autoregulation of the TNF-IKK-NF-κB signaling pathway is at the level of 
the IKK. This regulation is mediated by the A20 protein, whose expression is strongly 
and rapidly induced by TNFα in an NF-κB–dependent fashion. A20 is an ubiquitin 
ligase that associates with RIP and mediates its degradation, inhibiting TNF-induced 
NF-κB signaling and apoptosis (Aggarwal, 2004; Wertz et al., 2004). Without A20 
expression, TNFα induces chronic NF-κB activation and inflammation in a mouse 
model (Lee et al., 2000). A third level of feedback control involves the receptor and 
its signaling adapters. TRAF-1, target of NF-κB, is a unique member of the TRAF 
family that lacks the NH2-terminal RING finger motif (Chung et al., 2002). TRAF-1 
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is known to associate with TNFRI, II, CD30, and TNFS9 and it may influence 
caspase activation and affect cellular apoptosis. Therefore, TRAF-1 is involved in an 
autoregulation of the TNF–IKK–NF-κB signaling pathway by disrupting TNFR 
coupling with IKK. 
Finally, NF-κB regulates also the expression of proteins involved in reducing the 
stability of TNFα mRNA, thus damping the auto-stimulatory loop (Carballo et al., 
1998). 
 
NF-κB in cancer 
The activation of NF-κB is a double-edged sword. While needed for proper immune 
system function, inappropriate NF-κB activation can lead to chronic inflammation 
and carcinogenesis. NF-κB is a part of the cells’ auto-defense mechanisms to 
counteract in physiologically conditions the inflammatory cytotoxic effects and in 
tumors to mediate desensitization and chemoresistance (Wang et al., 1999a). 
 NF-κB is constitutively activated in numerous tumors like lymphomas (Bargou et al., 
1997), and carcinomas of the breast (Sovak et al., 1997), prostate (Suh et al., 2002), 
lung (Mukhopadhyay et al., 1995), colon (Kojima et al., 2004), pancreas (Wang et al., 
1999b), and head and neck (Nakayama et al., 2001). 
Several genes that mediate cell proliferation are regulated by NF-κB such as TNFα, 
IL1 and IL6 (Ahn and Aggarwal, 2005); besides growth factor NF-κB induces also 
cell cycle regulatory proteins (i.e. Cyclin D1) . 
Importantly for cancer progression, NF-κB plays a fundamental role in suppression of 
TNFα cytotoxic signals by regulating several anti-apoptotic proteins: NF-κB induces 
IAP-1, IAP-2, XIAP, cFLIP, TRAF1, Bcl2, Bcl-xL and Survivin (Dutta et al., 2006).  
Moreover NF-κB blunts JNK pathway activation by up-regulating Gadd45β and A20: 
Gadd45β binds directly MKK7 blocking its catalytic activity (De Smaele et al., 2001), 
while A20 mediates ubiquitination and degradation of RIP1 (Wertz et al., 2004). NF-
κB has been implicated in the migratory and invasive phenotype of tumor cells; the 
matrix metalloproteinases (MMP) and the serine protease urokinase-type plasminogen 
activator (uPA) are regulated by NF-κB (Bond et al., 1998; Novak et al., 1991). Those 
enzymes promote growth of cancer cells through the interaction of ECM molecules 
and integrins, cleaving insuline-like growth factors and shedding transmembrane 
  39 
precursors of growth factors (such as TGFβ). MMPs also regulate invasion and 
migration by degrading structural ECM components. 
 
 
Figure 10. NF-κB regulated processes. Nuclear factor κB (NF-κB) activation affects all six 
hallmarks of cancer through the transcription of genes involved in cell proliferation, angiogenesis, 
metastasis, inflammation and suppression of apoptosis. (Baud et al., 2009) 
In inflammatory tumors, stimulation of EMT (epithelial to mesenchimal transition) 
process is dependent on NF-κB: NF-κB affects through transcriptional and post-
translational mechanisms the activity of SNAIL, a master inducer of mesenchimal 
transition (Wu and Zhou, 2010). 
Moreover this transcriptional factor sustains tumor metastasis also with the up-
regulation of molecules of adhesion such as ICAM-1, ELAM-1 and VCAM-1 (van de 
Stolpe et al., 1994); those factors are required for the migration of cancer cells both 
into and out the vessel walls that transport them to other part of the body. It has been 
demonstrated that NF-κB can regulate the motility of breast cancer cells by directly 
up-regulating the expression of CXCR4, a surface receptor involved in the migration 
and organ-specific homing of metastatic breast cancer cells (Helbig et al., 2003). 
Finally NF-κB activation modulates the angiogenic process surrounding tumors 
through up-regulation of chemokines (i.e. IL-8) and growth factors such VEGF 
(Aggarwal et al., 2006). 
It can be concluded that NF-κB, through its regulated genes, is fundamental in 
different steps of tumorigenesis, and represents a major link between inflammation 
and cancer. 
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Potential pharmacological control of the TNF pathway in cancer 
The early promises that TNFα would be a powerful anticancer cytokine faded with 
the realization that administration of recombinant TNFα induces signs and symptoms 
of endotoxic shock.  
Local administration of TNFα may have more chances of success. For instance, 
TNFα was licensed for local treatment of irresectable soft tissue sarcoma of the limbs 
(Verhoef et al., 2007). This approach causes specific destruction of tumor vasculature, 
hemorrhagic necrosis and complete tumor disappearance. Nevertheless, this treatment 
prevents amputation of the affected limb but does not affect distant metastasis. In line 
with this concept, different strategies are being tested to formulate a tumor-targeted 
delivery of TNFα: the idea is to maximize the local concentration of TNFα in cancer 
cells and so significantly minimize the systemic toxicity (Szlosarek and Balkwill, 
2003). Downstream of TNFα, NF-κB is another ideal target for anticancer drug 
development. Several in-vitro studies have demonstrated that the resistance to TNFα 
of some tumors can be reversed by inactivation of NF-κB (Orlowski and Baldwin, 
2002). Selective NF-κB inhibitors or proteasome inhibitors (i.e bortezomib) have 
already entered the clinical phase in combination with conventional anti-neoplastic 
drugs (Papandreou and Logothetis, 2004). 
 Opposite strategies are exploring anti- TNFα treatments for cancer prevention 
and therapy. TNFα can be blocked with anti-TNFα neutralizing monoclonal 
antibodies, soluble TNF receptors, or TNFα auto-vaccination. This therapeutic 
approach is supported by experiments involving carcinogen-induced transplantable 
xenograft and genetic models of common epithelial primary cancer (Mocellin et al., 
2005). 
In phase I and II clinical trials, both inflaximab (anti- TNFα monoclonal antibody) 
and etanercept (recombinant human soluble TNFR2) achieved prolonged disease 
stabilization in patients with metastatic breast cancer, recurrent ovarian cancer, or 
immunotherapy-resistent or refractory renal cell carcinoma (Balkwill, 2009). 
Thalidomide, dexamethasone, aspirin, and non-steroidal anti-inflammatory drugs 
(NSAIDs) are all non-specific TNFα inhibitors, which modulate TNF-dependent and 
independent pathways. Dexamethasone, that inhibits TNFα transcription and 
translation, has widespread application in oncology. Thalidomide also represses 
TNFα in several ways, promoting decay of the mRNA transcript and decreasing NF-
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κB binding activity (Richardson et al., 2002). Several studies have confirmed that 
thalidomide has activity in a range of tumours, including multiple myeloma, renal cell 
and prostate carcinoma, melanoma, glioma, and Kaposi’s sarcoma. There is good 
epidemiological evidence for a protective role of aspirin and NSAIDs against 
colorectal cancer, and emerging data suggest a benefit in several other epithelial 
tumours (Turini and DuBois, 2002). 
However, due to complexity of the role that TNFα plays in carcinogenesis, the 
potential tumor-promoting effect of TNF-modulating strategies should be carefully 
evaluated: in fact, anti-TNF therapy might dampen tumor survellance by the immune 
system, thus favouring cancer development. 
 In conclusion, 150 years after Virchow observations it is clear that 
inflammation is involved in tumorigenesis, and it has been demonstrated that TNFα is 
a “double dealer” in cancer. Pharmacological research is producing different 
approaches both to control the cytotoxic effects of TNFα, or to suppress its oncogenic 
functions. What we still need to understand are the underlying oncogenic mutations 
that might determine the different behavior of tumor cells in response to TNFα and so 
to identify patients that are more likely to benefit from one approach rather than the 
other. 
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DAB2IP 
DAB2IP, also known as ASK1 Interacting Protein-1 (AIP1), was initially identified as 
a novel member of the RAS GTPase-activating family (Chen et al., 2002). It was 
cloned through a yeast two-hybrid screening for proteins interacting with disabled-2 
(DAB2). Disabled-2, also known as DOC-2 (differentially expressed in ovarian 
carcinoma 2), is a tumor suppressor gene: the absence of DAB2 expression is 
associated to malignant transformation in breast, prostatic and ovarian carcinoma 
(Fazili et al., 1999; Fulop et al., 1998; Schwahn and Medina, 1998; Zhou and Hsieh, 
2001). 
Subsequently other groups demonstrated that also DAB2IP is a bona fide tumor 
suppressor gene, regulating multiple pathways important for cancer development and 
progression (Chen et al., 2002; Min et al., 2010; Xie et al., 2010; Xie et al., 2009; 
Zhang et al., 2003). 
DAB2IP, via its GAP activity, inhibits Ras signaling reducing cell growth (Chen et 
al., 2002). On the other hand, DAB2IP functions as a positive regulator of apoptosis 
by mediating activation of the apoptotic kinase ASK1 (Zhang et al., 2003) and 
inhibiting activation of NF-κB (Min et al., 2010). In this respect, it can be said that 
DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-κB 
to prevent tumor growth and dissemination (Min et al., 2010). 
DAB2IP also negatively controls EMT (Xie et al., 2010) and neo-angiogenesis 
(Zhang et al., 2008), both crucial steps in tumor metastasis. In fact, DAB2IP knockout 
mice confirmed that deficiency of DAB2IP protein can strongly augment epithelial 
cell migration and inflammatory angiogenesis (Zhang et al., 2008). 
Consistent with such prominent role as inhibitor of cell survival, growth, and 
metastasis, DAB2IP expression is epigenetically silenced by DNA hypermethylation 
and/or histone modification in various human malignancies, including prostate cancer, 
breast cancer, lung cancer and hepatocellular carcinoma (Chen et al., 2003; Dote et 
al., 2005; Dote et al., 2004). 
The negative regulation of DAB2IP functions may not be confined to epigenetic 
silencing, as indicated by a report of a patient with acute myeloid leukemia. In this 
patient, the intron 9 of the MLL gene was translocated to the exon 2 of the DAB2IP 
gene, thereby disrupting DAB2IP structure (von Bergh et al., 2004). Recently two 
different studies reported that a genetic polymorphism (rs1571801) in intron 1 of 
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DAB2IP gene is significantly associated with increased risk of aggressive prostate 
and lung cancer (Duggan et al., 2007; Yang et al., 2011). 
Nonetheless, in many tumors DAB2IP is not mutated or silenced, and it is possible 
that cancer cells can develop alternative mechanisms to elude DAB2IP functions. 
 
Transcriptional regulation of DAB2IP gene 
The human DAB2IP gene is located on chromosome 9q33.1-q33.3 and spans 
approximately 86kb in the genome (Accession No.: AL365274). Two major 
transcripts have been identified at this locus: hDAB2IPa (NM_032552.2), a 5.2kb 
mRNA comprising 15 exons, and hDAB2IPb (NM_138709.1), a 3.5kb mRNA 
comprising 14 exons. They are generated by splicing of alternative first exons (1a or 
1b) to a common second exon and, hence, are transcribed from different promoters. In 
addition to these major isoforms, other splice variants may exist. Translation of 
hDAB2IPa starts at the end of exon 1, while that of hDAB2IPb starts within exon 2, 
generating different proteins (see below). 
There is a CpG island in the 5’ region of hDAB2IPa but not in that of hDAB2IPb. No 
TATA box is present within the 5’-upstream sequence of DAB2IP. Therefore, the 
TSS (transcriptional start site) can be heterogeneous. Broad TSS distributions 
(“dispersed” TSSs) are correlated with CpG islands and DAB2IP appears to be a 
typical gene with a TATA-less promoter. 
The gene appears to be expressed in most human tissues. Abundant DAB2IP mRNA 
levels were found in the brain, salivary gland, testis, kidney, lung, liver and in the 
heart. Organs such as seminal vesicle, ventral prostate, epididymis, and bladder 
express low levels of its transcript (Wang et al., 2002). As already mentioned, 
aberrant methylation of the DAB2IP promoter has been detected in many tumors 
(Table. 1) and cancer cell lines. Methylation of DAB2IP promoter is correlated to 
high frequency of lymph node metastasis, at least in breast and lung cancer (Dote et 
al., 2004; Yano et al., 2005). Similarly, in hepatocellular carcinoma (HCC) many 
clinico-pathologic features (i.e. tumor size, metastasis and portal vein tumor 
thrombosis) are correlated with DAB2IP expression, and low DAB2IP is a significant 
prognostic factor for poor survival in HCC patients (Zhang et al., 2011). 
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Table 1: DAB2IP promoter metylation frequencies in various types of tumor 
Tumor type Frequency  Notes References 
Prostate 37% – (Chen et al., 2005) 
Lung 36% associated to metastasis-poitive 
lymph nodes 
(Yano et al., 2005) 
Breast 38% associated to metastasis-poitive 
lymph nodes 
(Dote et al., 2004) 
Gastrointestinal 45% – (Dote et al., 2005) 
Endometrial 
carcinomas 
14,5% – (Liao et al., 2008) 
Bladder 
carcinomas 
48,1-72,7% Correlation of DAB2IP aberrant 
methylation with progression of 
cancer from a low to a high 
malignant potential 
(Kunze et al., 2006) 
HCC 
(hepatocellular 
carcinoma) 
80% No correlation between methylation 
status and lymph node spread 
(Qiu et al., 2007) 
 76,1% – (Calvisi et al., 2011) 
 
DNA methylation and histone deacetylation act cooperatively to silence DAB2IP. 
Treatment of cancer cell lines with TSA (an histone deacetylases inhibitor) or 5’Aza 
(an hypomethylation agent) significantly increased the steady-state levels of 
hDAB2IP (Chen et al., 2003). 
The mechanism of epigenetic silencing implicates the recruitment of different 
enzymes involved in histone modifications: these protein activities lead to histone H3 
lysine 9 methylation and lysine 27 trimethylation (H3K27me3). These modifications 
contribute to prevent promoter binding by transcription factors (Berger, 2007). 
The histone metyltransferase EZH2 (enhancer of zeste homolog), the catalytic subunit 
of Polycomb repressive complex-2 (PRC-2) is the major enzyme that methylates 
lysine 27 of histone H3, and is directly involved in the epigenetic down-regulation of 
DAB2IP (Chen et al., 2005; Simon and Lange, 2008). EZH2 is generally not 
expressed in adult tissue. However it is overexpressed in a broad range of 
hematopoietic and solid human malignancies, where its overabundance is often 
associated with poor prognosis (Kleer et al., 2003; Varambally et al., 2002). 
Emerging data indicate that EZH2 has a master function in controlling key signaling 
pathway involved in tumorigenesis (i.e. Wnt/β-catenin, RAS, Notch and AKT), 
through silencing of important regulatory components (Tsang and Cheng, 2011). 
One of the EZH2 regulated genes is DAB2IP, as verified by the presence of EZH2 
complex and HDAC at the level of DAB2IP promoter in prostatic cancer cell lines. 
Accordingly, an inverse correlation between EZH2 and DAB2IP expression was 
detected; increased EZH2 expression in normal prostatic cells could inhibit DAB2IP 
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expression, while EZH2 silencing restored DAB2IP levels in prostatic cancer cell 
lines (Chen et al., 2005). Finally, in mice experiments, EZH2-driven tumors showed 
invasive and metastatic capabilities similar to DAB2IP-deficient tumors; strikingly, 
the introduction of DAB2IP in EZH2 expressing cells suppressed tumor growth and 
prevented metastasis (Min et al., 2010). 
Despite the large amount of information about the epigenetic regulation of DAB2IP 
expression, very little is known about the transcription factors that co-ordinate 
DAB2IP expression in normal tissues. 
 In addition to transcriptional silencing, another step involved in mRNA 
regulation is RNA interference mediated by microRNA.  
DAB2IP can be a liable target for microRNA regulation, since its mRNA presents a 
long 3’UTR that is highly conserved among species. Moreover, DAB2IP can be 
considered a haploinsufficient gene, because just a reduction of DAB2IP levels can 
affect cellular behavior as happens in tumors in which its promoter is 
hypermethylated. 
In line with this speculation, a microRNA targeting DAB2IP was recently identified 
(miR-338) and shown to be able to reduce DAB2IP mRNA levels (Barik, 2008). miR-
338, is located within the eighth intron of the gene encoding apoptosis-associated 
tyrosine kinase (AATK), a protein essential for neuronal differentiation. This 
microRNA co-operates with AATK functions through the silencing of a family of 
mRNAs whose protein products are negative regulators of neuronal differentiation 
(Barik, 2008). The study did not address the role of DAB2IP in this scenario, and did 
not discuss the potential implications of miR-338 expression in tumors. 
 
DAB2IP protein 
The DAB2IP protein contains several domains and distinct regions involved in its 
functions (Figure 12):  
• Pleckstrin homology domain (PH domain) is a protein domain of 
approximately 120 amino acids that characterizes a wide range of proteins 
involved in intracellular signaling or as constituents of the cytoskeleton. The 
domain can bind phosphatidylinositol lipid within biological membranes (such 
as phosphatidylinositol (3,4,5)-triphosphate and phosphatidylinositol (4,5)-
bisphosphate), and proteins such as βγ-subunits of heterotrimeric G proteins, 
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and protein kinase C. Through these interactions, PH domains play a role in 
recruiting proteins to different membranes, thus targeting them to appropriate 
cellular compartments or enabling them to interact with other components of 
the signal transduction pathways (Ingley and Hemmings, 1994). 
• The C2 domain is a Ca2+-binding motif of approximately 130 residues in 
length originally identified in the Ca2+-dependent isoforms of protein kinase 
C. Single and multiple copies of C2 domains have been identified in a 
growing number of eukaryotic signaling proteins that interacts with cellular 
membranes and mediate a broad array of critical intracellular process, 
including membrane trafficking, the generation of lipid-second messengers, 
activation of GTPases and the control of phosphorylation. C2 domains have 
been shown to bind to phospholipid headgroups with a broader range of 
specificity than the PH domain. Finally, C2 domains mediate protein-protein 
interactions (Nalefski and Falke, 1996). 
• RasGAP homology domain is found in numerous proteins that transduce 
signals from plasma-membrane receptors and control cell adhesion, motility 
and shape. They act as molecular switches that stimulate the intrinsic GTPase 
activity of small G proteins. The RasGAP domain of DAB2IP shows a high 
degree of amino acid homology (40%-90%) to other RasGAPs (such as 
GAP120, NF1 or SynGAP) (Chen et al., 2002). 
• The PERIOD-like (PER) domain is involved in protein-protein interaction. 
• The Proline Rich (PR) domain in also implicated in the interaction with 
different partners, in particularly it constitutes a docking site for proteins with 
SH domains (Feller et al., 1994). 
• The leucine zipper domain. These hydrophobic motifs are usually found 
within the DNA-binding domain of transcription factors, but are also involved 
in protein dimerization. 
 
In man there are at least two isoforms of the DAB2IP protein, derived from the 
alternative transcripts described above. Up to now, only two DAB2IP variants have 
been characterized: hDAB2IPa (NP_115941), composed of 1132 amino acids with a 
molecular weight of approximately 130kDa, and hDAB2IPb (NP_619723), of 1065 
amino acids with a molecular weight of approximately 110kDa. While the central 
region is identical, the two isoforms present differences at the N- and C- terminus. 
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More specifically, hDAB2IPb has a shorter PH domain compared to hDAB2IPa, and 
is characterized by an alternative C-terminal sequence encoding a class-I PDZ 
interacting motif (Homayouni et al., 2003) that can mediate additional protin-protein 
interactions. 
Currently, nothing is known about the regulatory mechanisms and the biological 
specificity of these isoforms. Unpublished data (Sun-Kong, 2008) suggest that the 
longer PH-domain of hDAB2IPa might be important for cell cycle arrest and cell 
detachment. Nevertheless, most published works on DAB2IP were performed using 
the shorter hDAB2IPb isoform. 
Also very little is known about DAB2IP post-translational regulation. The only post-
translational modification characterized in DAB2IP is the phosphorylation of Ser-604 
by kinase RIP1, which is a necessary step for DAB2IP activation and re-localization 
from plasma membrane to the cytoplasm (see below) (Zhang et al., 2007). 
 
Biological activities of DAB2IP 
As already mentioned, DAB2IP interacts through its distinct domains with multiple 
partners, constituting a platform for formation of complexes involved in signal 
transduction, and representing a fundamental checkpoint to dampen oncogenic 
pathway activation (Fig. 11). 
 
Below are summarized the pathways that are regulated by DAB2IP. 
Figure 11. DAB2IP functional domains and interactome.  
Schematic representation of DAB2IP functional domains and the docking sytes of known DAB2IP 
interactors as described in the literature. (see the text for additional details). 
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Figure 12 Model of signaling pathways modulated by DAB2IP. 
 
DAB2IP and RAS: inhibition of cell proliferation and growth. 
As mentioned before, DAB2IP was initially identified as a DAB2 interactor. DAB2 
has been shown to modulate various signalling pathways, including the TGFβ, Wnt, 
JNK, Src pathways. Morover it has been demonstrated that DAB2, through binding to 
Grb2, reduces Ras pathway activation affecting cell proliferation in response to 
specific stimuli (Xu et al., 1998). DAB2IP is also able to interact with Grb2 through 
its PR domain (Wang et al., 2002), and it has been hypothesized that DAB2IP, DAB-
2 and Grb2 constitute a complex able to suppress Ras pathway activation in response 
to growth factors (such as EGF) or PKC activators (such as TPA); this complex may 
act through indirect mechanism like the inhibition of SOS, a guanine nucleotide 
exchange factor upstream of Ras, or through direct process involving DAB2IP 
RasGAP domain (Wang et al., 2002). 
Approximately 30% of human tumors express an oncogenic form of Ras genes (Ha-, 
K- and N-Ras), locked in the active conformation being insensitive to RasGAPs. 
Alternatively inactivation of Ras inhibitors such as in the case of DAB2IP has also 
been reported (Bernards and Settleman, 2005).  
DAB2IP is able to stimulate in-vitro and in-vivo GTPase activity of several RAS 
proteins (i.e. N-Ras, K-Ras and Ha-Ras) in prostatic and hepatocellualr cancer cell 
lines, and the GAP domain is necessary for this function: the single amino acid 
mutant DAB2IP R289L (a key amino acid within the GAP domain) loses the activity 
on Ras (Calvisi et al., 2011; Wang et al., 2002). 
These results have been recapitulated elegantly by the Cichowski group (Min et al., 
2010): they demonstrated that mouse injected with prostatic cancer cells expressing 
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H-RASV12 or depleted of DAB2IP develop tumors with similar kinetics and to a 
similar maximum size. Moreover, they showed that DAB2IP deficient cells 
reconstituted with wt DAB2IP significantly suppress tumor development, but cells 
reconstituted with DAB2IP R289L maintain tumorigenicity. Therefore, Ras-GAP 
activity is important for tumor suppression. Notably, tumors formed by cells 
expressing DAB2IP R289L did not disseminate, revealing another important function 
of DAB2IP, which is Ras-GAP independent, in preventing metastatsis (see below). 
 
DAB2IP and ASK1: induction of apoptosis in response to different stimuli. 
After the identification of DAB2IP as a DAB2 partner (Wang et al., 2002), another 
group identified DAB2IP as an ASK1 interactor and named it AIP1 (ASK1-
interacting protein 1) (Zhang et al., 2003). As described before, ASK1 (Apoptosis 
Signal-regulating Kinase 1) is a member of the MAPK kinase (MAP3K) family and is 
an upstream activator of JNK and p38 MAPK signaling cascades (Davis, 2000). 
ASK1 can be activated in response to diverse stress and apoptoic stimuli, including 
pro-inflammatory mediators such as TNF-α (Davis, 2000). As discussed earlier, TNF-
α can induce complex cellular responses ranging from cell proliferation, to 
inflammation, to cell death. These are essentially mediated by the activation of two 
distinct and functionally opposing pathways: NF-κB or JNK. Once activated, TNF-R1 
recruits TRAF-2 and RIP. This minimal complex can either recruit the IκB kinase 
complex (IKK) or ASK1, leading to activation of the NF-κB and JNK pathways, 
respectively.  
DAB2IP functions by specifying TRAF2 towards ASK1-JNK pathway activation, 
enforcing at different levels this signaling cascade. 
 
DAB2IP protein is supposed to be in a closed conformation in resting cells, through 
an intra-molecular interaction between its N-terminal and C-terminal regions, 
mediated by the PR domain (Zhang et al., 2004). It has been demonstrated that 
inactive DAB2IP localizes at the plasma membrane, possibly associated with inactive 
TNFR1 (Zhang et al., 2004). 
In response to TNF-α, DAB2IP dissociates from the inhibitory complex and opens its 
closed conformation. 
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Through the PER domain, DAB2IP interacts and sequesters TRAF2 from the NF-κB 
activating complex, allowing 
formation of a complex composed 
of TRADD, TRAF2, RIP1 and 
DAB2IP (the so called AIP1 
complex) in the cytoplasm (Zhang 
et al., 2004). 
RIP1 kinase associates with the 
GAP domain of DAB2IP 
mediating TNF-induced DAB2IP 
phosphorylation at Ser-604, 
creating a docking site for 14-3-3 
protein (Zhang et al., 2007). 
Mutation of DAB2IP at Ser-604 
(DAB2IP S604A) blocks TNF-
induced formation of the AIP1 
complex, as well as TNF-induced 
ASK1-JNK activation, suggesting 
that it plays a critical role in 
maintaining DAB2IP “opened” 
conformation (Zhang et al., 2007). 
DAB2IP subsequently recruits 
ASK1 through TRAF2 (Zhang et 
al., 2003). TRAF2 recruitment is 
necessary to allow association of 
DAB2IP with ASK1 through the 
C2 domain (Zhang et al., 2004). 
ASK1 is generally inhibited by 14-
3-3, a phosphoserine-binding 
molecule that binds to ASK1 
specifically recognizing 
phosphorylated Ser-967. The 
binding site of DAB2IP on ASK1 lies in a sequence surrounding the 14-3-3 binding 
site; it has been hypothesized that 14-3-3 protein has higher affinity for the 
Figure 13. A proposed model for DAB2IP as a 
transducer of TRAF2 in TNF-induced ASK1-JNK 
activation (see text for details) 
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phosphorylated Ser-604 of DAB2IP than phosphorylated Ser-967 of ASK1, and 
therefore may release the kinase and allow formation of a DAB2IP-ASK1 complex 
(Zhang et al., 2007). 
Moreover, DAB2IP binds through the GAP domain to the Ser/Thr phosphatase PP2A 
in resting and TNF-stimulated cells (Min et al., 2008). Therefore, DAB2IP functions 
as a scaffolding protein in TNF-induced recruitment of PP2A to ASK1, leading to 
dephosphorylation of Ser-967, and further activation of ASK1, that can finally trigger 
the JNK signaling pathway (Min et al., 2008). 
The DAB2IP-ASK1 complex is highly dynamic: it forms within 15 minutes after 
TNFα treatment, and after additional 15 minutes it is disassembled and DAB2IP re-
localizes at the plasma membrane (Zhang et al., 2004). 
This model, verified in endothelial cells, defines DAB2IP as the missing “direct 
target” of TRAF2 in the JNK pathway: DAB2IP specifically mediates TNF/TRAF2-
induced ASK1-JNK activation while inhibits IKK-NF-κB signaling (Zhang et al., 
2004), thus switching TNF-α from a cell growth to an apoptosis inducer. 
In addition to the response to TNF-α, the relevance of the DAB2IP-TRAF2-ASK1 
axis has been verified in different contexts. Proteins synthesized in the endoplasmatic 
reticulum (ER) are properly folded with the assistance of chaperones; accumulation of 
misfolded proteins in the ER triggers an adaptive stress response (Yoshida, 2007). 
One of the signaling pathways triggered by ER stress is mediated by IRE1 (inositol-
requiring enzyme-1), also known as ERN1 (endoplasmic reticulum to nucleus 
signaling 1), a kinase that stimulates expression of genes involved in protein 
degradation, but also stimulates pro-apoptotic JNK signaling through recruitment of 
the TRAF2-ASK1 complex. DAB2IP KO mice show impaired ER stress-induced 
IRE1 signaling in vivo (Luo et al., 2008), suggesting that DAB2IP is important for 
transducing the ER stress response. In fact, ER stress induces formation of a DAB2IP-
IRE1 complex, involving the PH domain. DAB2IP promotes the association between 
TRAF2 and IRE1 that in turn activates the ASK1-JNK cascade (Luo et al., 2008). 
 Recently, it has been reported that loss of DAB2IP expression in prostate cells 
contributes to their resistance to ionizing radiation (IR) (Kong et al., 2010). It has 
been demonstrated that an accelerated process of DNA DSB repair, a robust G2-M 
checkpoint, and a functional system to escape from apoptosis are the underlying 
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mechanisms. However, the molecular basis for the apparent role of DAB2IP in 
mediating cell sensitivity to IR are not known. 
The Min’s group demonstrated that TNF-α can trigger de-sumoylation of HIPK1 
(Homeodomain-interacting protein kinase 1) leading to its re-localization from the 
nucleus to the cytoplasm where, through the formation of a complex, synergizes with 
DAB2IP to induce the apoptotic pathway mediated by ASK1 (Li et al., 2008). 
HIPK1 is a kinase that leads to activation of apoptotic pathways upon genotoxic stress 
(Isono et al., 2006), and it is tempting to speculate that it might contribute to the 
recently reported DAB2IP functions in cells exposed to IR. 
 
DAB2IP and PI3K-AKT: coordination of cell survival and apoptosis 
The PI3-Kinase (PI3K) AKT signaling pathway plays a central role in modulating cell 
survival, proliferation and motility. This statement is supported by the evidence that 
in transformation, malignant cells develop different systems to over-activate this 
pathway (Vivanco and Sawyers, 2002). 
Members of class IA PI3Ks are heterodimers consisting of a 110kDa catalytic subunit 
(p110) and an 85kDa regulatory subunit (p85). Activation of PI3K occurs via the 
binding of p85 to phosphotyrosine proteins, which relieves the inhibitory effects of 
p85 on the p110, and then PI3K translocates from cytosol to plasma membrane. PI3K 
converts plasma membrane associated PI(4,5)P2 to PI(3,4,5)P3. PI(3,4,5)P3 and 
provides a phospholipid binding substrate for signaling effector molecules such a 
PDK1 (phosphatidylinositol-dependent kinase) and AKT. PDK1 or other kinases 
phosphorylate AKT on T308 and S473, triggering its ability to stimulate downstream 
oncogenic pathways. 
DAB2IP is able to cunteract this pathway, sequestering both PI3K and AKT. The PR 
domain of DAB2IP is a critical binding site for the SH3 domain of p85. Because 
DAB2IP is able to relocate from membrane to cytosol in response to different stimuli 
(e.g. TNF-α), formation of DAB2IP-p85-p110 complex may prevent the translocation 
to the membrane necessary for PI3K activation (Xie et al., 2009). Moreover, activated 
phspho-Ser-604 DAB2IP physically interacts with AKT1 through the PER domain, 
reinforcing its inhibitory effects in this pathway (Xie et al., 2009). 
DAB2IP-mediated binding and inhibition of PI3K-AKT also contributes indirectly to 
ASK1 activation, by preventing the inhibitory phsphorylation of ASK1 by AKT (Xie 
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et al., 2009). In a positive feedback loop, ASK1 increases phosphorylation of 
DAB2IP, a modification that significantly enhances its binding to AKT and PI3K 
(Xie et al., 2009). Therefore DAB2IP functions as a platform to modulate various 
signals by recruiting PI3K, AKT and ASK1 proteins via individual binding domains, 
and may control the balance between cell survival and apoptosis. 
 
DAB2IP and VEGF: controlling angiogenic programs 
Angiogenesis, the formation of new blood vessels, is an integral part of both normal 
developmental processes and numerous pathologies, ranging from tumor growth and 
metastasis to inflammation and ocular disease (Carmeliet, 2003). The VEGFs and 
their receptors are critical in regulating vessel formation in physiological and 
pathological processes (Ferrara et al., 2003). VEGF plays a major role in angiogenesis 
by inducing the proliferation of vascular endothelial cells, the production of 
proteolytic enzymes necessary for angiogenesis, and by increasing vascular 
permeability. A higher concentration of serum VEGF correlates with a poorer 
prognosis in cancer patients (Weidner et al., 1991). 
VEGF primarily utilizes its receptor VEGFR2 to induce angiogenic responses, by 
activating multiple signaling cascades, including PI3K-AKT, PLCγ-PKC, and MAPK 
(Ferrara et al., 2003). 
DAB2IP KO mice exhibit dramatically enhanced ischemia and inflammatory 
angiogenesis in several in vivo models (Zhang et al., 2008). Furthermore, VEGF-
induced neo-vascularization is greatly augmented in KO mice. In in vitro experiments 
using endothelial cells, overexpression of DAB2IP inhibits VEGF-induced migration 
and tube-formation, while knockdown enhances them (Zhang et al., 2008). From a 
biochemical point of view, it has been demonstrated that DAB2IP is recruited to the 
VEGFR2-PI3K complex at a late phase of VEGF response. DAB2IP via its C2 
domain associates with VEGFR2 while via its PR domain binds to PI3K leading to an 
inhibition of VEGFR2-mediated angiogenic signaling (Zhang et al., 2008). 
 
DAB2IP and the epithelial mesenchimal transition (EMT) 
Ephitelial-to-mesenchymal transition (EMT) is a highly conserved cellular process 
that allows the polarized and immotile epithelial cells to convert to motile 
mesenchymal cells. This process was initially recognized in embryonic development 
but was soon discovered to be very important in cancer (Thiery et al., 2009). EMT 
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endows cells with migratory and invasive properties, induces stem cell properties, and 
prevents apoptosis and senescence, thus orchestrating the initiation of metastasis 
(Grunert et al., 2003). Loss of ephitelial markers (E-cadherin, β-catenin) and gain of 
mesenchymal markers (N-cadherin, vimentin) are signature biochemical features 
associated with EMT. 
Recently DAB2IP levels have been correlated with EMT in a model of tumor 
progression of a prostate cell line (Marian et al., 2011); in particular, it has been 
noticed that in this EMT process, beside E-cadherin down-regulation, there is also a 
reduction of DAB2IP levels. Moreover loss of DAB2IP and E-cadherin as well as 
increased vimentin were clearly detected in tissues from prostate-cancer patients (Xie 
et al., 2010). 
A high heterogeneity of signals can regulate EMT in physiological and malignant 
conditions (Zhang et al., 2004); among them, a pivotal role is exerted by the PI3K-
Akt, NF-κB, and Wnt/βcatenin pathways. DAB2IP is able to counteract the activation 
of all those pathways, underscoring its potential role in negatively regulating EMT 
process. 
In particular, as already discussed, DAB2IP is able to funnel the TNF-α signaling 
cascade towards activation of the ASK1-JNK pathway by recruiting TRADD, TRAF2 
and RIP1 in a signaling complex; this activity interferes with formation of the IKK 
activating complex, and therefore inhibits NF-κB activation (Zhang et al., 2004). This 
may have relevant implications in the control of EMT. In fact, NF-κB mediates TNF-
α induced cell migration and metastasis by upregulating matrix metalloproteases and 
EMT-related proteins such as SNAIL (Wu and Zhou, 2010). 
The inhibitory role of DAB2IP on the NF-κB pathway was confirmed in-vivo in mice 
injected with prostatic cancer cells (Min et al., 2010). As already mentioned, prostatic 
cancer cells lacking DAB2IP formed tumors once injected in mice with the same 
frequency and efficiency as cells expressing H-RasV12. However, Ras-driven tumors 
remained noninvasive and never disseminated, while DAB2IP–deficient tumors were 
invasive and highly metastatic. Reconstitution of these cells with DAB2IP mutant 
R289L did not suppress primary tumor formation (indicating that RasGAP activity is 
essential for DAD2IP tumor suppressive function), but drastically suppressed 
metastasis formation. In contrast, reconstitution with DAB2IP mutant S604A, 
proficient for GAP activity but impaired for TRAF2 binding, reduced tumor 
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formation but did not suppress invasion and metastasis (Min et al., 2010). Additional 
experiments confirmed that this residue of DAB2IP is fundamental to suppress NF-
κB pathway, thus controlling invasion and EMT. 
DAB2IP involvement in EMT has been verified also in DAB2IP KO mice (Xie et al., 
2010): the prostate glandular epithelia in KO mice exhibit decreased E-cadherin, 
elevated vimentin expression, and strong nuclear β-catenin staining with respect to wt 
mice. β-catenin, acting as a membrane-associated structural protein, helps to link 
adhesion proteins such as E-cadherin to the actin cytoskeleton of the cells. Release of 
β-catenin from junctional E-cadherin not only disrupts intracellular adhesion, but may 
also play a role in activating transcriptional programs involved in EMT. The 
regulation of free β-catenin and its nuclear shuttling is primarily controlled by 
GSK3β, a ser/thr kinase that phosphorylates free β-catenin to target it for poly-
ubiquitination and proteosomal degradation. Activation of the WNT signaling 
pathway leads to phosphorylation of GSK3β on Ser9, causing inactivation of this 
kinase and accumulation of β-catenin. 
DAB2IP was recently shown to function as a scaffolding protein in modulating 
WNT/β-catenin signaling in EMT (Xie et al., 2010). In fact, DAB2IP interacts via its 
C2 domain with both PP2A and GSK3β, facilitating GSK3β activation through Ser9 
dephosphorylation. As a consequence, it decreases nuclear β-catenin accumulation 
and transcriptional activity (Xie et al., 2010). Moreover, as already discussed, 
DAB2IP inhibits activation of AKT, one of the kinases involved in GSK3β Ser9 
inhibitory phosphorylation (Oloumi et al., 2004). GSK3β also negatively controls 
stability of the transcription factor SNAIL (Yook et al., 2005), another important 
mediator of EMT. Thus, affecting GSK3β activation at multiple levels, DAB2IP may 
inhibit both β-catenin and Snail activities. 
From this complex picture it emerges that DAB2IP, by dampening the activation of 
multiple distinct oncogenic pathways, is a key negative modulator of EMT, and hence 
metastasis. 
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PART 1: A genome-scale protein interaction profile of 
Drosophila p53 uncovers additional nodes of the human p53 
network 
 
 
AIM OF THE PROJECT 
 
The tumor suppressor p53 has a crucial role in maintaining genome integrity and 
coordinating genoprotective responses to insults to which cells are constantly exposed 
(Levine and Oren, 2009; Muller et al., 2001). This is demonstrated indirectly by the 
high frequency of p53 mutations in human cancers (IARC TP53 Database), and 
directly by the observation that genetically engineered mice lacking p53 invariably 
die of cancer at young age (Donehower et al., 1992). 
Many years of research have now clearly shown that the biology of p53 is very 
complex and p53 is a highly connected protein, interfacing with a number of different 
pathways (Collavin et al., 2010). Another grade of complexity in the study of human 
p53 pathway is linked to the presence of two p53-related genes: p63 and p73 (Mills et 
al., 1999; Yang and McKeon, 2000; Yang et al., 1999). Interestingly, p63 and p73 are 
structurally similar and functionally related to p53, and hence the entire p53 family 
may be regarded as a unique signaling network controlling cell proliferation, 
differentiation, and death (Collavin et al., 2010). Therefore, a complete and thorough 
understanding of the signaling circuitry that regulates p53 family function is a 
primary objective for basic cancer research, since it may lead to development of 
important tools for diagnosis and therapy of human tumors. One crucial component of 
such knowledge is the protein interaction profile of p53 family. 
Drosophila melanogaster is a valued model for many aspects of human biology. 
Interestingly, Drosophila has a single p53 gene (Dmp53), which is more similar in 
sequence to mammalian p63, but shows considerable functional equivalence with 
p53. In fact Dmp53 has genoprotective activity, responds to DNA-damage signals, 
and triggers apoptosis (Mills, 2005; Sutcliffe and Brehm, 2004). In view of these 
considerations, the single p53 gene of Drosophila may be viewed as a “living 
ancestor” of the entire p53 family in vertebrates. 
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The aim of this project was to identify novel p53-interacting proteins in Drosophila by 
using an unbiased large-scale in vitro pull-down approach. Based on the hypothesis 
that functionally relevant connections are conserved during evolution, the results of 
such a screening provided a reference to isolate and characterize the mammalian 
orthologs of novel Dmp53 interactors. 
In addition, the use Drosophila p53 offered an additional advantage: the relatively 
small size of the Drosophila transcriptome, and the availability of a Unigene 
collection of about 12,000 non-redundant full-length cDNAs (the Drosophila Gene 
Collection, DGC) (Rubin et al., 2000), made it possible to screen a large portion of 
the entire proteome of this organism. 
The rationale behind this project was that mapping the protein-interaction profile of 
p53 in the Drosophila system would return novel insights on the protein-interaction 
profile of p53 and p53-related proteins in the human system, with fundamental 
implications on our understanding of the molecular circuitry regulating their 
functions. 
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The genomeof the fruitﬂyDrosophilamelanogaster contains a single
p53-like protein, phylogenetically related to theancestor of themam-
malian p53 family of tumor suppressors. We reasoned that a compre-
hensive map of the protein interaction proﬁle of Drosophila p53
(Dmp53) might help identify conserved interactions of the entire
p53 family in man. Using a genome-scale in vitro expression cloning
approach,we identiﬁed 91previously unreportedDmp53 interactors,
considerably expanding the current Drosophila p53 interactome.
Looking for evolutionary conservation of these interactions, we
tested 41 mammalian orthologs and found that 37 bound to one or
more p53-family members when overexpressed in human cells. An
RNAi-based functional assay for modulation of the p53 pathway
returnedﬁvepositivehits, validating thebiological relevanceof these
interactions. One p53 interactor is GTPBP4, a nucleolar protein in-
volved in 60S ribosome biogenesis. We demonstrate that GTPBP4
knockdown induces p53 accumulation and activation in the absence
ofnucleolardisruption. Inbreast tumorswithwild-typep53, increased
expression of GTPBP4 correlates with reduced patient survival,
emphasizing a potential relevance of this regulatory axis in cancer.
in vitro expression cloning | p73 | p63 | NOG1
The p53 tumor suppressor is a transcription factor capable ofsensing a wide range of stress signals and coordinating a
complex response that leads to cell-cycle arrest, DNA repair,
apoptosis, or senescence (1). In line with this crucial activity,
development of most tumors is associated with p53 mutation (2).
Because p53 activation and function involve a complex repertoire
of posttranslational modiﬁcations and protein interactions (3–5),
identiﬁcation of p53 regulators is essential to understand cellular
transformation and to identify potential drug targets for cancer
therapy. When considering the p53 pathway in mammals, it is
necessary to take into account two additional p53-related genes,
p63 and p73, that have essential functions in embryonic develop-
ment and differentiation (6, 7). Despite functional differences, all
p53-family proteins play a role in genome protection and share the
tumor-suppressive activity of p53 to some extent (8–10). Thus, the
entire p53 family forms a complex network, whose intricacy is
ampliﬁed by the fact that p53-related proteins are expressed in
multiple functionally nonredundant isoforms (7, 11). Interestingly,
there is a single p53-like gene in Drosophila as well as in other
arthropods, nematodes, and mollusks (6, 12). By sequence align-
ment, invertebrate p53 is more similar to p63 than to p53 or p73.
However, the single p53 in Drosophila melanogaster (Dmp53) is
dispensable for normal development but fundamental for DNA
damage-induced apoptosis (13, 14), in this respect being more
similar to p53 than to p63 or p73.Although phylogenesis of the p53
family remains controversial, recent evidence conﬁrmed that
Dmp53 incorporates functions of multiple p53 family members
(15). Thus, studying the single p53 in an invertebrate bears the
potential to illuminate core properties of the network, helping us
to better understand the functions of allmembers of the p53 family
in mammals.
Results
Small Pool in Vitro Expression Cloning (IVEC) Screen for Drosophila
p53 Interactors. TheDrosophilaGeneCollection (DGC) comprises
full-length annotated cDNAs of the majority of known genes in
D. melanogaster (16). Clones from DGC1.0 and DGC2.0 were pu-
riﬁed and pooled in groups of 24. Recombinant maltose binding
protein (MBP)-Dmp53 fusion protein was prepared from Bacu-
lovirus-infected insect cells and used as bait for in vitro pull-down
experiments with DGC pools (Fig. 1). We screened a total of 8,029
nonredundant cDNAs and identiﬁed 94 proteins that bound to
MBP-Dmp53 in vitro (Fig. S1 and Table S1). At the end of the
procedure, each positive hit had been repeatedly scored as Dmp53
interactant in a minimum of four independent pull-downs. One of
the identiﬁed proteins was Dmp53 itself. Another clone was a
putative transposon-encoded reverse transcriptase, not considered
here. The remaining 92 interactors are referred to as in vitro
Dmp53 interactors (IVDI). Their distribution in broad functional
categories is summarized in Fig. 1C. The IVDI dataset containsﬁve
Drosophila orthologs of mammalian p53 interactors (interologs),
providing proof of principle for functionality of this approach (Fig.
1D). We estimate that at least 64 additional p53 interologs were
present in the screened population; these are either false negatives
or proteins that do not interact with p53 in Drosophila.
The IVDI dataset was compared to known Dmp53 interactors
described in the literature and protein–protein interaction data-
bases. This list was named literature-curated Dmp53 interactors
(LCDI) and comprises 48 proteins (Table S2). Notably, only one
protein is common to IVDI and LCDI datasets. General features
of in vitro Dmp53 interactors were determined by comparing the
IVDI and LCDI datasets using GeneOntology (GO) annotations.
Whereas previous screens identiﬁed principally DNA binding and
nuclear proteins, the IVEC screen enriched for RNA binding and
cytoplasmic proteins (Fig. 1E). Interestingly, nine in vitro Dmp53
interactors are mitochondrial proteins. Enrichment analysis for
GO terms and phenotypes revealed signiﬁcant overrepresentation
of genes associated with gametogenesis, in particular of the female
germ line (Table S3).
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Evolutionary Conservation of Dmp53 Interactions. Of 92 identiﬁed
Dmp53 interactors, 60 have an ortholog in Homo sapiens (Table
S4).Wecollected epitope-tagged expression constructs for 41 such
orthologs. Plasmids were transfected in human cells, and expres-
sion of encoded proteins was conﬁrmed by immuoﬂuorescence,
revealing a variety of intracellular localizations (Fig. S2). To test
interaction with human p53, TAp63α, and TAp73α, we performed
coafﬁnity puriﬁcation (co-AP) assays in 293T cells (Fig. 2 and Fig.
S3). Using this assay, 37 of 41 proteins bound to one or more p53-
family members. Nineteen mammalian orthologs bound to all
baits, whereas the remaining 18 interactors displayed varying
degrees of speciﬁcity. All but one interacted with p73, whereas the
nucleolar protein GTPBP4 bound selectively to p53.
Functional Validation. To evaluate the functional relevance of new
potential interactions, we focused on p53. Human HCT116 colon
cancer cells bearingwild-typep53 (HCT116WT)were treatedwith
Nutlin-3, a drug that prevents p53 degradation byMdm-2, and cell
viability was measured using WST-1 colorimetric assay. Under
these conditions, Nutlin-3 induces a dose-dependent decrease in
WST signal, indicative of growth arrest (Fig. 3). The same setup
was used to analyze p53-dependent responses to DNA-damaging
drugs (Fig. S4). siRNApools targeting each of the 24 newpotential
p53-binding proteins were transfected and assayed in this cellular
model. The p53 dependency of any effects was veriﬁed in HCT116
p53−/− cells.
As shown in Fig. 3, silencing of MYL9, DAB2IP, or ASPM
resulted in more efﬁcient growth arrest, suggesting they may be
negative p53 modulators; silencing of GTPBP4 or SPSB1 resulted
in less efﬁcient growth arrest, suggesting they may be positive p53
modulators or downstream effectors. However, additional ex-
periments revealed that GTPBP4 behaves in fact as a negative p53
modulator (see below). Expression levels of these genes, and
efﬁciency of siRNA-mediated knockdown, were veriﬁed by RT-
qPCR (Fig. S4). Physical interaction of these proteins with p53was
conﬁrmed by coimmunoprecipitation (Figs. 3H and 4 A and B).
The functionally validated p53 interactors are unrelated pro-
teins. Abnormal spindle-like primary microcephaly (ASPM) is the
human ortholog of the Drosophila gene abnormal spindle. ASPM
is essential for mitotic spindle function in embryonic neuroblasts,
being required for proliferative division of neuroepithelial cells
during brain development (17). In humans, ASPM mutation is
associated with primary autosomal microcephaly (18). MYL9 is a
myosin light chain that localizes to the contractile ring in mitosis,
and to stress ﬁbers in interphase, thus controlling cytokinesis and
motility (19). Disabled 2 interactive protein (DAB2IP), also
known as ASK-interacting protein 1 (AIP1), mediates TNF-
induced activation of ASK1-JNK signaling pathways (20, 21).
Interestingly, DAB2IP is methylated in a variety of tumors (22).
SPSB1 belongs to a family of proteins with a central SPRY
(repeats in splA and RyR) domain and a C-terminal suppressor of
cytokine signaling (SOCS) box, whose molecular function is elu-
sive (23). Drosophila SPSB1, gustavus, is required for posterior
localization of polarity determinants in developing oocytes (24).
GTPBP4 is the human ortholog of yeast Nog1, a monomeric
GTPase that plays a crucial role in 60S ribosome biogenesis (25–
27). GTPBP4 is the only p53 interactor that does not bind p63 or
p73, so we further explored its relationship with p53.
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Fig. 1. Small-pool IVEC screen forDrosophila p53 interactors. (A) Schematic diagramof the small-poolDrosophila IVECapproachused to identifyDmp53binding
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Evidence of a Functional Link Between GTPBP4 and p53. Interaction
between GTPBP4 and p53 was conﬁrmed in various conditions.
EndogenousGTPBP4was copuriﬁedwithMBP-p53 in transfected
U2OS cells (Fig. 4A), and endogenous GTPBP4 was coimmuno-
precipitated with endogenous p53 from HCT116WT cells treated
with Nutlin-3 (Fig. 4B). Using puriﬁed proteins, we found that
GTPBP4 can bind to p53 in vitro (Fig. S5). To evaluate a possible
role in cancer,we analyzedpublic datasets to determine ifGTPBP4
might have predictive value in terms of survival. Using Cox uni-
variate analysis, we found that increased GTPBP4 expression
correlateswith reducedpatient survival in three large breast cancer
datasets: NKI (P = 0.00025), Pawitan (P = 0.00024), and Miller
(P=0.0015) (28–30). In theMiller study, where the status of p53 is
known for each sample, we found that GTPBP4 levels correlate
negatively with survival in tumors with wild-type p53 (Fig. 4C).
To deﬁne the functional link between GTPBP4 and p53, we
analyzed the cell cycle proﬁle of cells transfected with GTPBP4
siRNA, before and after drug treatment. As shown in Fig. 4,
depletionofGTPBP4 inhibited cell proliferation, causingamarked
p53-dependent reduction in the S-phase fraction. This result
apparently contradicts WST experiments indicating a less efﬁcient
arrest of GTPBP4 knockdown cells (see Fig. 3B), but can be
explained considering that cells depleted ofGTPBP4 tend to arrest
in the absence of drug treatment. Under these conditions, p53
activation does not induce a signiﬁcant further drop in cell pro-
liferation. This phenomenon is speciﬁc for GTPBP4, because
FACS analysis was consistent with WST results for all other func-
tional hits (Fig. S4). Immunoblotting revealed that silencing of
GTPBP4 induces amarked increase in p53 levels andaccumulation
of the p53 target p21Waf1 (Fig. 4F). GTPBP4 depletion caused
p53 accumulation in other cell lines, so this effect is not cell-context
speciﬁc (Fig. S5). To test if p53 is also transcriptionally active, we
analyzed selected p53-target genes by RT-qPCR, revealing in-
creased mRNA levels of p21, Hdm2, and Puma (Fig. 4G).
Because nucleolar stress induces p53 stabilization and activation
(31, 32), we asked if GTPBP4 knockdown might cause nucleolar
dysfunction. We used RT-qPCR to analyze transcription of rRNA
and found no signiﬁcant alterations in pre-rRNA levels (Fig. 4I).
We used immunoﬂuorescence to study nucleolar markers; local-
ization of Nucleolin and UBF (Fig. 4H), as well as B23/Nucleo-
phosmin and Fibrillarin (Fig. S5), was not affected. On the
contrary, treatment with actinomycin D altered localization of all
markers analyzed, including GTPBP4 (Fig. 4H). These data indi-
cate that GTPBP4 knockdown does not disrupt nucleolar struc-
ture. However, ribosomal stress can cause p53 stabilization in
the absence of evident nucleolar alteration (33). We therefore
measured p53 half-life after GTPBP4 knockdown in HCT116WT
cells; notably, no stabilization was detected (Fig. S5). Moreover,
GTPBP4 depletion did not impair p53 accumulation after DNA
damage (Fig. S5), conﬁrming that p53 can still be stabilized in
response to speciﬁc signals. Together, these data indicate that tran-
sient GTPBP4 knockdown does not disrupt nucleolar structure or
function, suggesting a more direct effect in regulating p53 levels.
Discussion
Taking advantage of the small size of the ﬂy proteome, we studied
the protein interaction proﬁle of Drosophila p53 by IVEC. This
approach identiﬁed many potential interactions that had escaped
detection in previous studies, including high-throughput whole-
genome yeast-two-hybrid screens (34, 35). This result suggests that
current protein interaction databases are probably far from satu-
ration and that exhaustive protein interaction maps can be gen-
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Fig. 2. Binding of human orthologs of Dmp53 interactors to p53 and p53-
related proteins. (A) Seven representative co-AP experiments. Shown are
examples of preys that interacted with all three p53-family proteins
(TRMT11), preys that bound to selected members of the p53 family (ASF1A,
GAS8, GTPBP4, and C22orf28), and preys that were scored as not interacting
(LHX2 and SART1). (Top) Tagged prey proteins after coafﬁnity puriﬁcation.
(Middle) Expression of prey in total lysates (1/40th of the input). (Bottom)
MBP-tagged baits after afﬁnity puriﬁcation. The Top and Middle are crop-
ped from the sameautoradiography (i.e., have the same exposure). (B) Table
summarizing the results of co-AP assays for 41 mammalian orthologs of
Dmp53 interacting proteins. Expression plasmids encoding the indicated
tagged proteins were cotransfected with pcDNA3-MBP, pcDNA3-MBP-p53,
pcDNA3-MBP-TAp63α, or pcDNA3-MBP-TAp73α in 293T cells. MBP fusion
proteins (baits) were puriﬁed on amylose beads, and copuriﬁed proteins
were detected by immunoblotting. Strength of interaction was scored
according to the fraction of the input prey protein that copuriﬁedwithMBP
baits. (C ) Venn diagrams summarizing protein interactions associated with
p53 family members in mammals. The results of this study are compared to
current data available in protein–protein interaction databases (BioGrid
release 2.0.45).
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erated only by combining multiple experimental approaches. GO
term analysis of the in vitro Dmp53 interactome revealed enrich-
ment of genes involved in gametogenesis. Because p53mutant ﬂies
accumulate an aberrant number of primordial germcells ectopic to
the gonads (36), and p53 and p63 are involved in genoprotective
apoptotic responses during mammalian gametogenesis (9, 37, 38),
novel interactors may help dissect this functional role of the p53
family. Another notable feature of the in vitroDmp53 interactome
is the high representation of cytoplasmic and mitochondrial pro-
teins.Mammalianp53has an important transcription-independent
function at mitochondria (39, 40); our results suggest that this
function may be evolutionarily ancient, and we shall look for
mitochondrial activities of all p53 family paralogs.
We tested binding of mammalian orthologs of Dmp53 inter-
actors to p53, p63, and p73. Notably, 90% bound to one or more
p53-family members in coafﬁnity puriﬁcation experiments, sug-
gesting that these interactions are evolutionarily conserved.
Surprisingly, most orthologs of in vitro Dmp53 interactors bound
efﬁciently to TAp73α. If conﬁrmed, these data may have pro-
vocative implications for p53 phylogenesis (6, 12, 15).
We functionally validated potential p53 interactors using RNAi.
Of ﬁve genes whose knockdown affected the p53 response, we
focusedon thenucleolarproteinGTPBP4.We found thatGTPBP4
knockdown induces accumulation of p53, resulting in reduced cell
proliferation. Because GTPBP4/Nog1 is essential for biogenesis of
the 60S ribosomal subunit (25–27), we cannot exclude that p53
accumulation after GTPBP4 siRNA is the indirect consequence of
a defect in ribosome biogenesis triggering a stress pathway (31, 41,
42). However, we provide evidence that nucleolar structure and
function are not altered by GTPBP4 depletion, at least in the time
frame of our experiments. Importantly, we ﬁnd that p53 half-life is
not increased in these cells, thus indirectly excluding ribosomal
stress pathways that act via inhibition of Mdm2 (31, 41, 42). A
mechanistic understanding of how p53 is activated by GTPBP4
depletion will require signiﬁcant additional work, but may have
relevant implications; in fact, in line with the observation that high
GTPBP4 expression correlates with reduced survival in breast
tumors, increased levels of GTPBP4 might contribute to dampen
p53 activities in cancer cells.
In conclusion, starting from an in vitro interaction screen with
Drosophila proteins, we uncovered an evolutionarily conserved
p53 interactor that might be relevant in cancer. This result
supports the potential impact of our approach. Despite the large
amount of available knowledge, we still lack an organic model of
how the p53 network responds to speciﬁc signals in diverse cel-
lular contexts, how p53-family proteins are ﬁne tuned to achieve
a wide spectrum of cellular responses, and how these are func-
tionally integrated with other signaling pathways. Given the
emerging importance of all p53 family members in tumor sup-
pression, our list of evolutionarily conserved potential interactors
may constitute a valuable platform to gain additional insights
into the mammalian p53 network.
Methods
Plasmids. Many expression vectors for mammalian orthologs of Dmp53 inter-
actorswerekindlyprovidedbyother investigators.Alternatively, full-lengthESTs
were purchased from I.M.A.G.E. clone distributors; the coding regions were
ampliﬁedbyPCRandclonedinframewiththeHAtaginamodiﬁedversionofthe
pCS2 expression vector. More detailed information on plasmids and primers is
available upon request.
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Fig. 3. Functional validation of p53 interactors by RNAi. (A) Schematic dia-
gram of the experimental procedure. p53-dependent growth inhibition was
assayed after knockdownof newly identiﬁedpotential p53 interactants. After
siRNA transfection, cells were trypsinized and counted, and identical numbers
of cells were seeded in 96-well plates. Drugswere added 12 h later, andWST-1
activity was measured after an additional 48 h. (B) Transient knockdown of
ﬁveputative p53 interactors affects the response ofHCT116WT cells toNutlin-
3. To control p53dependency, the same experimentwas done inHCT116 p53−/
− cells (*, P< 0.05; **, P< 0.01; n = 3). (C–G) Cellular localization of functionally
validated p53 interactors. C shows localization of endogenous ASPM in a
mitotic U2OS cell, with Hoechst counterstaining formetaphase chromosomes.
D–G show immunoﬂuorescence of the indicated HA-tagged proteins tran-
siently transfected in U2OS cells. (H) Coimmunoprecipitation of p53 with four
functionally validated interactors. Expression plasmids encoding the indicated
proteins were cotransfected in p53-null H1299 cells. After cell lysis, tagged
proteins were immunoprecipitated using antibodies cross-linked to protein G
beads and analyzed by immunoblotting. Expression of transfected proteins in
the lysate (1/40th of the input) is shown in the Lower part.
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Antibodies, Immunoblotting, and Immunoﬂuorescence. For immunoblotting
experiments,HCT116cellswere lysed inRIPAbuffer [150mMNaCl, 50mMTris·HCl
(pH8), 1 mM EDTA, 1% Nonidet P-40, 0.5% Na-deoxycholate] with proteases
inhibitors. Protein concentration was measured by Bradford assay (Bio-Rad).
Lysates were resolved by SDS/PAGE and transferred to nitrocellulose (Millipore).
Antibodies were detected by chemiluminescence (ECL; GE Healthcare). For
immunoﬂuorescence, cells were ﬁxed 24 h posttransfection in 4% parafor-
maldehyde at room temperature, and permeabilized in PBS plus 0.1% Triton
X-100. Proteins were visualized directly for GFP-tagged clones or using speciﬁc
antibodies. Images were captured using a Leica DM4000B epiﬂuorescence
microscope. Antibodies used are mouse anti-Flag (M2; Sigma), mouse anti-Myc
(9E10), mouse anti-HA (12CA5), mouse anti-HSP90 (Santa Cruz), mouse anti-p53
(DO-1; Santa Cruz), mouse anti-p21 (Santa Cruz), mouse anti-UBF1 (F-9; Santa
Cruz), mouse anti-Nucleolin (Zymed), goat anti-GST (GE Healthcare), rabbit anti-
GFP (self-produced), rabbit anti-MBP (self-produced), and rabbit anti-GTPBP4
(Proteintech).
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Fig. 4. Evidence of a functional link between the nucleolar protein GTPBP4 and p53. (A) Exogenous p53 binds endogenous GTPBP4. Coafﬁnity puriﬁ-
cation of GTPBP4 with overexpressed MBP-p53 in U2OS cells is shown. (Top) Endogenous GTPBP4 after coafﬁnity puriﬁcation. (Middle) Expression of
GTPBP4 in total lysates (1/40th of the input). (Bottom) MBP and MBP-p53 proteins after afﬁnity puriﬁcation. (B) Interaction between endogenous GTPBP4
and p53. Coimmunoprecipitation is shown of GTPBP4 with p53 in HCT116 WT cells untreated or treated for 12 h with 5 μM Nutlin-3. (Upper) Proteins
immunoprecipitated using the anti-p53 monoclonal antibody (DO-1). (Lower) Endogenous p53 and GTPBP4 proteins in the lysates (1/40th of the input). As
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analysis is shown of HCT116 WT and HCT116 p53−/− cells transfected with control or GTPBP4 siRNA. (E ) Knockdown of GTPBP4 reduces S-phase in cells
bearing p53. Average S-phase fraction is shown of HCT116 WT and HCT116 p53−/− cells transfected with control or GTPBP4 siRNA and treated for 24 h
with 5 μM Nutlin-3 or 0.05 μM Doxorubicin. Values are means ± SD (n = 3). (F ) Knockdown of GTPBP4 induces accumulation of p53 and p21 proteins.
Immunoblotting is shown of HCT116 WT cells transfected with control or GTPBP4 siRNA and left untreated (NT) or treated for 24 h with Nutlin-3 (5 μM) or
Doxorubicin (0.05 μM). A speciﬁc antibody to GTPBP4 conﬁrmed efﬁcient knockdown of the endogenous protein. Hsp90 was detected in the same lysates
as a loading control. (G) Knockdown of GTPBP4 promotes transcription of p53-target genes. RT-qPCR shows up-regulation of p53-target genes in HCT116
WT cells transfected for 48 h with GTPBP4 siRNA. mRNA expression is normalized to GAPDH. Analysis of GTPBP4 mRNA in the same samples conﬁrms the
efﬁciency of knockdown (*, P < 0.05; n = 3). (H) GTPBP4 knockdown does not affect localization of key nucleolar proteins. Immunoﬂuorescence analysis is
shown of GTPBP4, Nucleolin, and UBF in U2OS cells transfected for 48 h with either control or GTPBP4 siRNA. The same proteins were analyzed in U2OS
cells treated with 5 nM Actinomycin D for 12 h. Nuclei are counterstained with Hoechst. (I) GTPBP4 knockdown does not affect rRNA transcription. HCT116
WT cells were transfected with control or GTPBP4 siRNA, and prerRNA levels were quantiﬁed by RT-qPCR after 48 h, using primers speciﬁc for the 5′
external transcribed spacer of pre-rRNA and normalizing for GAPDH. Values are means ± SD.
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Coafﬁnity Puriﬁcations. Co-AP experiments were performed as described (43),
withminor changes. Plasmidswere transfected in human 293T cells. Forty-eight
hours after transfection cells were lysed in coafﬁnity puriﬁcation buffer [50mM
Tris·HCl (pH 8), 150 mM NaCl, 1 mM EDTA (pH 8), 1 mM DTT, 5% glycerol, pro-
tease inhibitors (Sigma), 1mMPMSF, 5mMNaF, 1mMbeta-glycerolphosphate]
for 30min on ice and cleared by centrifugation for 30min at 13,000 × g at 4 °C,
and protein complexes were collected on amylose beads. After extensive
washes, puriﬁed complexes were separated by SDS/PAGE, detected by immu-
noblotting, and visualized by ECL. Puriﬁed MBP baits were visualized by DAB
staining (Sigma).
Cell Viability and Proliferation Assays. Acustomlibrary containingthree siRNAs
(Ambion Silencer) for each p53 interactor was purchased from Applied Bio-
systems. For viability assays, HCT116 colon cancer cells were plated at low
density in six-well plates. Thirty-six hours postseeding, cells were transfected
withsiRNApools (60nM)usingRNAiMAXreagent (Invitrogen).Asecondround
of siRNA transfection was performed 24 h later using Lipofectamine 2000
(Invitrogen). After an additional 6 h, cells were detached, counted, and dis-
pensed into 96-well plates. Drugs were added 12 h later, and after 48 h, cell
viability was assayed using theWST-1 reagent (Roche). For FACS analysis, both
adherent and ﬂoating cells were collected and ﬁxed in ethanol. After rehy-
dration, cells were treated with 200 μg/mL RNAseA and 40 μg/mL propidium
iodide and analyzed on a ﬂow cytometer (FacsCalibur; BD). FACS data were
processed using FlowJo software, and cell cycle proﬁles were determined
using the Watson pragmatic model (Tree Star).
Additional methods are provided in SI Methods.
ACKNOWLEDGMENTS. We thank L. Carlsson, C. Y. Choi, R. Crosbie, G. Denis,
A. Dutta, T. Fujita, N. Galjart, P. Gonczy, T. Hollenberger, W. G. Kaelin, Jr., A.
I. Lamond, S. Lin-Chao, L. Liu, J. Loturco, C. Mitchell, R. I. Morimoto, F. Cilius
Nielsen, S. Ove Boe, J.-M. Peters, H. Takeshima, S. Taylor, S. Rosenbaum, R.
Samant, S. Stoney-Simons, Jr., N. Watanabe, and D. Wieczorek for providing
expression plasmids for many of the mammalian proteins used in this work.
We thank Stefano Gustincich and members of his lab for sharing reagents
and equipment. We acknowledge the important contribution of Fabio Fais
and Stefania Luppi, who helped during the IVEC screening. This work was
supported by grants from the Italian Association for Cancer Research, the
Italian Ministry for University and Research, and Regione Friuli Venezia
Giulia (LR26/2005) (to L.C.) and by grants from the Italian Association for
Cancer Research, the Italian Ministry for University and Research, European
Community FP6 contracts 503576 and 502983 (to G.D.S.).
1. VousdenKH,LuX (2002) Liveor letdie:Thecell’s response top53.NatRevCancer2:594–604.
2. Hainaut P, et al. (1997) Database of p53 gene somatic mutations in human tumors
and cell lines: Updated compilation and future prospects.Nucleic Acids Res 25:151–157.
3. Mantovani F, et al. (2007) The prolyl isomerase Pin1 orchestrates p53 acetylation and
dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol 14:912–920.
4. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM (2007) Monoubiquitylation
promotes mitochondrial p53 translocation. EMBO J 26:923–934.
5. Kruse J-P, Gu W (2009) Modes of p53 regulation. Cell 137:609–622.
6. Yang A, Kaghad M, Caput D, McKeon F (2002) On the shoulders of giants: p63, p73
and the rise of p53. Trends Genet 18:90–95.
7. Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7:
165–168.
8. Flores ER, et al. (2005) Tumor predisposition in mice mutant for p63 and p73: Evidence
for broader tumor suppressor functions for the p53 family. Cancer Cell 7:363–373.
9. Suh EK, et al. (2006) p63 protects the female germ line during meiotic arrest. Nature
444:624–628.
10. Rosenbluth JM, Pietenpol JA (2008) The jury is in: p73 is a tumor suppressor after all.
Genes Dev 22:2591–2595.
11. Bourdon JC, et al. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes
Dev 19:2122–2137.
12. Lu W-J, Amatruda JF, Abrams JM (2009) p53 ancestry: Gazing through an
evolutionary lens. Nat Rev Cancer 9:758–762.
13. Sogame N, Kim M, Abrams JM (2003) Drosophila p53 preserves genomic stability by
regulating cell death. Proc Natl Acad Sci USA 100:4696–4701.
14. Lee JH, et al. (2003) In vivo p53 function is indispensable for DNA damage-induced
apoptotic signaling in Drosophila. FEBS Lett 550:5–10.
15. Fan Y, et al. (2009) Dual roles of Drosophila p53 in cell death and cell differentiation.
Cell Death Differ, 10.1038/cdd.2009.182.
16. Stapleton M, et al. (2002) The Drosophila gene collection: Identiﬁcation of putative
full-length cDNAs for 70% of D. melanogaster genes. Genome Res 12:1294–1300.
17. Fish JL, Kosodo Y, Enard W, Pääbo S, Huttner WB (2006) Aspm speciﬁcally maintains
symmetric proliferative divisions of neuroepithelial cells. Proc Natl Acad Sci USA 103:
10438–10443.
18. Bond J, et al. (2003) Protein-truncating mutations in ASPM cause variable reduction in
brain size. Am J Hum Genet 73:1170–1177.
19. Iwasaki T, Murata-Hori M, Ishitobi S, Hosoya H (2001) Diphosphorylated MRLC is
required for organization of stress ﬁbers in interphase cells and the contractile ring in
dividing cells. Cell Struct Funct 26:677–683.
20. Zhang H, et al. (2004) AIP1/DAB2IP, a novel member of the Ras-GAP family,
transduces TRAF2-induced ASK1-JNK activation. J Biol Chem 279:44955–44965.
21. Min W, et al. (2008) AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-
induced ASK1-JNK activation. Circ Res 102:840–848.
22. Yano M, et al. (2005) Aberrant promoter methylation of human DAB2 interactive
protein (hDAB2IP) gene in lung cancers. Int J Cancer 113:59–66.
23. Kleiber ML, Singh SM (2008) Divergence of the vertebrate sp1A/ryanodine receptor
domain and SOCS box-containing (Spsb) gene family and its expression and
regulation within the mouse brain. Genomics 93:358–366.
24. Styhler S, Nakamura A, Lasko P (2002) VASA localization requires the SPRY-domain
and SOCS-box containing protein, GUSTAVUS. Dev Cell 3:865–876.
25. Lapik YR, Misra JM, Lau LF, Pestov DG (2007) Restricting conformational ﬂexibility of
the switch II region creates a dominant-inhibitory phenotype in Obg GTPase Nog1.
Mol Cell Biol 27:7735–7744.
26. Jensen BC, Wang Q, Kifer CT, Parsons M (2003) The NOG1 GTP-binding protein is
required for biogenesis of the 60S ribosomal subunit. J Biol Chem 278:32204–32211.
27. Fuentes JL, Datta K, Sullivan SM, Walker A, Maddock JR (2007) In vivo functional
characterization of the Saccharomyces cerevisiae 60S biogenesis GTPase Nog1. Mol
Genet Genomics 278:105–123.
28. van de Vijver MJ, et al. (2002) A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med 347:1999–2009.
29. Pawitan Y, et al. (2005) Gene expression proﬁling spares early breast cancer patients
from adjuvant therapy: Derived and validated in two population-based cohorts.
Breast Cancer Res 7:R953–R964.
30. Miller LD, et al. (2005) An expression signature for p53 status in human breast cancer
predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad
Sci USA 102:13550–13555.
31. Rubbi CP, Milner J (2003) Disruption of the nucleolus mediates stabilization of p53 in
response to DNA damage and other stresses. EMBO J 22:6068–6077.
32. Opferman JT, Zambetti GP (2006) Translational research? Ribosome integrity and a
new p53 tumor suppressor checkpoint. Cell Death Differ 13:898–901.
33. Fumagalli S, et al. (2009) Absence of nucleolar disruption after impairment of 40S
ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53
induction. Nat Cell Biol 11:501–508.
34. Giot L, et al. (2003) A protein interaction map of Drosophila melanogaster. Science
302:1727–1736.
35. Stanyon CA, et al. (2004) A Drosophila protein-interaction map centered on cell-cycle
regulators. Genome Biol 5:R96.
36. Yamada Y, Davis KD, Coffman CR (2008) Programmed cell death of primordial germ
cells in Drosophila is regulated by p53 and the outsiders monocarboxylate
transporter. Development 135:207–216.
37. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency develop-
mental abnormalities in p53-deﬁcient mice. Curr Biol 5:931–936.
38. Yin Y, Stahl BC, DeWolf WC, Morgentaler A (1998) p53-mediated germ cell quality
control in spermatogenesis. Dev Biol 204:165–171.
39. Murphy ME, Leu JI, George DL (2004) p53 moves to mitochondria: A turn on the path
to apoptosis. Cell Cycle 3:836–839.
40. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR (2005) PUMA
couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309:
1732–1735.
41. Zhang Y, Lu H (2009) Signaling to p53: Ribosomal proteins ﬁnd their way. Cancer Cell
16:369–377.
42. Sun XX, Dai MS, Lu H (2007) 5-Fluorouracil activation of p53 involves an MDM2-
ribosomal protein interaction. J Biol Chem 282:8052–8059.
43. Rual JF, et al. (2005) Towards a proteome-scale map of the human protein-protein
interaction network. Nature 437:1173–1178.
6 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1002447107 Lunardi et al.
Supporting Information
Lunardi et al. 10.1073/pnas.1002447107
SI Methods
IVEC Procedure. Production and puriﬁcation of MBP-Dmp53. The ORF
of Drosophila p53 (NM_206545) was cloned in a modiﬁed version
of the pFastBac baculovirus expression vector, in frame with
maltose binding protein (MBP) at the N terminus (pFB6-MBP-
Dmp53). Baculovirus expressingMBP-Dmp53 (orMBP alone as a
control)wasprepared andused for proteinproduction inSf9 insect
cells. MBP proteins were puriﬁed from baculovirus-infected Sf9
cells using amylose beads under nondenaturing conditions [lysis
buffer: 20mMTris·HCl (pH7.5), 200mMNaCl, 1mMEDTA(pH
8), 10 mM beta-mercaptoethanol]; after extensive washes, beads
were used for in vitro pull-down experiments. We observed that
best results were obtained using fresh preparations of MBP-
Dmp53 and MBP proteins, so each round of pull-down experi-
ments was performed with a different batch of recombinant pro-
teins.
Preparation of small pools. We prepared pools of 24 clones corre-
sponding to single rows of 384-well plates. For theDGC1.0 library,
we puriﬁed plasmid DNA from mixed bacterial cultures. For the
DGC2.0 library, we puriﬁedDNA from individual clones using 96-
well format minipreps and made pools by mixing plasmid prepa-
rations. This procedure required a greater effort in the preparation
phase, but greatly facilitated retrieval of positive clones during
sib selection.
In vitro pull-down.Radiolabeled proteins were obtained fromDNA
pools by in vitro transcription–translation in the presence of [35S]
methionine, using rabbit reticulocyte lysates (TnT; Promega) and
appropriate RNA polymerases. Plates 1–4 of DGC1.0 are cloned
in pBluescript vectors and translate with poor efﬁciency. To
overcome this problem, we used primers with vector sequences to
amplify the inserts by PCR, the upper primer containing a T7
RNA polymerase promoter for in vitro transcription, exactly as
described by others (1).
PCR products were directly used as templates for coupled in
vitro transcription–translation. Plates 1–8 of DGC2.0 are cloned
in pFLC vectors and do not translate efﬁciently in reticulocyte
lysates. Expression of these clones was not improved by a PCR-
based approach, so they had to be excluded from this study.
Radiolabeled proteins were added to small aliquots of recom-
binantMBP-Dmp53boundtoamylosebeads.Aftera1h incubation
inpull-downbuffer [50mMTris·HCl (pH7.5), 150mMNaCl, 0.1%
Nonidet P-40, 5% glycerol, protease inhibitors (Sigma), 1 mM
PMSF, 5 mM NaF, 1 mM beta-glycerolphosphate], the reactions
were transferred to plastic miniﬁlters (Wizard Minicolumn;
Promega) mounted on a vacuum manifold, and the beads were
washed by passing a large volume of pull-down buffer through the
column. Bound proteins were eluted with hot Laemmli sample
buffer by brieﬂy centrifuging the ﬁlters on top of 1.5-mL tubes.
Eluted proteins were analyzed by SDS/PAGE followed by auto-
radiography.
Bioinformatics and Statistical Analysis. Data compilation. The list of
literature-curated Drosophila p53 interactions (LCDI) includes
proteins with at least one experimental evidence of physical
interaction with Dmp53 and excludes phenotypic and functional
associations. It was compiled by searching a number of protein–
protein interaction databases: BioGrid, MINT, DroID, IntAct,
BIND, and HPRD. It also contains additional physical inter-
actions involving Dmp53 described in the literature. The data in-
cluded in the LCDI dataset were last updated on February 27,
2009. Human orthologs were deﬁned according to Homologene
and Inparanoid databases (http://inparanoid.sbc.su.se/). For genes
lacking a human ortholog in these databases, we performed
BLAST analysis vs. human protein sequences and focused our
attention on hits with a signiﬁcant similarity score. We used the
BLASTO interface (http://oxytricha.princeton.edu/BlastO/) to
compare peptide sequences vs. clusters of eukaryotic orthologous
groups (NCBI_KOG and MultiParanoid) (2). Finally, we em-
ployed TreeFam (http://www.treefam.org/) to construct phyloge-
netic trees of putative ortholog groups. In some cases, humans
have more than one gene with signiﬁcant similarity to a single
Drosophila gene: if the human genes are phylogenetically related
toeachother (i.e., paralogs) theywereall consideredorthologs (e.g.,
Drosophila Imp vs. human IGFBP1, IGFBP2, and IGFBP3). In
other cases, Drosophila has two or more paralogs with signiﬁcant
similarity to a single human gene (e.g., Drosophila eyeless and twin-
of-eyeless vs. human Pax6): In such instances, the human gene was
considered an ortholog to both. In some cases we detected strong
similarity only within a speciﬁc domain of the protein, with poor
conservation along the remaining peptide sequence. In those in-
stances, we considered them orthologs only if the two proteins
scored as reciprocal best matches in BLAST analysis.
Overrepresentation analysis. Overrepresentation analysis of Gene
Ontology and phenotypes among the interactors was performed
using Fisher’s exact test. The background populations are the lists
of all ﬂy genes represented in the DGC 1.0 and 2.0 libraries (6,607
FlyBase IDs). Gene Ontology and phenotype annotations were
obtained from FlyBase. For both Gene Ontology and phenotype
annotation we took into account the hierarchical nature of the
annotation ontologies by assigning to each gene all of the anno-
tation terms that are ancestors in the ontology of the terms that
are directly assigned to the gene. To avoid very generic GO terms
the analysis was limited to terms with a total prevalence <2,000 in
the background population.
Relevance to cancer. We analyzed publicly available breast cancer
gene expression datasets to determine which of the functionally
validated human interactors have prognostic predictive power.
The datasets analyzed are as follows:
NKI: Described in ref. 3. Normalized expression data and
clinical data were obtained from the paper’s website (http://
www.rii.com/publications/2002/nejm.html).
Miller (4): Normalized expression data and clinical data were
obtained from the Gene Expression Omnibus (GEO) website
(http://www.ncbi.nlm.nih.gov/projects/geo/) under accession
GSE3494.
Pawitan (5): Normalized expression data and clinical data
were obtained from GEO under accession GSE1456.
We considered only probesets associated unambiguously with
one of the functionally validated human interactors by the an-
notation ﬁle provided by Affymetrix. For the NKI datasets, the
mapping between accession numbers provided in the original
dataset and Entrez Gene IDs was obtained through Unigene. We
used univariate Cox analysis to determine signiﬁcant (P ≤ 0.05)
correlations between the logarithmic expression of each micro-
array probeset and patient survival. For GTPBP4 in p53-wild-
type breast tumors we also compared the survival probabilities of
high- and low-GTPBP4 tumors with a log-rank test. For this
analysis the logarithmic expression levels of the two Affymetrix
probes associated with GTPBP4 were averaged.
Databases.Databasesusedwereasfollows:FlyBaserelease2008_05;
BioGridrelease2.0.45;DroIDversion4.0;Homologeneversion62,
released June 12, 2008; Inparanoid version 6.0, released August
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2007; NCBI_KOG release 2003; MultiParanoid release 2006;
TreeFam version 6.0, released June 6, 2008; Entrez Gene, down-
loaded 26 October 2008; Gene Ontology release 20081012; Affy-
metrix HGU133 annotations, version 26; and Unigene, Homo
sapiens build 216.
Cell Culture and Transfection Methods. SF9 insect cells were cul-
tured at 27 °C in SF900II medium (Gibco) supplemented with
10% FBS and gentamycin (10 μg/mL). HEK293T, HCT116, and
U2OS mammalian cell lines were cultured in Dulbecco’s modi-
ﬁed Eagle’s medium supplemented with 10% FBS, penicillin
(100 units/mL), and streptomycin (100 μg/mL). Calcium phos-
phate was used for DNA transfection of HEK293T and U2OS.
siRNAs were transfected using RNAiMAX and Lipofectamine
2000 reagent (Invitrogen).
Quantiﬁcation of Cell Viability UsingWST-1.Cell viability was assayed
using theWST-1 reagent (Roche), according to themanufacturer’s
protocol. Absorbance was measured on a microplate ELISA
reader (Envision Xcite; Perkin-Elmer) at a 450-nm detection
wavelength. Normalized WST was calculated as follows: WST
(%) = [(A450 of treated sample – A450 of blank)/(A450 of un-
treated sample – A450 of blank)] × 100. Blank represents wells
containing culture medium only.
For any given siRNA pool, the difference in normalized WST
between untreated and drug-treated cells [ΔWST = WST(un-
treated) − WST(treated)] reﬂects the amplitude of the effect of
p53 activation. ΔWST values of cells transfected with interactor-
speciﬁc siRNAs were compared to ΔWST values of cells trans-
fected with control siRNAs (two independent nontargeting
siRNAs were used as controls). A greater ΔWST indicates more
efﬁcient arrest, and a smaller ΔWST indicates less efﬁcient ar-
rest. Differences were considered signiﬁcant if they were >10
normalized WST units [i.e., ΔWST(interactor siRNA) − ΔWST
(control siRNA) > |10|].
Real-Time RT-PCR. Total RNA was isolated using the TRIZOL
reagent (Invitrogen), following the manufacturer’s instructions.
Single-strand cDNA was obtained from 1 μg of puriﬁed RNA,
using the iSCRIPT cDNA Synthesis Kit (Bio-Rad) according to
manufacturer’s instructions. Quantitative RT-PCR (qPCR) was
performed using SYBR-Green PCR Master Mix (Applied Bio-
systems) and an iCycler IQ Real-time PCR System (Bio-Rad).
Expression of the gene of interest was analyzed using speciﬁc
oligonucleotides designed using the software BeaconDesigner 2.0
(Premier Biosoft International). Primer sequences are available
upon request. The annealing temperature of all of the primers
described was 60 °C. The results were normalized to GAPDH and
the initial amount of the template of each sample was determined
as relative expression vs. that of one of the samples chosen as
reference. The relative expression of each sample was calculated
by the equation 2DDCt (User Bulletin 2 of the ABI Prism 7700
Sequence Detection System).
Protein Interaction Studies. Expression vectors encoding MBP-fusion
proteins. For coafﬁnity puriﬁcation assays, the MBP coding seq-
uence from pMalC2x was PCRampliﬁed and cloned in pcDNA3.1
expression vector, with a Kozak consensus for efﬁcient transla-
tion in mammalian cells. The coding regions of human p53,
TAp63alpha, and TAp73alpha were inserted in frame at the C
terminus of MBP to generate the pcDNA3-MBP-p53, pcDNA3-
MBP-p63, and pcDNA3-MBP-p73 plasmids.
Coimmunoprecipitation. Co-IP experiments with endogenous pro-
teins were performed in HCT116 cell lines using co-AP buffer
[50 mM Tris·HCl (pH 8), 150 mM NaCl, 1 mM EDTA (pH 8), 1
mM DTT, 5% glycerol, protease inhibitors (Sigma), 1 mM
PMSF, 5 mM NaF, 1 mM beta-glycerolphosphate]. Samples
were cleared by centrifugation for 30 min at 13,000 × g at 4 °C
and incubated for 2 h at 4 °C with anti-p53 antibody (DO-1;
Santa Cruz). After 1 h incubation with protein G-Sepharose (GE
Healthcare), immunoprecipitates were washed three times in co-
AP buffer, resuspended in sample buffer, and analyzed by im-
munoblotting. To avoid cross-reaction with Ig heavy chains, im-
munoprecipitated p53 was detected using rabbit polyclonal FL393
(Santa Cruz) followed by HRP-Protein A (Pierce). For Co-IP of
overexpressed proteins, p53-null H1299 cells were transfected
with appropriate expression vectors and processed 48 h later. Lysis
was performed in co-AP buffer supplemented with phosphatase
and protease inhibitors. Cleared lysates were incubated overnight
with anti-GFPor anti-HAantibody covalently bound toProteinG-
Sepharose (GE Healthcare), using 10 mg/mL dimethylpimelimi-
date (Pierce). Immunoprecipitated proteins were separated by
SDS/PAGE and analyzed by immunoblotting. Coimmunopreci-
pitated p53 was directly detected using HRP-conjugated DO-1
monoclonal antibody (Santa Cruz).
In vitro pull-down using puriﬁed proteins. The MBP and MBP-p53
baitswerepuriﬁed fromH1299cells transfectedwith the respective
pcDNA3 expression vectors. Cells were lysed in co-AP buffer and
MBP-fusion proteins were recovered on amylose beads (NEB).
For expression in bacteria, the coding region of humanGTPBP4
was cloned in frame at the C terminus of GST in pGEX4T1.
RecombinantGSTandGST-GTPBP4proteinswerepuriﬁed from
BL21 after induction with 1 mM IPTG for 2 h at 37 °C. Bacteria
were lysed in 50 mM Tris·HCl (pH 8.0), 300 mM NaCl, 0.1%
Nonidet P-40, 0.1% Triton X-100, 0.1% Tween 20, 1 mM EDTA,
plus 0.2 mg/mL lysozyme and protease inhibitors. After 30 min on
ice, lysates were sonicated, clariﬁed by centrifugation, and in-
cubated with glutathione beads (GE Healthcare). After puriﬁ-
cation, GST and GST-GTPBP4 proteins were eluted with 10 mM
reduced glutathione and used as prey for in vitro pull-down on
MBP and MBP-p53 beads. After 1 h binding at 4 °C in co-AP
buffer, beads were washed and bound proteins were analyzed by
Western blot.
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Fig. S1. In vitro pull-down experiments relative to the 94 cDNA hits identiﬁed during the screening. Each ﬁrst lane is 1/40th of the input. Each second lane is
the eluate of MBP beads. Each third lane is the eluate of MBP-Dmp53 beads. Numbers represent the position of each clone in 384-well plates of the DGC1.0 and
DGC2.0 libraries. Clone 12L14 is Dmp53 (FBgn0039044). Clone 17E07 (LD46618P) is not annotated in FlyBase and corresponds to a “probable RNA-directed DNA
polymerase from transposon BS.” Identity of the Drosophila genes corresponding to all remaining clones can be found in Table S1.
Lunardi et al. www.pnas.org/cgi/content/short/1002447107 3 of 13
Fig. S2. Cellular localization of 41 mammalian orthologs of Dmp53 interacting proteins. Vectors expressing the indicated proteins were transiently trans-
fected in U2OS cells. Localization of encoded proteins was analyzed by immunoﬂuorescence after 24 h. Proteins were visualized using antibodies to speciﬁc
epitope tags or by GFP as indicated.
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Fig. S3. Co-AP experiments relative to mammalian orthologs of Dmp53 interacting proteins. (A) Expression plasmids encoding tagged versions of the in-
dicated proteins were cotransfected with pcDNA3-MBP, pcDNA3-MBP-p53, pcDNA3-MBP-TAp63a, or pcDNA3-MBP-TAp73a in 293T cells. After cell lysis, MBP
fusion proteins (baits) were puriﬁed on amylose beads. Copuriﬁed proteins were detected by immunoblotting using antibodies to speciﬁc tags. (Top) Tagged
prey proteins after afﬁnity puriﬁcation, demonstrating binding to the indicated MBP-tagged bait proteins or MBP alone as a control (−). (Middle) Expression of
the tagged prey in the lysate (1/40th of the input). (Bottom) Expression of MBP-tagged bait proteins after afﬁnity puriﬁcation. Top and Middle are cropped
from the same autoradiographic ﬁlm (i.e., have the same exposure). (B) As proof of concept for sensibility and reliability of the assay, co-AP experiments using
two human p53 interologs (Daxx and Rpa70) are also shown.
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Fig. S4. Functional validation of p53 interactors by RNA-mediated interference. (A) Primary screening for modulators of p53-dependent growth inhibition.
HCT116 cells bearing wild-type p53 (HCT116 WT) were transfected with control siRNA (siCTRL) or siRNA pools targeting each of 24 newly identiﬁed p53 in-
teractants. Cell viability was measured by WST-1 after treatment with Nutlin-3, Doxorubicin, or Etoposide as indicated. The difference in normalized WST
between untreated and treated samples (ΔWST) was used to quantify the decrease in cell viability after p53 activation. For each gene-speciﬁc siRNA, this value
was compared to that of control siRNA; differences in ΔWST were considered signiﬁcant only if reproducibly >10 normalized WST units (see SI Methods for
details). (B) Transient knockdown of ﬁve unique p53 interactors affects the response of HCT116 cells to Doxorubicin. The experiment was performed as de-
scribed in Fig. 3A. As a control for p53 dependency, the same experiment was performed in HCT116 p53−/− cells (*, P < 0.05; **, P < 0.01). (C) Functionally
validated p53 interactors are expressed at comparable levels in HCT116 WT (gray bars) and HCT116 p53−/− cells (black bars). mRNA levels of the indicated genes
were analyzed by RT-qPCR. A single representative experiment is reported. (D) All siRNA pools reduce the levels of target mRNAs to ≤50%. Expression levels of
the ﬁve functionally validated p53 interactors were determined by RT-qPCR in HCT116 WT cells transfected with control or speciﬁc siRNA pools under the
experimental conditions used for WST assays. Data are averages ± SD. (E) Cell-cycle analysis of cells transiently transfected with siRNA pools targeting four
different functional hits. HCT116 p53 WT cells were lipofected with the indicated siRNA pools, treated with Nutlin-3 (5 mM) or Doxorubicin (0.05 mM) for 24 h,
stained with propidium iodide (PI), and analyzed by ﬂow cytomtery. The distribution (percentage) of cell-cycle phases was determined using FlowJo software.
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Fig. S5. Additional evidence of physical and functional interaction between GTPBP4 and p53. (A) Puriﬁed GTPBP4 and p53 interact in vitro. Recombinant GST
and GST-GTPBP4 proteins were expressed in bacteria, puriﬁed on glutathione-Sepharose beads, eluted, and used for in vitro pull-down assays on amylose
beads loaded with MBP or MBP-p53 puriﬁed from transfected H1299 cells (SI Methods). GST-GTPBP4 is produced with poor efﬁciency in bacteria, so the protein
was detected by immunoblotting. (Upper) GST-GTPBP4 (Left) or GST (Right) proteins copuriﬁed with MBP or MBP-p53 beads, compared to 1/30th of the input.
(Lower) Afﬁnity-puriﬁed MBP baits. (B) Knockdown of GTPBP4 induces accumulation of p53 in multiple cell lines. p53 expression was analyzed by immuno-
blotting of the indicated human transformed cells after transfection of control or GTPBP4 siRNA. A speciﬁc antibody to GTPBP4 conﬁrmed efﬁcient knockdown
of the endogenous protein. Hsp90 was detected in the same lysates as a loading control. (C) GTPBP4 knockdown does not affect localization of key nucleolar
proteins. Immunoﬂuorescence analysis is shown of GTPBP4, B23/nucleophosmin, and ﬁbrillarin in U2OS cells transfected for 48 h with either control or GTPBP4
siRNA. Nuclei are counterstained with Hoechst. (D) GTPBP4 knockdown does not induce p53 stabilization. Quantiﬁcation is shown of the ratio of p53 to Hsp90
(measured by densitometry on Western blots) in HCT116 WT cells transfected with GTPBP4 siRNA (solid diamonds) or control siRNA (open circles) for 48 h and
treated for the indicated times with 50 μM Cycloheximide (CHX). Data are means ± SD for three independent experiments. (E) Representative Western blot
used for the analysis of p53 half-life. To obtain a comparable p53 signal, the gel was loaded with 15 μg lysate of control siRNA samples (Left), and 7.5 μg lysate
of GTPBP4 knockdown samples (Right). Immunoblotting for GTPBP4 conﬁrmed efﬁcient knockdown of the endogenous protein. (F) Depletion of GTPBP4 does
not impair p53 accumulation in response to DNA damage. HCT116 WT cells were transfected with GTPBP4 siRNA or control siRNA for 48 h and treated for the
indicated times with Cisplatin (CDDP) or Doxorubicin. The same amount of total lysate was loaded in all lanes. Blotting for GTPBP4 conﬁrmed efﬁcient
knockdown of the endogenous protein. Hsp90 was detected in the same lysates as a loading control.
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Table S1. List of Dmp53 interactors identiﬁed in the screening (IVDI)
DGC clone FlyBase ID Gene Name
01K10 FBgn0003514 CG3595 SPAGHETTI SQUASH
01N03 FBgn0038876 CG5919 CG5919
02I02 FBgn0025463 CG4303 BRAHMA ASSOCIATED PROTEIN 60KD
02K16 FBgn0034091 CG8448 MRJ
02K24 FBgn0036194 CG11652 CG11652
02M23 FBgn0010173 CG9633 REPLICATION PROTEIN A 70 (*)
03B09 FBgn0014455 CG11654 ADENOSYLHOMOCYSTEINASE AT 13
03B22 FBgn0013773 CG10240 CYP6A22
03C13 FBgn0037814 CG6325 CG6325
03G23 FBgn0087035 CG7439 ARGONAUTE 2 (partial)
03K05 FBgn0011768 CG6598 FORMALDEHYDE DEHYDROGENASE
03K16 FBgn0045063 CG8824 FUSED LOBES
03K24 FBgn0032690 CG10333 CG10333 (partial)
04M20 FBgn0000099 CG8376 APTEROUS
05C12 FBgn0027532 CG7139 CG7139
05C15 FBgn0021944 CG3433 COPROPORPHYRINOGEN OXIDASE
05D12 FBgn0035600 CG4769 CG4769
05G11 FBgn0028530 CG18124 MITOCHONDRIAL TRANSCRIPTION TERMINATION FACTOR
05H10 FBgn0023519 CG3109 MITOCHONDRIAL RIBOSOMAL PROTEIN L16
05H12 FBgn0038487 CG4060 TWEEDLEW
05I12 FBgn0000146 CG6137 AUBERGINE
05I24 FBgn0028473 CG8801 CG8801
05N04 FBgn0016041 CG12157 TRANSLOCASE OF OUTER MEMBRANE 40
05N16 FBgn0029969 CG10932 CG10932
06K11 FBgn0038194 CG3050 CYP6D5
07C11 FBgn0037544 CG11035 CG11035
07C17 FBgn0029094 CG9383 ANTI-SILENCING FACTOR 1
07I12 FBgn0033438 CG1794 MATRIX METALLOPROTEINASE 2
07N13 FBgn0010340 CG9852 UPSTREAM OF RPII140
08D07 FBgn0001133 CG33133 GRAUZONE
08K22 FBgn0038546 CG7379 CG7379 (*)
08N19 FBgn0033235 CG8728 CG8728
09C09 FBgn0019650 CG11186 TWIN OF EYELESS
09M03 FBgn0031191 CG14617 CG14617
10N07 FBgn0037245 CG14648 GROWL
11D05 FBgn0000351 CG11330 CORTEX
12A20 FBgn0001222 CG5748 HEAT-SHOCK FACTOR
12C03 FBgn0066365 CG15013 DUSKY-LIKE (partial)
12C07 FBgn0035852 CG7387 CG7387
12C18 FBgn0037250 CG1074 CG1074
12E10 FBgn0050059 CG30059 CG30059
12H10 FBgn0033367 CG8193 CG8193
12H23 FBgn0039654 CG14514 BRD8
13B16 FBgn0038860 CG10825 CG10825
13B17 FBgn0036397 CG8783 CG8783
14C01 FBgn0038607 CG7669 CG7669
14M15 FBgn0026238 CG2944 GUSTAVUS
15D22 FBgn0052627 CG32627 CG32627
15E14 FBgn0020616 CG3423 STROMALIN
15E20 FBgn0035416 CG17569 GRYZUN
15E23 FBgn0032388 CG6686 CG6686
15K05 FBgn0031820 CG9537 DAXX-LIKE PROTEIN (partial) (*)
15K06 FBgn0000140 CG6875 ABNORMAL SPINDLE (partial)
15K10 FBgn0051108 CG31108 CG31108
15M01 FBgn0052306 CG32306 CG32306
15M17 FBgn0037705 CG9381 MURASHKA
16A07 FBgn0000504 CG11094 DOUBLESEX
16A15 FBgn0003721 CG4898 TROPOMYOSIN 1
16F15 FBgn0024987 CG3056 CG3056
16K04 FBgn0030235 CG1691 IGF-II MRNA-BINDING PROTEIN
16K11 FBgn0029764 CG3249 YU
16P06 FBgn0051738 CG31738 CG31738
17C04 FBgn0032679 CG10302 BICOID STABILITY FACTOR
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Table S1. Cont.
DGC clone FlyBase ID Gene Name
17C05 FBgn0259165 CG42270 CG42270
17C12 FBgn0032129 CG4405 JUNCTOPHILIN
17C13 FBgn0002872 CG1960 MUTATOR 2
17C16 FBgn0021760 CG32435 CHROMOSOME BOWS
2_11C13 FBgn0038266 CG3610 CG3610
2_11G15 FBgn0050418 CG30418 NORD (partial)
2_11G21 FBgn0034532 CG13436 CG13436
2_11H15 FBgn0037101 CG7634 CG7634
2_11J23 FBgn0034007 CG8102 CG8102
2_11N09 FBgn0033258 CG8712 CG8712
2_12F05 FBgn0031546 CG8851 CG8851 (partial)
2_12G16 FBgn0029667 CG14271 GROWTH ARREST SPECIFIC PROTEIN 8
2_12I11 FBgn0037454 CG1137 CG1137
2_12I15 FBgn0033953 CG12861 CG12861
2_12K16 FBgn0037626 CG8236 CG8236
2_12L20 FBgn0036731 CG6333 CG6333
2_13A23 FBgn0039124 CG13597 CG13597 (partial)
2_13J13 FBgn0033706 CG13167 CG13167
2_13K20 FBgn0039731 CG15524 SPINDLE ASSEMBLY ABNORMAL
2_14E02 FBgn0029940 CG1958 CG1958
2_14H06 FBgn0033186 CG1602 CG1602
2_14H24 FBgn0000996 CG8171 DOUBLE PARKED
2_14M21 FBgn0050362 CG30362 CG30362
2_14M24 FBgn0001250 CG9623 INFLATED (partial)
2_15N05 FBgn0034037 CG8214 CG8214
2_15O05 FBgn0036273 CG10426 CG10426
2_16G03 FBgn0032781 CG9987 CG9987
2_16M06 FBgn0052985 CG32985 CG32985 (partial)
2_16M16 FBgn0015542 CG7951 SIMILAR (partial)*
*Known Dmp53 interactors and ﬂy orthologs of mammalian proteins already reported to bind p53, p63, or p73
(FlyBase version FB2008_5, released May 30, 2008).
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Table S2. List of known Dmp53 interactors (LCDI)
FlyBase ID Gene Name Ref.
FBgn0053554 CG33554 nipped-A (1)
FBgn0020388 CG4107 Gcn5/PCAF (1)
FBgn0030891 CG7098 diskette (1)
FBgn0037555 CG9638 Ada2b (1)
FBgn0000044 CG10067 Act57B (2)
FBgn0000166 CG1034 bicoid (2)
FBgn0010602 CG3018 lesswright* (2)
FBgn0003479 CG7948 Spindle-A* (2)
FBgn0023526 CG2865 CG2865 (2)
FBgn0025674 CG15218 CycK (2)
FBgn0026602 CG1851 Ady43A (2)
FBgn0030459 CG12723 CG12723 (2)
FBgn0030882 CG6835 GS (2)
FBgn0031894 CG4496 CG4496 (2)
FBgn0031957 CG14534 TwdlE (2)
FBgn0028509 CG31811 cenG1A (2)
FBgn0023091 CG8667 dimmed (2)
FBgn0035021 CG4622 CG4622 (2)
FBgn0035357 CG1244 CG1244 (2, 3)
FBgn0035397 CG11486 CG11486 (2)
FBgn0035641 CG5568 CG5568 (2)
FBgn0037944 CG6923 CG6923 (2, 3)
FBgn0034410 CG15104* dTopors* (3, 4)
FBgn0000633 CG17716 faint sausage (3)
FBgn0003891 CG9450 tudor (3)
FBgn0010328 CG5965 woc (3)
FBgn0011474 CG3307 pr-set7 (3)
FBgn0012049 CG11494 BtbVII (3)
FBgn0026262 CG2009 bip2/DmTAF3 (3, 5)
FBgn0027499 CG12340 CG12340 (3)
FBgn0027514 CG1024 CG1024 (3)
FBgn0027603 CG12359 Ulp1 (3)
FBgn0031597 CG17612 CG17612 (3)
FBgn0031719 CG18269 CG18269 (3)
FBgn0033636 CG10897 toutatis (3)
FBgn0034976 CG4049 CG4049 (3)
FBgn0035038 CG13588 CG13588 (3)
FBgn0035047 CG3691 Pof (3)
FBgn0035849 CG7404 ERR (3)
FBgn0036668 CG9715 CG9715 (3)
FBgn0037344 CG2926 CG2926 (3)
FBgn0037643 CG11963 CG11963 (3)
FBgn0039923 CG1793 MED26 (3)
FBgn0053208 CG33208 MICAL (3)
FBgn0250754 CG42232 CG42232 (3)
FBgn0036622 CG4753 CG4753 (6)
FBgn0031820 CG9537 DLP* (7)
FBgn0031129 CG1324 CG1324 (8)
*Orthologs of mammalian proteins already reported to bind p53, p63, or
p73.
1. Kusch T, Guelman S, Abmayr SM, Workman JL (2003) Two Drosophila Ada2 homologues function in different multiprotein complexes. Mol Cell Biol 23:3305–3319.
2. Stanyon CA, et al. (2004) A Drosophila protein-interaction map centered on cell-cycle regulators. Genome Biol 5:R96.
3. Formstecher E, et al. (2005) Protein interaction mapping: A Drosophila case study. Genome Res 15:376–384.
4. Secombe J, Parkhurst SM (2004) Drosophila Topors is a RING ﬁnger-containing protein that functions as a ubiquitin-protein isopeptide ligase for the hairy basic helix-loop-helix
repressor protein. J Biol Chem 279:17126–17133.
5. Bereczki O, et al. (2008) TATA binding protein associated factor 3 (TAF3) interacts with p53 and inhibits its function. BMC Mol Biol 9:57.
6. Giot L, et al. (2003) A protein interaction map of Drosophila melanogaster. Science 302:1727–1736.
7. Bodai L, et al. (2007) Daxx-like protein of Drosophila interacts with Dmp53 and affects longevity and Ark mRNA level. J Biol Chem 282:36386–36393.
8. DroID (V4.0), available at http://www.droidb.org/.
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Table S3. Enrichment analysis of gene ontology (GO) deﬁnitions and phenotypes in the IVDI
dataset
GO or phenotype ID Description No. of genes Expected P value
GO:0007279 (BP) Pole cell formation 4 0.15 <10−4
GO:0007277 (BP) Pole cell development 4 0.18 <10−4
GO:0003704 (MF) Speciﬁc RNA polymerase II
transcription factor activity
5 0.53 <10−3
GO:0007282 (BP) Cystoblast division 3 0.15 <10−3
GO:0007276 (BP) Gamete generation 13 4.41 <10−3
GO:0019953 (BP) Sexual reproduction 13 4.54 <10−3
GO:0007349 (BP) Cellularization 5 0.68 <10−3
GO:0045143 (BP) Homologous chromosome
segregation
2 0.04 <10−3
GO:0000922 (CC) Spindle pole 3 0.19 <10−3
GO:0009994 (BP) Oocyte differentiation 6 1.14 <10−3
FBcv0000366 Female sterile 12 4.08 0.00069
FBcv0000364 Sterile 13 5.43 0.0027
FBcv0000435 Neuroanatomy defective 10 4.26 0.0097
FBcv0000433 Cytokinesis defective 3 0.51 0.014
FBcv0000398 Memory defective 3 0.63 0.024
FBcv0000397 Learning defective 2 0.32 0.040
FBcv0000370 Male sterile 5 2.00 0.049
BP, biological process; CC, cell compartment; MF, molecular function.
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Table S4. Manually curated list of human orthologs of Dmp53 interactors identiﬁed during the
screening
Human ortholog(s)*
Drosophila gene Gene symbol Deﬁnition
Regulation of transcription and chromatin binding
HEAT SHOCK FACTOR HSF1, HSF2,
HSF4
Heat-shock transcription factor 1, 2, 4
APTEROUS LHX2 LIM homeobox 2
TWIN OF EYELESS PAX6 Paired box 6
ANTI-SILENCING FACTOR 1 ASF1A, ASF1B ASF1 anti-silencing function 1 homolog A, B
CG14514 BRD8 Bromodomain containing 8
Chaperones
CG7387 DNAJA3 DnaJ (Hsp40) homolog, A3
MRJ DNAJB6 DnaJ (Hsp40) homolog, B6
CG11035 DNAJC30 DnaJ (Hsp40) homolog, C30
RNA binding and processing
YU AKAP1 A kinase (PRKA) anchor protein 1
CG10333 DDX23 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23
IGF-II MRNA-BINDING
PROTEIN
IGF2BP1,
IGF2BP2,
IGF2BP3
Insulin-like growth factor 2 mRNA binding
protein 1, 2, 3
BICOID STABILITY FACTOR LRPPRC Leucine-rich PPR-motif containing
GROWL MTHFSD Methenyltetrahydrofolate synthetase
domain containing
AGO2 EIF2C1,
EIF2C2,
EIF2C3,
EIF2C4
Argonaute 1, 2, 3, 4
AUBERGINE PIWIL1,
PIWIL2,
PIWIL3
Piwi-like 1, 2, 3
Cell cycle
DOUBLE PARKED CDT1 Chromatin licensing and DNA replication
factor 1
STROMALIN STAG1,
STAG2
Stromal antigen 1, 2
Centrosomes and cytoskeleton
ABNORMAL SPINDLE ASPM asp (abnormal spindle) homolog,
microcephaly associated
CHROMOSOME BOWS CLASP1 Cytoplasmic linker associated protein 1
SPINDLE ASSEMBLY ABNORMAL 6 SASS6 Spindle assembly 6 homolog
SPAGHETTI SQUASH MYL9 Myosin, light chain 9, regulatory
TROPOMYOSIN 1 TPM3 Tropomyosin 3
Enzymatic activity
FORMALDEHYDE
DEHYDROGENASE
ADH5 Alcohol dehydrogenase 5 (class III)
ADENOSYLHOMOCYSTEINASE
AT 13
AHCY S-adenosylhomocysteine hydrolase
CG11652 DPH1 DPH1 homolog, OVCA1
CG10426 INPP5E Inositol polyphosphate-5-phosphatase, 72
kDa
CG1074 TRMT11 tRNA methyltransferase 11 homolog
CG31108 TTLL5 Tubulin tyrosine ligase-like family member 5
Various
CG32627 AGBL2,
AGBL3
ATP/GTP binding protein-like 2, 3
CG32560 DAB2IP,
RASAL2
DAB2 interacting protein, RAS protein
activator-like 2
GAS8 GAS8 Growth arrest-speciﬁc 8
CG8801 GTPBP4 GTP binding protein 4
JUNCTOPHILIN JPH1, JPH2,
JPH3
Junctophilin 1, 2, 3
CG7139 N4BP2 NEDD4 binding protein 2
MURASHKA RNF38, RNF44 Ring ﬁnger protein 38, 44
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Table S4. Cont.
Human ortholog(s)*
Drosophila gene Gene symbol Deﬁnition
CG6686 SART1 Squamous cell carcinoma antigen
recognized by T cells
GUSTAVUS SPSB1, SPSB4 splA/ryanodine receptor domain and SOCS
box containing 1, 4
Unknown
GRYZUN C4orf41
CG13436 C6orf165
CG8783 C16orf35
CG9987 C22orf28
p53 interologs
DAXX-LIKE PROTEIN DAXX Death-associated protein 6
SIMILAR HIF1A Hypoxia-inducible factor 1, alpha subunit
CG7379 ING1,ING2 Inhibitor of growth family, member 1, 2
REPLICATION PROTEIN A 70 RPA1 Replication protein A1, 70 kDa
BAP60 SMARCD1,
SMARCD2,
SMARCD3
SWI/SNF related, matrix associated,
actin-dependent regulator of chromatin,
subfamily D, member 1, 2, 3
Mitochondrial
CG10932 ACAT1 Acetyl-CoA acetyltransferase
UPSTREAM OF RPII140 C3orf1
COPROPORPHYRINOGEN OXIDASE CPOX Coproporphyrinogen oxidase
CG4769 CYC1 Cytochrome c-1
MITOCH. RIBOSOMAL PROTEIN
L16
MRPL16 Mitochondrial ribosomal protein L16
CG8102 NDUFV1 NADH dehydrogenase (ubiquinone)
ﬂavoprotein 1
CG8728 PMPCA Peptidase (mitochondrial processing) alpha
TOM40 TOMM40 Translocase of outer mitochondrial
membrane 40 homolog
Extracellular, intraorganelle, integral to plasma membrane
NORD C4orf31 Unknown protein (contains N-terminal
signal peptide)
CG31738 FNDC3A Fibronectin type III domain containing 3A
CG30059 GNS Glucosamine (N-acetyl)-6-sulfatase
(Sanﬁlippo disease IIID)
CG5919 IDI1 Isopentenyl-diphosphate delta isomerase 1
INFLATED ITGA8, ITGAV Integrin alpha 8, alpha V
MMP2 MMP17 Matrix metallopeptidase 17
(membrane-inserted)
Databases: Homologene, version 62, released June 12, 2008; Inparanoid, version 6.0, updated August 2007;
TreeFam, version 6.0, released June 6, 2008.
*Orthologs were deﬁned according to Homologene and Inparanoid databases, protein BLAST searches, and
phylogenetic tree analysis.
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PART 2: Exploring mutant p53 gain of functions: inhibition 
of DAB2IP as a means to foster multiple oncogenic 
pathways. 
 
 
AIM OF THE PROJECT 
Tumor necrosis factor (TNF) alpha is a pro-inflammatory cytokine that plays 
important roles in cell survival, proliferation, differentiation and death, and is 
involved in inflammation-associated carcinogenesis (Wang and Lin, 2008). TNFα can 
activate distinct signaling pathways, such as nuclear factor κB (NF-κB) and c-Jun N-
terminal kinase (JNK). NF-κB promotes cell survival, while sustained JNK activation 
induces cell death. In cancer, TNFα acts as a double-dealer; on one hand it can be a 
cancer killer, inducing apoptosis. On the other hand it can be a cancer promoter, 
increasing cell proliferation, invasion, and metastasis (Wang and Lin, 2008). 
The RasGAP protein DAB2IP plays an important role in determining the cellular 
responses to TNFα through its capability to funnel the signaling cascade induced by 
TNFα on the activation of the ASK1- JNK pathway, and counteracting stimulation of 
NF-κB (Zhang et al., 2004). Notably, in addition to promoting ASK1 activation, 
DAB2IP can affect multiple pathways involved in cancer progression. DAB2IP can 
bind and inhibit PI3K and AKT, thus controlling cell survival and apoptosis (Xie et 
al., 2009). Moreover, DAB2IP can prevent the EMT process, possibly through its 
capability to modulate GSK-3β activation and β-catenin signaling (Xie et al., 2010). 
Finally, DAB2IP’s capacity to coordinately inhibit both RAS and NF-κB signaling 
was recently shown to be crucial to prevent growth and metastasis of prostate cancer 
cells (Min et al., 2010). Consistent with such a prominent role as inhibitor of cell 
survival, growth, and metastasis, DAB2IP expression is epigenetically silenced in 
many human cancers (Dote et al., 2005; Yano et al., 2005). Nonetheless, in many 
tumors DAB2IP is not mutated or silenced, and it is possible that cancer cells develop 
alternative mechanisms to elude the DAB2IP “checkpoint”. 
The tumor suppressor p53 is mutated in about 50% of human cancers, and 
solid evidence supports the importance of mutant p53 (mut-p53) gain-of-function for 
tumorigenesis (Oren and Rotter, 2010). Recent studies showed that mut-p53 potently 
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promotes cell migration and invasion, and this activity might actually be its primary 
oncogenic function in vivo (Adorno et al., 2009; Muller et al., 2009). In addition to 
inhibiting the anti-metastatic functions of p63 (Adorno et al., 2009; Muller et al., 
2009), mutant p53 fosters tumor progression and invasion by reinforcing and up-
regulating multiple oncogenic pathways including RAS, PI3K-AKT, β-catenin, and 
NF-kB (Dong et al., 2009; Muller et al., 2009; Sauer et al., 2010; Schneider et al., 
2010; Weisz et al., 2007a). As mentioned above, these pathways are all coordinately 
antagonized by DAB2IP (Figure 14).  
 
In the host laboratory, DAB2IP was recently cloned as a novel interactor of 
p53-family proteins (Lunardi et al., 2010). Unpublished additional experiments 
revealed that tumor-derived mutant p53 can bind efficiently to DAB2IP. This 
observation suggests a direct interplay between the two proteins: the capability of 
mut-p53 to bind and sequestrate a single highly integrated factor such as DAB2IP 
could provide a mechanism by which mutant p53 can act on multiple pathways to 
promote tumor progression and metastasis. 
We therefore decided to study the role of mut-p53/DAB2IP interaction in cell 
transformation. Specifically, we are testing the hypothesis that some gain-of-function 
properties of mutant p53 might depend on sequestration and functional inactivation of 
DAB2IP, particularly in the context of TNF-induced cell migration and invasion. We 
Figure 14. Model of signaling pathways regulated by DAB2IP and mutant p53 . 
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are also dissecting biochemically the interaction between DAB2IP and mutant p53; if 
the functional relevance of such interaction is confirmed, we plan to test the 
possibility to interfere with this binding using a decoy molecule derived form the 
region of DAB2IP that is recognized by mut-p53. 
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RESULTS 
Mutant p53 is required to sustain proliferation of metastatic cancer cell lines. 
Mutant p53 does not directly induce metastasis, but likely diverts cellular signals 
towards activation of pathways promoting cell growth, survival, and motility (Adorno 
et al., 2009; Muller et al., 2009). According to this premise, and consistent with other 
studies, we analyzed the effects of p53 knockdown in MDA-MB-231 cell lines 
(metastatic breast cancer, bearing mut-p53 R280K). 
Cells were transfected with a siRNA directed to p53 (sip53 ORF) or with a 
negative control (siC-). After 96 hours post-transfection, we analyzed their cell-cycle 
distribution by propidium iodide (PI) staining and FACS analysis (Fig. 15A). In these 
cells, ablation of mut-p53 reduces significantly the proliferation rate (measured as 
percentage of cells in S-phase). The reproducibility of this result with a different 
siRNA (sip53 3’UTR) confirms the specificity of this phenotype, and indirectly 
excludes potential off-target effects (Fig. 15A). The efficiency of endogenous mut-
p53 depletion was confirmed through Western-Blot analysis of the same cells (Fig 
15B). 
ERK1/2 and AKT1 are downstream effectors of the RAS and PI3K pathways, 
respectively. These signal transduction pathways sustain abnormal proliferation of 
most tumor cells, and there are evidences that link mutant p53 to their up-regulation  
(Dong et al., 2009; Muller et al., 2009; Sauer et al., 2010; Schneider et al., 2010; 
Weisz et al., 2007a). For this reason, we investigated if depletion of mut-p53 could 
affect ERK1/2 and AKT1 activities, correlating with the cell-cycle phenotype. Using 
phospho-specific antibodies (phospho-Thr202/Tyr204 of ERK1/2 and phospho-
Ser473 of AKT1), we observed that mut-p53 knockdown reduces ERK1/2 
phosphorylation, and, to a lesser extent, it also affects the phosphorylation of AKT1 
(Fig. 15C). 
Having confirmed that mut-p53 has a primary role in sustaining proliferation 
of MDA-MB-231 cells, we verified if this phenotype might be extended to other cells 
bearing mutant p53. To this aim we evaluated the effects of p53 knockdown in 
different cell lines: ovarian cancer cell lines TOV112D (p53-R175H) and OVCAR-3 
(p53-R248Q), HT29 (p53-R273H) colon adenocarcinoma cells, and pancreatic tumor 
cell line PANC-1 (p53-R273H). 
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Cells were silenced for p53, and their cell cycle profile was analyzed after 96 hours. 
As shown in Fig. 15D, knockdown of mutant p53 reduced proliferation of all the cell 
lines analyzed, with a more evident effect in TOV112D, OVCAR3, and PANC-1. 
 
Figure 15: Tumor cell lines show addiction to mutant p53 expression. 
A) Transient depletion of mutant p53 inhibits proliferation of MDA-MB-231 metastatic breast cancer 
cells. Cells were silenced for 96 hours with control siRNA (siC-), or siRNAs targeting p53 mRNA in 
the coding region (sip53 ORF) or in the 3’UTR (sip53 3’UTR). Cells were analyzed by flow cytometry 
and DNA content was evaluated by Propidium Iodide (PI) staining. B) Western blot of MDA-MB-231 
cells treated as in A confirmed efficent p53 knockdown. Hsp90 protein has been analyzed as loading 
control. C) Depletion of mutant p53 in MDA-MB-231 reduces phospho-ERK and phospho-AKT. Cells 
were treated for 96 hours with indicated siRNAs, and analyzed by western blot with phospho-specific 
antibodies. p53 was blotted to control knockdown efficiency. Hsp90 was detected as loading control. 
D) Transient depletion of mutant p53 inhibits proliferation of other cancer cell lines. The indicated 
cells were silenced for 96 hours with siRNA p53ORF or a control siRNA, and proliferation was 
analyzed as in A. E) Mutant p53 depletion affects the activation of ERK and AKT pathways in a cell-
specific manner. The indicated cells were treated and analyzed exactly as in C. Actin was used as 
loading control. 
  83 
In parallel, we analyzed the effects of mut-p53 depletion on ERK1/2 and AKT1 
activities (Fig. 15E). The results uncovered intrinsic differences in these cell lines. As 
observed in MDA-MB-231, knockdown of mutant p53 caused a reduction of 
phospho-ERK1/2 and phospho-AKT1 levels in TOV112D and OVCAR-3 cell lines. 
In PANC-1 cells, we detected only a reduction in phospho-AKT1 while in HT29 
cells, we did not observed any effect of p53 silencing on both this markers. 
Taken together these results support the role of mut-p53 in promoting aberrant cell 
growth, at least in part by sustaining the activation of different oncogenic pathways. 
 
Mutant p53 binds to DAB2IP in-vitro and in-vivo. 
Using Co-AP (Co-affinity purification) experiments we had previously observed that 
mut-p53 R175H can bind to DAB2IP (preliminary data). 
We therefore asked if this property is specific for the R175H substitution or can be 
extended to other mutant p53 hot-spots frequently detected in cancer. To this purpose, 
we repeated the Co-AP experiments including three additional DNA contact mutants: 
p53 R248W, p53 R273H, and p53 R280K expressed in fusion with MBP. As shown 
in Fig. 16A, all tested p53 mutants are able to interact with DAB2IP efficiently. 
Having confirmed and extended the interaction between mutant p53 and DAB2IP in 
over-expression experiments, we explored the existence of this complex at the 
endogenous level. 
As a first step, we analyzed the levels of DAB2IP in different cell lines carrying 
mutant p53: MDA-MB-231 (R280K) breast cancer cell line, OVCAR-3 (R248Q) and 
TOV112D (R175H) ovarian cancer cells, and colon adenocarcinoma cells HT29 
(R273H). As a reference, we also analyzed DAB2IP protein in PC3 prostate cancer 
cells (null for p53), a cell line in which DAB2IP is expressed at low levels by 
methylation process of its promoter (Chen et al., 2003). 
DAB2IP is clearly expressed at higher levels in all tested cell lines, when compared to 
PC3 (Fig. 16B). Interestingly, depending on the cell lines, two different bands could 
be detected (110kDa and 130kDa); these very likely correspond to two different 
DAB2IP isoforms generated by usage of alternative transcription star sites (for more 
details see the introduction section). Expression of these isoforms is variable: while in 
OVCAR-3 and HT29 both are present, in MDA-MB-231 the shorter form is 
prevalent, while in TOV112D only the 130kDa isoform is detected. 
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Little is known about the regulation and function of these different isoforms, therefore 
we decided to analyze the binding of mut-p53 to both. To this aim we tested DAB2IP 
interaction with mut-p53 in MDA-MB-231 and TOV112D cells by co-
immunoprecipitation. As shown in Fig. 16C, in both cell lines we detected binding 
between the two proteins, demonstrating that this complex formation occurs at the 
endogenous level. These experiments also demonstrate that mutant p53 can bind both 
DAB2IP isoforms.  
 
Figure 16: Characterization of DAB2IP-mutant p53 interaction. 
A) DAB2IP binds to multiple p53 hot-spot mutants. 293T cells were co-transfected with a HA-
DAB2IP expressing construct together with plasmids encoding the indicated p53 mutants fused to 
MBP. After purification with amylose resin, samples were analyzed by western-blot. In the first panel 
are shown DAB2IP levels in the total lysate (1/40 of inputs); the middle panel shows HA-DAB2IP co-
purified with p53 mutants. Both panels derive from the same autoradiography film (have the same 
exposure). In the bottom panel are shown MBP-p53 fusion proteins (baits) after purification, visualized 
by DAB staining. B) DAB2IP protein is expressed in human cancer cell lines bearing mutant p53. 
Lysates were carefully quantified and 10µg were loaded on each lane of the gel. The DAB2IP promoter 
is hyper-methylated in PC3 cells (null for the p53 gene) therefore this line provides a reference for 
DAB2IP protein levels in cells in which the gene is silenced. Hsp90 provides a loading control. C) 
Mutant p53 binds endogenous DAB2IP in cells. Co-immunoprecipitation of DAB2IP and mut-p53 in 
MDA-MB-231 (p53 R280K) and TOV112D (p53 R175H) cell lines. After immunoprecipitation with 
anti-p53 (DO-1) monoclonal antibody, complexes were analyzed by western-blot with DAB2IP 
polyclonal antibody. The input is 1/50 of the total lysate used for IP. 
 
Mutant p53 can bind DAB2IP in the cytoplasm 
Inactive DAB2IP is localized to plasma membrane in resting cells; in response to 
specific signals, it shuttles into the cytoplasm, where it exerts its function binding 
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different partners. Therefore interaction between mutant p53 and DAB2IP should 
occur in the cytoplasm.  
 
 
Figure 17: Mutant p53 binds DAB2IP in the cytoplasm. 
A) Cytoplasmic localization of ectopically expressed mutant p53. H1299 cells were infected with a 
retrovirus expressing p53 R175H or with control pLPC vector. Mut-p53 is visualized by indirect 
immunofluorescence using a monoclonal anti-p53 antibody (DO-1). Nuclei are visualized with 
Hoechst. B) Cytoplasmic localization of DAB2IP in cancer cells with mut-p53. MDA-MB-231 were 
infected with a retrovirus expressing DAB2IP or the control pLPC vector. DAB2IP is visualized by 
indirect immunofluorescence using a polyclonal anti-DAB2IP antibody. C) Mutant p53 is detected in 
the cytoplasm of tumor cell lines. MDA-MB-231, TOV112D, and PANC-1 cells were subjected to 
biochemical fractionation to separate nuclei and cytoplasm. Equal fractions of the purified lysates were 
analyzed by western-blot. Tubulin (a cytoplasmic protein) and HMGA (a nuclear protein) were 
detected to verify purity of the fractions. D) Mutant p53 binds DAB2IP in the cytoplasm. Co-
immunoprecipitation of endogenous DAB2IP and mut-p53 in cytoplasmic fractions of MDA-MB-231 
and PANC-1 cells is shown in the left panels. The experiment was performed as in Fig. 2C. The input 
is 1/40 of total cytoplasmic fraction used for IP. Tubulin (a cytoplasmic protein) and Lamin A (a 
nuclear protein) were detected to verify purity of the fractions. 
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Although p53 is mainly nuclear, there are evidences of cytoplasmatic localization of 
mut-p53 (Morselli et al., 2008). By immunofluorescence, we confirmed that over-
expressed mutant p53 localizes both in the nucleus and in the cytoplasm (Fig. 17A), 
while DAB2IP is present just in the cytoplasm (Fig 17B). 
We also evaluated the subcellular distribution of endogenous mut-p53 by biochemical 
fractionation: we purified cytoplasmic and nuclear extracts of MDA-MB-231, 
TOV112D, and PANC-1 cells, and investigated mutant p53 distribution by 
immunoblotting. The efficiency of the fractionation process was verified by analyzing 
the distribution of Tubulin (cytoplasmatic) and HMGA (nuclear) proteins. 
As shown in Fig. 17C, mut-p53 could be detected in the cytoplasmic fraction of all 
cell lines tested. In detail, TOV112D and PANC-1 cells showed a significant fraction 
of mut-p53 in the cytoplasm, while in MDA-MB-231 cells mut-p53 has a 
predominantly nuclear localization. 
To verify interaction between mut-p53 and DAB2IP in the cytoplasm, we performed 
Co-IP experiments from the cytoplasmic fraction of MDA-MB-231 and PANC-1 
cells. As reported in Fig. 17D, DAB2IP was co-immunoprecipitated with cytoplasmic 
mutant p53 in both cell lines. Notably, in MDA-MB-231 cells, even if cytoplasmic 
p53 is less abundant, we observed a higher affinity of complex formation. 
Together these results confirm the cytoplasmic localization of mutant p53 and 
indicate that mut-p53 can bind DAB2IP in its physiological compartment. 
 
Characterization of protein domains involved in DAB2IP-mutant p53 interaction 
DAB2IP is a scaffolding molecule that recruits multiple signaling proteins through its 
distinct domains. To map the region of DAB2IP involved in mutant p53 binding we 
generated by PCR different DAB2IP constructs containing selected domains 
(schematically represented in Fig. 18B). 
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Figure 18: Characterization of the domains involved in DAB2IP-mutant p53 interaction. 
A) DAB2IP binds to mut-p53 through the C2 domain. Interaction between MBP-p53 R175H and 
various DAB2IP deletion constructs was analyzed by Co-AP as in Fig. 16A. Inputs are 1/40 of the 
lysate. B) Schematic representation of the structure and functional domains of full-length DAB2IP and 
the fragments used in Co-AP experiments. Their capability to interact with p53 R175H in Co-AP assay 
is also indicated. C) Mutant p53 binds to DAB2IP through the DNA binding (DBD) domain. 
Interaction between the DAB2IP 80-186 fragment and various mut-p53 deletions fused to MBP was 
analyzed by Co-AP as in Fig. 16A. The input is 1/40 of the lysate. The upper panels derive from the 
same autoradiography (have the same exposure). D) Schematic representation of the structure and 
domains of p53, and the fragments used as baits in Co-AP experiment. Their capability to interact with 
DAB2IP 80-186 is also indicated. 
 
We transfected them in 293T cells together with MBP-p53 R175H or MBP alone, and 
performed Co-AP analysis. Mutant p53 binds efficiently to all DAB2IP constructs 
containing the C2 domain (Fig. 18A and 18B), unveiling the relevance of this region 
for interaction. The C2 domain is a protein-protein interaction domain involved also 
in the binding to ASK1 and VEGFR (see introduction section). 
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Using a similar approach, we performed Co-AP assays with a set of mut-p53 deletion 
constructs in fusion with MBP, and we mapped the complementary domain of mutant 
p53 involved in DAB2IP binding (Fig. 18C and 18D): the experiments indicate that 
the DNA binding domain of mutant p53 is necessary for this interaction. 
Notably, the isolated N-terminal region of DAB2IP appears to bind mutant p53 with a 
higher affinity than full-length DAB2IP, suggesting that its C-terminus might 
interfere with interaction (Fig. 18A). Indeed, DAB2IP has been suggested to exist in a 
closed conformation in resting cells through an intra-molecular interaction between its 
N-terminal and C-terminal domains (Zhang et al., 2003). Therefore, it is possible that 
mutant p53 may bind with higher affinity – or even selectively – to activated (i.e. 
open) DAB2IP. 
 
Correlation of DAB2IP expression to p53 status in cancer cell lines. 
DAB2IP is inactivated by epigenetic silencing in a wide range of tumors (see 
introduction); nevertheless, in many of the patients analyzed for those methylation 
studies, as well as in a variety of other cancers, DAB2IP promoter is not hyper-
methylated. It is thus possible that cancer cells can develop alternative ways to get rid 
of DAB2IP onco-suppressive functions. 
One established mechanism of mutant p53 gain-of-function is its capability to interact 
and sequester onco-suppressive proteins, preventing their function; therefore mut-p53 
may be able to suppress DAB2IP activities by sequestering it in an inactive complex. 
According to this hypothesis, we would expect that in tumors carrying mutant forms 
of p53 there should be less selective pressure to inactivate DAB2IP at the 
transcriptional level, because the protein is already – at least partially – functionally 
inactive. 
To test this hypothesis, we analyzed by RT-qPCR the levels of DAB2IP mRNA in 
different cancer cell lines for which the status of p53 is known. Samples were divided 
in two groups: those with wild-type p53 or having no p53 (CA1A, SKOV-3, U2OS, 
HeLa, H1299, 293T, MCF7, HCT116, MG63 and PC3), and those with mutant p53 
(HT29, OVCAR-3, MDA-MB-231, MDA-MB-468, MDA-MB-157, SUM-149, 
DU145, SKBR-3, TOV112D, and PANC-1). As a control, we analyzed two different 
housekeeping genes: GAPDH and H3. As shown in Fig. 19A, while there were no 
significant variations in the expression of GAPDH and H3, a statistically significant 
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difference was detected for DAB2IP in the two sample groups: DAB2IP is expressed 
at higher levels in cell lines with mut-p53. 
In various published studies the methylation status of DAB2IP promoter has been 
analyzed in different cancer cell lines (see introduction). We collected such data, and 
calculated the frequency of DAB2IP promoter hyper-methylation in cell lines with 
mutant p53, compared to cells with wild-type or no p53 (Fig. 19B). Interestingly, cell 
lines with mut-p53 have a remarkably lower frequency of DAB2IP promoter hyper-
methylation with respect to other cancer cell lines. 
Figure 19: DAB2IP expression in tumor cell lines with or without p53 mutations. 
A) DAB2IP expression is collectively higher in cancer cell lines bearing mutant p53. DAB2IP mRNA 
levels were analyzed by RT-qPCR in a panel of 20 tumor cell lines, subdivided in two groups 
according to p53 status, as indicated (see text for details of the lines used). The boxplots show relative 
expression (median and quartiles) of the indicated genes, normalized to 18S rRNA, and compared to 
their expression in the MCF10A cell line used as a reference (i.e. considered as 100%). MCF10A is a 
non tumorigenic human mammary epithelial cell line, with wild-type p53 status. The H3 and GAPDH 
transcripts were analyzed as controls (*, P<0,05%). B) DAB2IP promoter is less frequently methylated 
in cell lines bearing mut-p53. The pie charts summarize the methylation status of the DAB2IP 
promoter as described in the literature for a total of 39 different cancer cell lines, subdivided according 
to their p53 status derived from the “p53 mutation database” of IARC . 
 
In conclusion, using two different approaches (analysis of DAB2IP mRNA levels by 
RT-qPCR, and review of literature on DAB2IP promoter methylation) we observed 
that DAB2IP tends to be less frequently silenced in cell lines that express mutant p53; 
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this observation, although not conclusive, is in line with the hypothesis that mut-p53 
might functionally inactivate DAB2IP protein by direct interaction. 
 
DAB2IP ablation can functionally rescue depletion of mutant p53 in cancer cell 
lines 
If mut-p53 exerts part of its oncogenic functions by inactivating DAB2IP, we expect 
that active DAB2IP is released when mut-p53 is depleted by siRNA in cancer cells 
expressing mutant p53, eventually contributing to inhibit their proliferation (see Fig. 
15). 
To test this hypothesis, MDA-MB-231 cells were transfected with siRNAs targeting 
p53 (sip53) or DAB2IP (siDAB2IP), or with a combination of both oligos. After 96 
hours, cell proliferation was verified by P.I. staining and FACS analysis as described 
in Figure 15. As shown in Figure 20A and 20B, depletion of DAB2IP had no effects 
on proliferation of these cells while, as in previous experiments, p53 knockdown 
significantly reduced cell cycle progression and in particular S-phase (Fig. 20A). 
Notably, concomitant DAB2IP silencing abolished the proliferation arrest induced by 
depletion of mut-p53. This result suggests that part of the inhibitory effect of mut-p53 
knockdown may be dependent on the release of DAB2IP, since such effect is reduced 
by DAB2IP down-regulation. 
In addition to measuring cell proliferation, we analyzed the effects of DAB2IP and 
mut-p53 depletion on the activation of oncogenic signaling pathways. In line with 
FACS results, reduction of phospho-ERK1/2 due to p53 silencing was also rescued by 
DAB2IP down-regulation (Fig. 20C). To verify specificity of the observed results, 
and to exclude off-target effects, we repeated these experiments using additional 
siRNAs targeting DAB2IP mRNA both in the ORF and in the 3’UTR. When analyzed 
in FACS experiments, all DAB2IP siRNAs could rescue the cell cycle arrest induced 
by p53 depletion, although with variable efficiency (Fig. 20E). 
As shown in Fig. 20D all siRNAs tested efficiently reduce DAB2IP protein levels. It 
is also important to stress that co-transfection of any DAB2IP siRNAs had no 
detectable effect on the concomitant down-regulation of mutant p53 (Fig. 20D); 
therefore, the phenotypic rescue is not due to less efficient silencing of mut-p53 but is 
dependent on DAB2IP protein status. 
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Together, these data support the existence of an epistasis between mutant p53 and 
DAB2IP, whereby mut-p53 interplay with DAB2IP may be an important component 
of its gain-of-function. 
 
Figure 20 DAB2IP silencing rescues the phenotype induced by mutant p53 depletion in MDA-
MB-231 cells.  
A) DAB2IP silencing rescues the proliferative arrest caused by mutant p53 depletion. Cells were 
treated with siRNA against p53 or DAB2IP, alone or in combination, as indicated. Cell treatments and 
analysis were performed as indicated in Fig. 15. B) The histogram summarizes the quantitation of the 
S-phase fraction of MDA-MB231 cells treated as in A. Data correspond to the average of three 
independent experiments. Error bars are standard deviation. C) DAB2IP silencing rescues the effects of 
mut-p53 depletion on ERK activation. Western-blot analysis of phopsho-ERK1/2 in MDA-MB-231 
cells silenced with siRNA against p53 or DAB2IP, alone or in combination, as indicated. Blot for p53 
and DAB2IP confirms depletion of the proteins. Actin is blotted as a loading control. D-E) The effects 
of DAB2IP silencing are reproducible with different siRNA, and are not dependent on a reduced 
efficiency of p53 knockdown. D) MDA-MB-231 cells were transfected with siRNA against p53, alone 
or in combination with three different DAB2IP siRNAs as indicated. D) Cell cycle effects were 
evaluated by FACS analysis as in A: the histogram summarizes the percentage of cells in S phase as in 
B (*, P<0,01%). E) Western blot for p53 and DAB2IP confirms depletion of the proteins with all 
siRNA combinations. Actin is blotted as a loading control. 
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Mutant p53 is important in TNF-induced cell migration 
As extensively discussed in the introduction, inflammatory cytokines, and in 
particular TNFα, can promote various aspects of cell transformation, including 
increased cell motility, invasion, and acquisition of mesenchymal features by 
epithelial cells. For example, TNFα can increase SNAIL transcription and protein 
stability activating both PI3K-AKT and NF-κB pathways, fostering in this way EMT 
and metastasis (Wu and Zhou, 2010). 
The current evidence indicates that mutant p53 does not directly induce metastasis, 
but rather can funnel extra-cellular signals - such as TGFβ (Adorno et al., 2009) or 
EGF (Muller et al., 2009) - towards activation of pathways promoting cell motility. 
Since mut-p53 can sustain both the AKT and the NF-κB pathways (Dong et al., 2009; 
Weisz et al., 2007a), we asked if mutant p53 might be involved in TNF-induced cell 
migration/invasion. 
Cancer cells treated with macrophage-conditioned culture medium are induced to 
migrate and invade in vitro, and this response is strictly dependent on TNFα produced 
by activated macrophages (Wu et al., 2009). In a similar experimental setup, we 
treated cells with culture medium conditioned by LPS-activated murine dendritic cells 
(DCCM – dendritic cells conditioned medium), and performed in vitro invasion 
assays. We found that DCCM dramatically increased the invasive ability of different 
cancer cell lines, when compared with regular medium (Fig. 21 and data not shown). 
It is important to note that these transformed metastatic cells have an intrinsic 
migratory and invasive behavior, and the effect of DCCM is to trigger a significant 
increase in such activity. 
We used this model to investigate mut-p53 involvement in TNF-induced cell 
migration. MDA-MB-231, MDA-MB-468, and OVCAR-3 cells were transfected with 
p53 or control siRNAs, and 48 hours later we performed Matrigel invasion assays 
treating cells with DCCM or control medium (T.C-). As summarized in Fig. 21C-E, 
the increase in invasion triggered by DCCM is abolished (in MDA-MB-231 cells) or 
compromised (in MDA-MB-468 and OVCAR-3 cells) by mutant p53 knockdown. 
Since activated dendritic cells secrete a variety of cytokines and growth factors in 
addition to TNFα, it is important to determine whether the observed phenotype is 
actually dependent on TNFα. As shown in Fig. 21A, the addition of a TNFα blocking 
antibody to the medium suppressed the increase in cell invasion induced by DCCM. 
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Dendritic cells also secrete TGFβ (Moustakas et al., 2002), and MDA-MB231 cells 
produce TGFβ and TGF receptors in an autocrine stimulatory loop (Adorno et al., 
2009). Given that mut-p53 can efficiently steer TGFβ signaling to promote a 
metastatic behavior (Adorno et al., 2009), we asked whether the effect of DCCM 
might be dependent on TGFβ signaling. As shown in Figure 21B, treatment of MDA-
MB231 cells with a specific TGFβ inhibitor (SB431542) did not affect the increase in 
invasion triggered by DCCM. 
Together these results uncover a previously unrecognized role of mutant p53 in 
inducing cell migration and invasion in response to TNFα.  
 
 
Figure 21: Mutant p53 has a role in TNF-induced cell migration. 
A) Dendritic cells conditioned medium (DCCM) stimulates the invasive behavior of MDA-MB-231 
cells through TNFα. Invasion assay of MDA-MD-231 cells treated for 22 hours with DCCM or control 
medium (TC-) in the presence or absence of TNFα blocking antibody (10 µg/ml). Invasion was 
measured as number of cells counted per average field. Histogram represents the fold increase in cells 
migrated with respect to control. Error bars indicate standard deviation (n = 3). B) TGFβ signaling is 
not required for DCCM-induced invasive behavior of MDA-MB-231 cells. Invasion assay of MDA-
MD-231 cells treated as in A, in the presence or absence of the TGFβ inhibitor SB431542 (10µM). 
Histogram represents the fold increase in cells migrated with respect to control. Error bars indicate 
standard deviation (n = 3). C-E) Knockdown of mutant p53 blunts the pro-invasive effect of DCCM. 
The metastatic cell lines MDA-MB-231 (C), OVCAR-3 (D), and MDA-MB-468 (E) were treated with 
the indicated siRNAs; 48 hours post-transfection invasion assays were performed as in A. The upper 
panels summarize the fold increase in cells migrated with respect to control. Error bars indicate 
standard deviation (n = 3). Bottom panels show western blots of the respective cells, to confirm 
efficiency of mutant p53 depletion. 
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Pathways stimulated by mutant p53 in response to TNFα  
Several reports link mutant p53 to the pathways affected by TNFα (Kitamura et al., 
2009; Weisz et al., 2007a). To further characterize the cellular behaviors 
demonstrated above, we investigated at the molecular level the effects of mutant p53 
depletion in the signaling cascades activated by this pro-inflammatory cytokine. 
MDA-MB-231 and MDA-MB-468 cells were transfected with p53-specific or control 
siRNAs (sip53 and siC-). After 96h from silencing, we treated cells with TNFα for 
various times and analyzed the activation of p38 MAPK and JNK (kinases 
downstream to ASK1), and AKT by immunoblotting with phospho-specific 
antibodies. 
As shown in Fig. 22A, in MDA-MB-231 cells knockdown of mutant p53 stimulates 
the intensity and duration of p38 MAPK and JNK phosphorylation in response to 
TNFα, suggesting that mut-p53 might counteract activation of this pathway. 
Oppositely, mutant p53 knockdown compromised AKT phosphorylation after 
cytokine treatment, indicating that mut-p53 is necessary to transduce TNFα signaling 
to PI3K-AKT activation. 
Interestingly, in MDA-MB-468 cells we did not observe a requirement of mutant p53 
in PI3K-AKT activation (Fig. 22B). Nevertheless, in this cell line mut-p53 appears to 
have an essential role to counteract p38 MAPK and especially JNK activation in 
response to TNFα. 
The role of mutant p53 in transducing TNFα signaling to AKT activation was also 
analyzed in MEFs derived from p53 knock-out (KO) and p53(R172H) knock-in mice 
(Fig. 22C). Cells were treated with TNFα for different times and analyzed by western 
blot with phospho-specific antibodies. In line with results in human breast cancer cell 
lines, mut-p53 Ki MEFs presented a higher steady-state AKT activation then KO 
MEFs; importantly, this difference was further amplified after TNFα treatment (Fig. 
22C). 
We also asked if mut-p53 might have a role in mediating activation of the NF-κB 
pathway in cells exposed to TNFα. One good model to study the effects of chronic 
inflammation in cell transformation is the pancreatic cancer cell line PANC1; in this 
model, a role for mutant p53 has been suggested (Blandino et al., 2012). We therefore 
used this cell line, and to analyze NF-κB activation we measured by RT-qPCR the 
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mRNA levels of two target genes, IL8 and ICAM-1, after chronic (i.e. long term) 
TNFα stimulation. 
 
Figure 22: Mutant p53 depletion affects various pathways downstream of TNFα . 
A) Mutant p53 depletion in MDA-MB-231 cells reduces AKT and increases p38 and JNK activation 
by TNFα. Cells were treated for 96 hours with control or p53 siRNAs, stimulated with TNFα (10 
ng/ml) for the indicated time-frames, and analyzed by western blot with phospho-specific antibodies. 
Blot for p53 confirms efficient knockdown of the protein. Blot for Hsp90 provides a loading control. 
B) Mutant p53 depletion in MDA-MB-468 cells increases p38 and JNK activation by TNFα. Cells 
were treated and analyzed as in A. C) Mouse embryo fibroblasts (MEF) derived from mutant p53 
(R172H) knock-in mouse (mutp53 ki) display stronger AKT activation in response to TNFα than 
MEFs derived form p53 nullizygous mice (p53KO). The indicated MEF cell lines, immortalized with 
H-RASV12, were treated for different times with TNFα (10 ng/ml) and analyzed by western blot with 
phospho-specific AKT antibodies. Actin provides a loading control. D) Mutant p53 is important for 
induction of NF-κB target genes in response to TNFα. PANC-1 cells were silenced for 48 hours with 
control or p53 siRNAs, and treated for 24 hours with different concentrations of TNFα as indicated. 
The graphs show IL8 and ICAM1 expression levels as measured by RT-qPCR. Data are normalized to 
Actin, and compared to expression levels of untreated cells transfected with control siRNA (siC-). 
Error bars indicate standard deviation (n = 3). Efficiency of mutant p53 depletion was confirmed by 
western blot of the same cells (panel on the right). 
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Cells were transfected with p53-specific or control siRNAs (sip53 and siC-), and 48 
hours later different concentrations of TNFα were added for additional 24 hours. As 
shown in Fig. 22D, TNFα efficiently stimulates the transcription of IL8 and ICAM-1 
in control cells, while induction is compromised by mutant p53 silencing, suggesting 
that mut-p53 is required to diverge TNFα signals to NF-κB activation. 
Although still preliminary, these data indicate that mutant p53 can steer the TNFα 
signaling cascade towards a pro-oncogenic response: it dampens activation of p38 
MAPK and JNK, while it promotes AKT and NF-κB responses, counteracting TNFα 
cytotoxicity and sustaining tumor progression.  
 
DAB2IP knockdown can rescue the effects of mutant p53 depletion in response 
to TNFα  
In sharp contrast to mutant p53 (see above), DAB2IP is known to modulate the TNFα 
signaling cascade towards activation of the pro-apoptotic ASK1-JNK axis, 
counteracting activation of the pro-survival AKT and NF-κB pathways. Therefore, 
the interaction between mutant p53 and DAB2IP could be relevant in the regulation of 
this “TNFα switch”. 
To test this hypothesis, we verified if the knockdown of mutant p53 can be 
phenotypically rescued by DAB2IP depletion in the context of TNFα-induced cell 
migration/invasion. MDA-MB-231 cells were transfected respectively with sip53 and 
siDAB2IP, or with a combination of both siRNAs. 48 hours post-transfection, we 
performed invasion assays stimulating cells with DCCM or control medium. As 
shown in Figure 23A, DAB2IP silencing had no significant effects in the migratory 
response to DCCM, which was instead dramatically blunted by mut-p53 knockdown 
(see also Fig. 21). Strikingly, the impaired response to DCCM of p53 knockdown 
cells was totally rescued by the concomitant silencing of DAB2IP (Fig. 23A). 
Oppositely, overexpression of DAB2IP in MDA-MB-231 clearly decreased the 
invasive response of these cells to DCCM (Fig. 23B), indicating that DAB2IP is 
sufficient to abrogate inflammatory cytokine-induced invasion. Under these 
conditions, overexpression of DAB2IP appears to phenocopy mut-p53 knockdown. 
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Figure 23: DAB2IP silencing rescues the phenotype induced by mutant p53 depletion in the pro-
invasive response to TNFα . 
A) DAB2IP silencing restores the invasive behavior of p53-depleted MDA-MB-231 cells under DCCM 
stimulation. Cells were treated with siRNA against p53 or DAB2IP, alone or in combination, as 
indicated. Invasion assays were performed and quantified as in Fig. 21. Error bars indicate standard 
deviation (n = 3). Efficiency of DAB2IP and mutant p53 depletion was confirmed by western blot of 
the same cells (panel on the right). B) Over-expression of DAB2IP abolishes the pro-invasive response 
of MDA-MB-231 cells to DCCM. Cells were infected with a retrovirus expressing DAB2IP or a 
control vector (pLPC). Invasion assays were performed and quantified as in Fig. 21. Error bars indicate 
standard deviation (n = 3). The panel on the right shows DAB2IP and p53 expression analyzed by 
western blot of the same cells. C) DAB2IP silencing restores TNFα induced transcriptional activation 
of NF-κB target genes in cells depleted of mut-p53. PANC-1 cells were transfected with siRNAs 
against p53 or DAB2IP, alone or in combination, as indicated. The graphs show IL8 and ICAM1 
expression as measured by RT-qPCR. Cells were treated and analyzed as described in Fig. 22D. 
Efficiency of p53 and DAB2IP depletion was confirmed by western blot of the same cells (lower 
panel). 
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We also analyzed the role of DAB2IP in the regulation of NF-κB transcriptional 
activity downstream of TNFα. To this purpose, PANC-1 cells were transfected with 
sip53, siDAB2IP, or with a combination of both siRNAs. After 48 hours, cells were 
treated with 1 ng/ml TNFα for additional 24 hours and the levels of IL-8 and ICAM-1 
mRNA were analyzed by RT-qPCR (Fig. 23C). As expected, mut-p53 knockdown 
blunted expression of NF-κB targets after TNFα treatment. Notably, the concomitant 
silencing of DAB2IP restored the NF-κB transcriptional response in cells depleted of 
mut-p53 (Fig. 23C). 
It should be noted that knockdown of DAB2IP increased steady-state expression of 
IL8 and – to a lesser extent – ICAM in untreated cells, underscoring the primary role 
of DAB2IP in controlling NF-κB activity. Nevertheless, while mut-p53 silencing 
drastically compromises TNFα-induced NF-κB activity in cells with DAB2IP, it has 
no effect in cells in which this gene has been already removed. This is compatible 
with a model in which mutant p53 is sequestering a fraction of DAB2IP which is 
released upon p53 silencing. 
Collectively we have demonstrated the existence of an epistasis between 
DAB2IP and mutant p53 in inflammatory cytokine-induced invasion. In this specific 
context, mutant p53 oncogenic properties appear to be strictly dependent on DAB2IP 
status. 
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DISCUSSION 
 
Inflammation has been recognized as a significant factor in the development 
of cancer, with opposing effects (Colotta et al., 2009): acute inflammation usually 
counteracts tumor development, while chronic inflammation promotes it. In line with 
this concept, the key pro-inflammatory cytokine TNFα can either induce apoptosis or 
increase cell survival and motility, depending on cell type, growth conditions, and 
molecular interactions with other signaling pathways (Balkwill, 2009). 
The RasGAP protein DAB2IP is a key modulator of the cellular response to 
TNFα, since it promotes activation of the pro-apoptotic kinase Ask1 (Zhang et al., 
2003), while it counteracts cell survival and migration mediated by NF-κB activation 
(Min et al., 2010). In addition to its function downstream of TNFα, DAB2IP can also 
influence the output of other crucial oncogenic pathways such as Ras (Chen et al., 
2002; Min et al., 2010), PI3K-AKT (Xie et al., 2009) and WNT/β-catenin (Xie et al., 
2010). Indeed, acting as a multi-domain regulatory scaffold, DAB2IP is able to 
attenuate many of the extracellular signals involved in cancer progression, thus 
behaving as a bona fide tumor-suppressor. DAB2IP is rarely mutated in tumors, 
instead its expression is abolished by epigenetic silencing (Chen et al., 2003; Dote et 
al., 2005; Dote et al., 2004). In addition to promoter methylation, it is conceivable that 
other mechanisms exist through which tumor cells can bypass DAB2IP functions. 
The tumor-suppressor p53 is mutated in more than 50% of human cancers, and 
these mutations not only cause p53 loss-of-function, but also confer new oncogenic 
properties to the protein (gain of function, or GOF) (Brosh and Rotter, 2009). A 
significant amount of research is currently focused on mutant p53 GOF, because of its 
obvious implications in devising prognostic and therapeutic strategies for cancer. 
Notably, there are experimental evidences that tumor-derived p53 mutants can exert a 
stimulatory role in all the signaling pathways that are normally counteracted by 
DAB2IP (i.e. Ras-MAPK, PI3K-AKT, NF-κB, and WNT/β-catenin) (Dong et al., 
2009; Muller et al., 2009; Sauer et al., 2010; Schneider et al., 2010; Weisz et al., 
2007a). This observation is one of the main evidences that encouraged us to undertake 
the present study. 
In a first set of experiments, we confirmed some published data on the “addiction” on 
cancer cell lines to mut-p53 expression, and we extended these observations verifying 
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that mutant p53 sustains activation of Ras-MAPK and PI3K-AKT pathways in 
various cellular models. We noticed variability in the p53-dependency of the 
activation of these pathways in different cell lines, and we believe this underlies the 
complexity of the tumorigenic process. In fact, mutation of the p53 gene doesn’t 
usually occur in the first steps of transformation, but rather is involved in the 
subsequent phases to foster tumor development (Petitjean et al., 2007). Accordingly, 
different cancer cell lines are characterized by alterations of specific oncogenic 
pathways, and the role of mutant p53 must be searched not in its capability to affect 
universally a single signaling cascade, but instead in its inclination to modify a 
plethora of processes. Therefore, it is possible that in some cell lines mutant p53 
stimulates cell growth fostering RAS and/or PI3K pathways, while in other cell lines 
the functional interaction of mutant p53 with other signaling cascades is more 
relevant. 
 
Mutant p53 binds to DAB2IP 
Starting from our observation that mutant p53 can physically interact with 
DAB2IP, we decided to study the potential role of this interaction in transformed 
cells. More specifically, we set out to test the hypothesis that some gain-of-function 
properties of oncogenic p53 mutants might depend – at least in part – on sequestration 
and functional inactivation of DAB2IP in cancer cells. We confirmed that DAB2IP 
interacts with various tumor derived (hot-spot) p53 mutants in vitro and in cells at 
endogenous expression levels; therefore, this complex can potentially form in all 
tumors carrying mutant p53. 
Given the high concentration of mut-p53 protein in tumor cells, relatively weak 
molecular interactions, which are marginal within the wt p53 protein, may be 
amplified by mass action and reach a threshold that allows them to exert a measurable 
impact on biochemical processes within the cell (Strano et al., 2007). In particular this 
principle can be relevant for cytoplasmic p53; even if the majority of mut-p53 
activities has been reported to occur in the nucleus (Brosh and Rotter, 2010), the mut-
p53 cytoplasmic fraction may be fundamental to understand gain-of-function of this 
oncogene. This concept is well highlighted by the recent evidence that cytoplasmic 
mutant p53 can affect autophagy (Morselli et al., 2008). In line with this reasoning, 
we demonstrated that mutant p53 can bind DAB2IP in the cytoplasm, thus suggesting 
another possible mechanism for its gain-of-function. 
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We determined that mutant p53 binds to the N-terminal C2 domain of 
DAB2IP. In physiological conditions this region is the docking site for ASK1, 
GSK3β, and VEGFR2, so mutant p53 can potentially affect the association of 
DAB2IP with those partners, with implications for its function. We also determined 
that mut-p53 binds to DAB2IP through its “core” DNA-binding domain (DBD). This 
was not surprising, since the core domain of mutant p53 is not only the major site of 
missense mutations, but gains additional functions serving as a protein–protein 
interaction module that sequesters and inactivates cellular proteins with 
oncosuppressive activities (Goh et al., 2011). 
In resting cells, DAB2IP has been suggested to exist in a closed conformation due to 
intra-molecular interaction between its N-terminal and C-terminal domains (Zhang et 
al., 2003). Our experiments suggest that mutant p53 may bind with higher affinity to 
activated (i.e. open) DAB2IP, since the N-terminal half of DAB2IP appears to bind 
mutant p53 much better than full-length DAB2IP (Fig. 18). Thus, mutant p53 might 
not bind all DAB2IP in the cell, but rather might associate with the active DAB2IP 
fraction in the cytoplasm in response to specific signaling. This may be relevant for 
the stoichiometry of mut-53/DAB2IP association and its functional impact. To 
confirm this possibility, we plan to analyze the kinetics of complex formation after 
treatment with TNFα. In this respect, a phospho-specific antibody for DAB2IP has 
been described (Xie et al., 2009); this reagent may be used to evaluate the fraction of 
activated DAB2IP that co-immunoprecipitates with mut-p53 in stimulated or resting 
cells. 
 
Evidence of a mutant p53 DAB2IP regulatory axis in cancer cell lines 
As mentioned before, cancer cells may develop different mechanisms to 
abrogate DAB2IP functions besides hyper-methylation of its promoter: in fact, we 
hypothesize that mutant p53 ability to bind DAB2IP may be one of these alternative 
mechanisms. In this respect, it would be interesting to analyze the frequency of 
DAB2IP methylation in human tumors where p53 is mutated as an early event, 
compared to tumors where p53 is retained, lost, or mutated as a late event in the 
transformation process. However, this analysis may prove difficult to perform, since 
there are few papers reporting gene expression data on primary tumors with defined 
p53 status (Miller et al., 2005), and unfortunately those studies employed microarray 
platforms lacking a reliable probeset for DAB2IP. 
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As a proof of principle, we decided to analyze DAB2IP expression by RT-qPCR in a 
set of cancer cell lines for which the p53 status is known. We also retrieved all 
published data on the methylation status of DAB2IP in cancer cell lines. We found 
that DAB2IP is less frequently silenced in cell lines with mutant p53. These data are 
clearly not conclusive, but they suggest that cancer cells with mutant p53 may have a 
reduced selective pressure to down-regulate DAB2IP at the transcriptional level, 
supporting the hypothesis that mutant p53 might inhibit DAB2IP protein functions. 
In line with this hypothesis, we found that DAB2IP depletion could rescue the 
growth-inhibitory effects of mutant p53 knockdown in metastatic cancer cell lines 
(Fig. 20). We believe these data support the existence of an epistasis between mutant 
p53 and DAB2IP, and therefore mutant p53 interplay with DAB2IP may be important 
for its gain-of-function. 
In fact, regulation of cell cycle progression and ERK activation might be just the tip 
of the iceberg of a more intricate scenario: the inhibitory effect of mutant p53 on 
DAB2IP may be relevant for other pathways modulated by this tumor suppressor. 
 
A possible mutant p53-DAB2IP axis in oncogenic responses to TNFα 
It has been established that TNFα, fundamental in chronic inflammation, can 
promote EMT and metastasis in transformed cells by activating the PI3K-AKT and 
NF-κB pathways (Wu et al., 2009; Wu and Zhou, 2010). At the same time, DAB2IP 
plays a crucial role in defining the cellular responses to TNFα, and in particular 
modulates the process of EMT at various levels (see introduction). 
Mutant p53 has a fundamental role in fostering motility and invasive capabilities of 
tumor cells (Girardini et al., 2011; Solomon et al., 2011). In particular, different 
physiological stimuli such as TGFβ (Adorno et al., 2009) or EGF (Muller et al., 2009) 
are thwarted by mutant p53 to induce cellular programs involved in metastasis. 
Therefore we asked whether mutant p53 might have a specific role in the context of 
TNFα- induced cancer invasion and aggressiveness. 
We discovered that tumor cells bearing mutant p53 respond to TNFα with a pro-
invasive behavior (Fig. 21). We excluded that this phenomenon requires the well 
established TGFβ/Smad/mut-p53/p63 axis (Adorno et al., 2009), and therefore we 
might have uncovered a novel facet of mutant p53 gain-of-function, perhaps most 
relevant for inflammatory tumors. Tumor stroma is characterized by the presence of 
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pro-inflammatory cytokines, which are produced by cells of the immune-system or by 
tumor cells in an autocrine mode (Allavena et al., 2008; Mantovani and Pierotti, 
2008). In this microenvironment, cancer cells bearing mutation of p53 gene could be 
selected for their metastatic propensity. 
Some reports suggest the involvement of mutant p53 in pathways downstream of 
TNFα (Kitamura et al., 2009; Weisz et al., 2007a). Therefore we investigated at the 
molecular level the effects of mutant p53 knockdown on the signaling cascades 
activated by this pro-inflammatory cytokine. In cellular models we verified that 
mutant p53 is important to sustain TNFα-induced activation of AKT and NF-κB 
pathways, while counteracting TNF-induced p38-MAPK and JNK activities (Fig. 22). 
Additionally, in preliminary experiments, we observed that mut-p53 depletion 
sensitizes cancer cells to TNFα-induced apoptosis (data not shown). Therefore, the 
role of mutant p53 in inflammation-induced tumorigenesis might not be limited to 
stimulation of cell motility and invasion, but might also extend to protection from the 
cytotoxic effects of inflammatory cytokines. If these data will be confirmed, the 
mutational status of p53 gene may represent a key to decode the contradictory effects 
of TNFα in tumor development: mutant p53 might be able to reduce its cytotoxic 
effects and – at the same time – amplify its pro-metastatic potentialities. 
Collectively, our data indicate that mut-p53 can manipulate TNFα activities in tumor 
cells: it counteracts TNFα cytotoxicity while stimulating survival and motility 
through activation of NF-κB and AKT pathways. In contrast, DAB2IP shifts the 
TNFα signaling cascade from activation of AKT and NF-κB to activation of ASK1, 
important for the cytotoxic effects of this cytokine (Min et al., 2010; Xie et al., 2009; 
Zhang et al., 2003). Therefore, we asked if the mutant p53-DAB2IP axis could be 
relevant in controlling this TNFα “switch”. We found that DAB2IP depletion could 
rescue TNFα-induced invasiveness and NF-κB transcriptional activity in cells 
depleted of mut-p53 (Fig. 23). Moreover, DAB2IP over-expression was sufficient to 
abolish TNFα-induced invasiveness and NF-κB activity in MDA-MB231 cells, in this 
respect resembling the phenotype of mutant p53 knockdown. 
 
In conclusion, we demonstrated the existence of an epistasis between DAB2IP 
and mutant p53 in inflammatory cytokine-induced invasion. In this context, mutant 
p53 oncogenic properties appear to be strictly dependent on DAB2IP status.  
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Although we still need to demonstrate that these phenotypes depend on the physical 
interaction between DAB2IP and mutant p53, the data presented here support our 
initial hypothesis that one of the mechanisms of mutant p53 gain-of-function could 
depend on its capability to sequester and functionally inactivate a fundamental brake 
of inflammation-induced tumorigenesis, such as DAB2IP. Therefore, besides the 
suggested nuclear role of mutant p53 in enforcing NF-κB transcriptional activities 
(Weisz et al., 2007a), we propose that mutant p53 may also act upstream in the TNFα 
signaling cascade, justifying its pleiotropic effects on multiple “cytoplasmic” 
pathways through one single gain-of-function mechanism: the block of DAB2IP 
functions. 
If confirmed, this hypothesis could have two important repercussions. First, the 
inhibitory effect of mut-p53 on DAB2IP might help clinicians predict the biological 
responses of tumor cells to TNFα, thus allowing a better use of TNF inhibitors in 
cancer treatment. Second, the physical interaction between mutant p53 and DAB2IP 
might become a potential target for development of drugs (small molecules or peptide 
mimics) that, interfering with their binding, could potentially counteract tumor 
progression by restoring DAB2IP function in tumor cells bearing mut-p53. 
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MATERIALS AND METHODS 
 
Cell Culture, Transfections, Retroviral Transductions and treatments. MDA-
MB-231, MDA-MB-468, PANC-1, HT29, 293T, 293GP cells were cultured in 
DMEM medium supplemented with 10% FCS (ECS0180L, Euroclone), and 
antibiotics (DE17-602E, Lonza). TOV112D, OVCAR-3, T47D, H1299, and PC3 cells 
were cultured in RPMI medium supplemented with 10% FCS and antibiotics.  
MEFs (Mouse Embryonic Fibroblasts) were generated by crossing mice of the 
appropriate genotype and collecting cells from 13.5 d.p.c. embryos as described in 
(Zacchi et al., 2002). MEF p53KO and MEF Ki p53R172H were immortalized 
through retroviral transduction of H-RasV12. 
HEK293T or 293GP were transfected using calcium-phospate. For siRNA 
transfections, cells were transfected with 50 nM siRNA oligonucleotides using 
Lipofectamine RNAiMax (Invitrogen), following manufacturer’s instructions.  
siRNAs used in this work are listed in the following table: 
siRNA Sequence Purchase from/ Reference 
Control siRNA 
(SiQ) 
Unknown All star negative control 
(1027281,Qiagen) 
sip53 ORF GACUCCAGUGGUAAUCUAC Eurofins MWG 
sip53 3’UTR GGUGAACCUUAGUACCUAA Eurofins MWG 
siDAB2IP A GGAGCGCAACAGUUACCUG Eurofins MWG 
siDAB2IP B GGUGAAGGACUUCCUGACA Eurofins MWG 
siDAB2IP 3’UTR GUAAUGUAACUAUCUCACC Eurofins MWG 
 
For retrovirus production, low confluency (∼20%) 293GP packaging cells, stably 
expressing retroviral gag and pol proteins, were transfected by calcium-phosphate 
precipitation. Briefly, cells were plated the day before the transfection in 10 cm2 
dishes in exactly 10 ml of medium. Each different virus was produced by co-
transfection of 10 µg of the vector of interest and 5 µg of pEnv-encoding vector. After 
8 hours, medium was changed with 10 ml of medium and cells incubated at 32°C. 
After 48-72h the virus-containing medium was filtered (0,45 µm filter) and 
supplemented with 10% FCS and 8 ug/ml polybrene. The culture medium of target 
cells growing at low confluence (∼30-40%) was replaced by the appropiate viral 
supernatant and incubated at 32°C for 24h. Infected cells were selcted through 
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puromycin treatment (2µg/ml). TNFα was purchased from Invitrogen; TGF-β 
inhibitor, SB431542 was purchased from Sigma. 
 
Plasmids. pCS2-DAB2IP FL and deletions were generated by clonig PCR products 
generated using specific primers; DAB2IP was amplified from pLENTI-DAB2IP 
(kindly provided by dr. K. Cichowski) with AccuPrime™ Taq DNA Polymerase High 
Fidelity (Invitrogen), following manufacturer’s instructions. pLPC-DAB2IP and 
pLPC-p53R175H vector were obtained by cloning respectively DAB2IP and 
p53R175H coding region into pLPC empty vector. 
pcDNA3-MBP and MBP-p53 wt were described previously (Lunardi et al., 2010); the 
coding sequences of p53 hot-spot mutants were PCR amplified from corresponding 
expression plasmids and cloned in frame with MBP in the pcDNA3-MBP vector. 
 
Western blot analysis and antibodies. Total cell extracts were prepared in RIPA 
buffer without SDS (150mM NaCl, 50mM Tris-HCl pH8, 1mM EDTA, 1% NP-40, 
0,5% Na-deoxycholate) supplemented with 1 mM PMSF, 5 mM NaF, 1 mM Na3VO4, 
10µg/ml CLAP, 1µM TSA and 5µM nicotinamide. Protein concentration was 
determined with Bio-Rad Protein Assay Reagent (#500-0006, Bio-Rad). Lysates were 
resolved by SDS/PAGE and transferred to nitrocellulose (Millipore). Western blot 
analysis was performed according to standard procedures using the following primary 
antibodies: 
 
Target Antibody 
phospho-p44/42 
MAPK 
#9101 (Cell Signaling) 
p44/42 MAPK #9102 (Cell Signaling) 
phospho-p38 
MAPK 
#9211 (Cell Signaling) 
p38 MAPK #9212 (Cell Signaling) 
phospho-JNK #9251 (Cell Signaling) 
JNK sc-571 (Santa Cruz) 
phospho-AKT 
(Ser473) 
#9271 (Cell Signaling) 
AKT1 (2H10) #2967 (Cell Signaling) 
HA  12CA5 home made preparation 
HSP90 sc-13119 (Santa Cruz) 
Actin #A9718 (Sigma) 
Snail ab63371 (Abcam) 
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p53 (DO1) sc-126 (Santa Cruz) 
Vimentin #3295 (Cell Signaling) 
N- Cadherin 610920 (BD) 
E- Cadherin #4065 (Cell Signaling) 
RAS F235 (Santa Cruz) 
DAB2IP  A302-440A (Bethyl) 
Tubulin T5168 (Sigma) 
HMGA ab109706 (Abcam) 
Lamin A ab16048 (Abcam) 
MBP home-made rabbit polyclonal  
 
 
Coaffinity purification. Co-AP experiments were performed as described (Lunardi et 
al., 2010), with minor changes. Plasmids were transfected in human 293T cells. Forty-
eight hours after transfection cells were lysed in coaffinity purification buffer (50 mM 
Tris·HCl pH8, 150 mM NaCl, 1 mM EDTA pH8, 1 mM DTT, 5% glycerol, protease 
inhibitors (Sigma), 1 mM PMSF, 5 mM NaF, 1 mM beta-glycerolphosphate) for 30 
min on ice and cleared by centrifugation for 30 min at 13,000 × g at 4 °C, and protein 
complexes were collected on amylose beads. After extensive washes, purified 
complexes were separated by SDS/PAGE, detected by immunoblotting, and 
visualized by ECL (Amersham). Purified MBP baits were visualized by DAB staining 
(Sigma). 
 
Co-immuno precipitation. Co-IP experiments with endogenous proteins were 
performed using Co-IP buffer (NaCl 120mM, Tris-HCl pH8 20mM, EDTA 1mM, 
NP40 0,5%) with protease inhibitors. Samples were cleared by centrifugation for 30 
min at 13,000g at 4 °C and incubated for 2 h at 4 °C with anti-p53 antibody (DO-1; 
Santa Cruz). After 1 h incubation with protein G-Sepharose (GE Healthcare), 
immunoprecipitates were washed three times in Co-IP buffer, resuspended in sample 
buffer, and analyzed by immunoblotting. To avoid cross-reaction with Ig heavy 
chains, immunoprecipitated p53 was detected using HRP-conjugated DO-1 
monoclonal antibody (Santa Cruz). 
 
Nucleus-cytoplasm fractionation. Cells were scraped in PBS and washed two times. 
The pellet obtained after the last centrifugation was resuspended in RSBS buffer 
(10mM Tris-HCl pH7,5, 10mM NaCl, 5mM Mg Acetate) supplemented with 
inhibitors (1mM PMSF, 5mM NaF, 10mg/ml CLAP, 1mM Na3VO4); lysis was 
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performed maintaining cells for 30’ in ice and subsequently with the addition of NP-
40 0,3%. Cells were homogenized using potter Tight of 1ml, and inputs were 
collected at this step. 
The samples were then centrifuged at 12000 rcf for 10’ at 4°C; the supernatant was 
collected as the cytoplasmic fraction. Nuclei in the pellet were resuspended in Wash 
buffer (0,88M Surcose, 5mM Mg-acetate) and sedimented again by centrifugation at 
2000 rcf for 20’. Washed nuclei were lysed in RIPA buffer without SDS with protease 
inhibitors. 
 
Immunofluorescence. Cells were fixed in 4% paraformaldehyde at room 
temperature, and permeabilized in PBS plus 0.1% Triton X-100. Permeabilized cells 
were incubated with primary antibodies, followed by FITC or TRITC conjugated 
secondary antibodies. Images were captured using a Leica DM4000B epifluorescence 
microscope or a Zeiss Axiovert 100M confocal microscope. 
  
RNA extraction and RT-qPCR. Total RNA was extracted with QIAzol lysis reagent 
(Qiagen) following manufacturer’s instructions. 1µg of total RNA was reverse-
transcribed with QuantiTect Reverse Transcription (Qiagen). The genes of interest 
were amplified with Fast SYBR® Green Master Mix (Applied Biosystems) following 
manufacturer’s instructions. A StepOnePlus™ Real-Time PCR System (Applied 
Biosystems) was used for qPCRs. List of primers used: 
 
Target Sequence 
DAB2IP Fw 5’CACATCACCAACCACTAC3’ 
Rev 5’TCCACCTCTGACATCATC3’ 
p53 Fw 5’CTCCTCTCCCCAGCCAAAGA3’ 
Rev 5’GGAACATCTCGAAGCGCTCA3’ 
IL8 GGUGAACCUUAGUACCUAA 
ICAM1 Fw 5’GGGCATAGAGACCCCGTTGCCT3’ 
Rev 5’ GGGTGCCAGTTCCACCCGTTC 
Actin Fw 5’CGCCGCCAGCTCACCATG3’ 
Rev 5’CACGATGGAGGGGAAGACGG3’ 
H3 Fw 5’GAAGAAACCTCATCGTTACAGGCCTGGT- 3’ 
Rev 5’CTGCAAAGCACCAATAGCTGCACTCTGGAA 3’ 
GAPDH Fw 5'CATGCCATCACTGCCACCC 3' 
Rev 5'ACCTGGTCCTCAGTGTAGC 3' 
18S Fw 5’GTAACCCGTTGAACCCCATT3’ 
Rev 5’CCATCCAATCGGTAGTAGCG3’ 
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FACS analysis. For FACS analysis, adherent and floating cells were harvested, 
permeabilized with 0.1% NP-40 in PBS containing RNase A (200 µg/ml) and then 
stained with 50 µg/ml Propidium Iodide (#P4865, Sigma). At least 20.000 cells were 
counted in each experiment, using a FACSCalibur flow cytometer (Becton-
Dickinson). Cell cycle analysis was performed with FlowJo software 
(http://www.flowjo.com/). 
 
Migration and invasion assays. For migration analysis, transfected cells (0,5-1x105) 
were plated on 24 well PET inserts (8.0 µm pore size, Falcon), according to the 
manufacturer’s instructions. For invasion assays cells (0,5-1x105) were plated on 
matrigel-coated filters (8.0 µm pore size, Falcon) and the lower part of the chamber 
was filled with DCCM medium. After 16 h cells on the upper part of the membrane 
were removed with a cotton swab and cells that passed through the filter were fixed in 
4% PFA, stained with 0.05% crystal violet and counted. 
 
DCCM media preparation. Dendritic Cell Conditioned Media was kindly provided 
by the group of Dr. F. Benvenuti (ICGEB, Trieste). Briefly, precursor cells were 
extracted from mice bone marrow and grown in IMDM (Iscove’s Modified 
Dulbecco’s Medium, GIBCO) supplemented with 10% fetal bovine serum (FBS), 
primocin, and beta-mercaptoethanol 50µM. The cells were induced to differentiate 
through addiction of 30% GM-CSF (Granulocyte-macrophage colony-stimulating 
factor), produced harvesting the conditioned culture media of J558 cells. Dendritic 
cells were maintained in IMDM medium for 7-8 days. Subsequently, they were 
stimulated O/N with LPS (1ug/ml). The supernatant was then harvested and 
centrifuged to remove cells in suspension. DCCM was aliquoted and stored at -80°C. 
 
  110 
ACKNOWLEDGMENTS 
 
 
First of all, I would like to acknowledge Dott. Licio Collavin who gave me the 
opportunity to work in his lab and to realize this project, born from the curiousity and 
passion for science that he transmitted to me. 
I am deeply indebted to Andrea Lunardi that represented a model from which 
learning, learning and learning again. 
I want to acknowledge Arianna Bellazzo for her passion, patience, support and 
indispensable contribution to this work.  
I thank all the people that worked in these years at LNCIB, in particular all the 
members of the “LC group” and my past and present colleagues of the 117 room.  
I really want to thank my parents - to whom this thesis is dedicated -, my brother and 
all my friends for their support. 
Finally, a simple but huge thank to Alice for believing in me and for all the moments 
we shared in these years and we will have together in the future. 
 
 
  111 
BIBLIOGRAPHY 
 
 
Aas, T., Borresen, A.L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J.E., Akslen, L.A., and 
Lonning, P.E. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in 
breast cancer patients. Nat Med 2, 811-814. 
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., 
Rondina, M.B., Guzzardo, V., et al. (2009). A Mutant-p53/Smad complex opposes p63 to empower 
TGFbeta-induced metastasis. Cell 137, 87-98. 
Aggarwal, B.B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev 
Immunol 3, 745-756. 
Aggarwal, B.B. (2004). Nuclear factor-kappaB: the enemy within. Cancer Cell 6, 203-208. 
Aggarwal, B.B., Shishodia, S., Sandur, S.K., Pandey, M.K., and Sethi, G. (2006). Inflammation and 
cancer: how hot is the link? Biochem Pharmacol 72, 1605-1621. 
Ahn, K.S., and Aggarwal, B.B. (2005). Transcription factor NF-kappaB: a sensor for smoke and stress 
signals. Ann N Y Acad Sci 1056, 218-233. 
Albor, A., Kaku, S., and Kulesz-Martin, M. (1998). Wild-type and mutant forms of p53 activate human 
topoisomerase I: a possible mechanism for gain of function in mutants. Cancer Res 58, 2091-2094. 
Allavena, P., Garlanda, C., Borrello, M.G., Sica, A., and Mantovani, A. (2008). Pathways connecting 
inflammation and cancer. Curr Opin Genet Dev 18, 3-10. 
Andren-Sandberg, A., Dervenis, C., and Lowenfels, B. (1997). Etiologic links between chronic 
pancreatitis and pancreatic cancer. Scand J Gastroenterol 32, 97-103. 
Arnott, C.H., Scott, K.A., Moore, R.J., Robinson, S.C., Thompson, R.G., and Balkwill, F.R. (2004). 
Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. 
Oncogene 23, 1902-1910. 
Attardi, L.D., and Jacks, T. (1999). The role of p53 in tumour suppression: lessons from mouse models. 
Cell Mol Life Sci 55, 48-63. 
Au, W.Y., Fung, A., Wong, K.F., Chan, C.H., and Liang, R. (2006). Tumor necrosis factor alpha 
promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese 
population. Leuk Lymphoma 47, 2189-2193. 
Aziz, S.A., Pervez, S., Khan, S., Kayani, N., Azam, S.I., and Rahbar, M.H. (2001). Case control study 
of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical 
experience. Breast J 7, 398-404. 
Balkwill, F. (2009). Tumour necrosis factor and cancer. Nat Rev Cancer 9, 361-371. 
Bargou, R.C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M.Y., Arnold, W., Royer, H.D., 
Grinstein, E., Greiner, A., Scheidereit, C., et al. (1997). Constitutive nuclear factor-kappaB-RelA 
activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100, 
2961-2969. 
  112 
Barik, S. (2008). An intronic microRNA silences genes that are functionally antagonistic to its host 
gene. Nucleic Acids Res 36, 5232-5241. 
Barrientos, S., Stojadinovic, O., Golinko, M.S., Brem, H., and Tomic-Canic, M. (2008). Growth factors 
and cytokines in wound healing. Wound Repair Regen 16, 585-601. 
Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C.A., 
Gannon, J.V., and Lane, D.P. (1991). Aberrant expression of the p53 oncoprotein is a common feature 
of a wide spectrum of human malignancies. Oncogene 6, 1699-1703. 
Beg, A.A., and Baldwin, A.S., Jr. (1993). The I kappa B proteins: multifunctional regulators of 
Rel/NF-kappa B transcription factors. Genes Dev 7, 2064-2070. 
Bemelmans, M.H., van Tits, L.J., and Buurman, W.A. (1996). Tumor necrosis factor: function, release 
and clearance. Crit Rev Immunol 16, 1-11. 
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., 
Numico, G., Comino, A., et al. (2003). p53 polymorphism influences response in cancer chemotherapy 
via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402. 
Berger, S.L. (2007). The complex language of chromatin regulation during transcription. Nature 447, 
407-412. 
Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. (1995). Complete sequencing of 
the p53 gene provides prognostic information in breast cancer patients, particularly in relation to 
adjuvant systemic therapy and radiotherapy. Nat Med 1, 1029-1034. 
Bernards, A., and Settleman, J. (2005). GAPs in growth factor signalling. Growth Factors 23, 143-149. 
Blandino, G., Deppert, W., Hainaut, P., Levine, A., Lozano, G., Olivier, M., Rotter, V., Wiman, K., 
and Oren, M. (2012). Mutant p53 protein, master regulator of human malignancies: a report on the 
Fifth Mutant p53 Workshop. Cell Death Differ 19, 180-183. 
Blandino, G., Levine, A.J., and Oren, M. (1999). Mutant p53 gain of function: differential effects of 
different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477-485. 
Blons, H., and Laurent-Puig, P. (2003). TP53 and head and neck neoplasms. Hum Mutat 21, 252-257. 
Bode, A.M., and Dong, Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev 
Cancer 4, 793-805. 
Boffetta, P. (2006). Human cancer from environmental pollutants: the epidemiological evidence. Mutat 
Res 608, 157-162. 
Bond, M., Fabunmi, R.P., Baker, A.H., and Newby, A.C. (1998). Synergistic upregulation of 
metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for 
transcription factor NF-kappa B. FEBS Lett 435, 29-34. 
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., and Sacchi, A. (2006). Mutant p53 gain of 
function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 
expression. Oncogene 25, 304-309. 
Bossi, G., Marampon, F., Maor-Aloni, R., Zani, B., Rotter, V., Oren, M., Strano, S., Blandino, G., and 
Sacchi, A. (2008). Conditional RNA interference in vivo to study mutant p53 oncogenic gain of 
function on tumor malignancy. Cell Cycle 7, 1870-1879. 
Brooks, C.L., and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell 21, 307-315. 
  113 
Brosh, R., and Rotter, V. (2009). When mutants gain new powers: news from the mutant p53 field. Nat 
Rev Cancer 9, 701-713. 
Brosh, R., and Rotter, V. (2010). Transcriptional control of the proliferation cluster by the tumor 
suppressor p53. Mol Biosyst 6, 17-29. 
Bubici, C., Papa, S., Dean, K., and Franzoso, G. (2006). Mutual cross-talk between reactive oxygen 
species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25, 6731-
6748. 
Buchhop, S., Gibson, M.K., Wang, X.W., Wagner, P., Sturzbecher, H.W., and Harris, C.C. (1997). 
Interaction of p53 with the human Rad51 protein. Nucleic Acids Res 25, 3868-3874. 
Bullock, A.N., and Fersht, A.R. (2001). Rescuing the function of mutant p53. Nat Rev Cancer 1, 68-76. 
Cabioglu, N., Gong, Y., Islam, R., Broglio, K.R., Sneige, N., Sahin, A., Gonzalez-Angulo, A.M., 
Morandi, P., Bucana, C., Hortobagyi, G.N., et al. (2007). Expression of growth factor and chemokine 
receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol 18, 1021-1029. 
Calvisi, D.F., Ladu, S., Conner, E.A., Seo, D., Hsieh, J.T., Factor, V.M., and Thorgeirsson, S.S. (2011). 
Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in 
human liver cancer. J Hepatol 54, 311-319. 
Carballo, E., Lai, W.S., and Blackshear, P.J. (1998). Feedback inhibition of macrophage tumor necrosis 
factor-alpha production by tristetraprolin. Science 281, 1001-1005. 
Carmeliet, P. (2003). Angiogenesis in health and disease. Nat Med 9, 653-660. 
Caulin, C., Nguyen, T., Lang, G.A., Goepfert, T.M., Brinkley, B.R., Cai, W.W., Lozano, G., and Roop, 
D.R. (2007). An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-
function p53 mutations. J Clin Invest 117, 1893-1901. 
Chen, H., Pong, R.C., Wang, Z., and Hsieh, J.T. (2002). Differential regulation of the human gene 
DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79, 573-
581. 
Chen, H., Toyooka, S., Gazdar, A.F., and Hsieh, J.T. (2003). Epigenetic regulation of a novel tumor 
suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 278, 3121-3130. 
Chen, H., Tu, S.W., and Hsieh, J.T. (2005). Down-regulation of human DAB2IP gene expression 
mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280, 
22437-22444. 
Chicas, A., Molina, P., and Bargonetti, J. (2000). Mutant p53 forms a complex with Sp1 on HIV-LTR 
DNA. Biochem Biophys Res Commun 279, 383-390. 
Chung, J.Y., Park, Y.C., Ye, H., and Wu, H. (2002). All TRAFs are not created equal: common and 
distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 115, 679-688. 
Collavin, L., Lunardi, A., and Del Sal, G. (2010). p53-family proteins and their regulators: hubs and 
spokes in tumor suppression. Cell Death Differ 17, 901-911. 
Colotta, F., Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2009). Cancer-related 
inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30, 1073-
1081. 
  114 
Colpaert, C.G., Vermeulen, P.B., Benoy, I., Soubry, A., van Roy, F., van Beest, P., Goovaerts, G., 
Dirix, L.Y., van Dam, P., Fox, S.B., et al. (2003). Inflammatory breast cancer shows angiogenesis with 
high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 88, 718-725. 
Cordenonsi, M., Dupont, S., Maretto, S., Insinga, A., Imbriano, C., and Piccolo, S. (2003). Links 
between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. 
Cell 113, 301-314. 
Cuzick, J., Otto, F., Baron, J.A., Brown, P.H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., 
Meyskens, F., Senn, H.J., et al. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer 
prevention: an international consensus statement. Lancet Oncol 10, 501-507. 
Davis, R.J. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252. 
Dawood, S., and Cristofanilli, M. (2011). Inflammatory breast cancer: what progress have we made? 
Oncology (Williston Park) 25, 264-270, 273. 
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D.U., Jin, R., Jones, J., Cong, R., and Franzoso, G. 
(2001). Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 
414, 308-313. 
de Visser, K.E., Eichten, A., and Coussens, L.M. (2006). Paradoxical roles of the immune system 
during cancer development. Nat Rev Cancer 6, 24-37. 
Deng, Y., Ren, X., Yang, L., Lin, Y., and Wu, X. (2003). A JNK-dependent pathway is required for 
TNFalpha-induced apoptosis. Cell 115, 61-70. 
Deyoung, M.P., and Ellisen, L.W. (2007). p63 and p73 in human cancer: defining the network. 
Oncogene 26, 5169-5183. 
Dhar, G., Banerjee, S., Dhar, K., Tawfik, O., Mayo, M.S., Vanveldhuizen, P.J., and Banerjee, S.K. 
(2008). Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast 
cancer cells by silencing CCN5/WISP-2. Cancer Res 68, 4580-4587. 
Di Como, C.J., Gaiddon, C., and Prives, C. (1999). p73 function is inhibited by tumor-derived p53 
mutants in mammalian cells. Mol Cell Biol 19, 1438-1449. 
Dickens, M., Rogers, J.S., Cavanagh, J., Raitano, A., Xia, Z., Halpern, J.R., Greenberg, M.E., Sawyers, 
C.L., and Davis, R.J. (1997). A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 
277, 693-696. 
Digel, W., Stefanic, M., Schoniger, W., Buck, C., Raghavachar, A., Frickhofen, N., Heimpel, H., and 
Porzsolt, F. (1989). Tumor necrosis factor induces proliferation of neoplastic B cells from chronic 
lymphocytic leukemia. Blood 73, 1242-1246. 
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M., Finlay, C., and Levine, A.J. 
(1993). Gain of function mutations in p53. Nat Genet 4, 42-46. 
Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A., Jr., Butel, J.S., and 
Bradley, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous 
tumours. Nature 356, 215-221. 
Dong, P., Xu, Z., Jia, N., Li, D., and Feng, Y. (2009). Elevated expression of p53 gain-of-function 
mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the 
EGFR/PI3K/AKT pathway. Mol Cancer 8, 103. 
  115 
Dote, H., Toyooka, S., Tsukuda, K., Yano, M., Ota, T., Murakami, M., Naito, M., Toyota, M., Gazdar, 
A.F., and Shimizu, N. (2005). Aberrant promoter methylation in human DAB2 interactive protein 
(hDAB2IP) gene in gastrointestinal tumour. Br J Cancer 92, 1117-1125. 
Dote, H., Toyooka, S., Tsukuda, K., Yano, M., Ouchida, M., Doihara, H., Suzuki, M., Chen, H., Hsieh, 
J.T., Gazdar, A.F., et al. (2004). Aberrant promoter methylation in human DAB2 interactive protein 
(hDAB2IP) gene in breast cancer. Clin Cancer Res 10, 2082-2089. 
Doyle, B., Morton, J.P., Delaney, D.W., Ridgway, R.A., Wilkins, J.A., and Sansom, O.J. (2010). p53 
mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic 
rhabdomyosarcoma. J Pathol 222, 129-137. 
Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000). Smac, a mitochondrial protein that promotes 
cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33-42. 
Duggan, D., Zheng, S.L., Knowlton, M., Benitez, D., Dimitrov, L., Wiklund, F., Robbins, C., Isaacs, 
S.D., Cheng, Y., Li, G., et al. (2007). Two genome-wide association studies of aggressive prostate 
cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 99, 1836-1844. 
Dutta, J., Fan, Y., Gupta, N., Fan, G., and Gelinas, C. (2006). Current insights into the regulation of 
programmed cell death by NF-kappaB. Oncogene 25, 6800-6816. 
El-Hizawi, S., Lagowski, J.P., Kulesz-Martin, M., and Albor, A. (2002). Induction of gene 
amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res 62, 3264-3270. 
El-Omar, E.M., Carrington, M., Chow, W.H., McColl, K.E., Bream, J.H., Young, H.A., Herrera, J., 
Lissowska, J., Yuan, C.C., Rothman, N., et al. (2000). Interleukin-1 polymorphisms associated with 
increased risk of gastric cancer. Nature 404, 398-402. 
Esser, C., Scheffner, M., and Hohfeld, J. (2005). The chaperone-associated ubiquitin ligase CHIP is 
able to target p53 for proteasomal degradation. J Biol Chem 280, 27443-27448. 
Esteve, P.O., Chin, H.G., and Pradhan, S. (2007). Molecular mechanisms of transactivation and 
doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 282, 2615-2625. 
Fazili, Z., Sun, W., Mittelstaedt, S., Cohen, C., and Xu, X.X. (1999). Disabled-2 inactivation is an early 
step in ovarian tumorigenicity. Oncogene 18, 3104-3113. 
Feller, S.M., Ren, R., Hanafusa, H., and Baltimore, D. (1994). SH2 and SH3 domains as molecular 
adhesives: the interactions of Crk and Abl. Trends Biochem Sci 19, 453-458. 
Ferrara, N., Gerber, H.P., and LeCouter, J. (2003). The biology of VEGF and its receptors. Nat Med 9, 
669-676. 
Flores, E.R., Sengupta, S., Miller, J.B., Newman, J.J., Bronson, R., Crowley, D., Yang, A., McKeon, 
F., and Jacks, T. (2005). Tumor predisposition in mice mutant for p63 and p73: evidence for broader 
tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373. 
Freed-Pastor, W.A., Mizuno, H., Zhao, X., Langerod, A., Moon, S.H., Rodriguez-Barrueco, R., 
Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012). Mutant p53 Disrupts Mammary Tissue 
Architecture via the Mevalonate Pathway. Cell 148, 244-258. 
Fulop, V., Colitti, C.V., Genest, D., Berkowitz, R.S., Yiu, G.K., Ng, S.W., Szepesi, J., and Mok, S.C. 
(1998). DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational 
trophoblastic diseases. Oncogene 17, 419-424. 
  116 
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., and Prives, C. (2001). A subset of tumor-derived mutant 
forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol 
Cell Biol 21, 1874-1887. 
Gillen, C.D., Walmsley, R.S., Prior, P., Andrews, H.A., and Allan, R.N. (1994). Ulcerative colitis and 
Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35, 1590-1592. 
Gilmore, T.D. (2006). Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 
6680-6684. 
Girardini, J.E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L., 
Quinlan, P., Thompson, A., et al. (2011). A Pin1/mutant p53 axis promotes aggressiveness in breast 
cancer. Cancer Cell 20, 79-91. 
Goh, A.M., Coffill, C.R., and Lane, D.P. (2011). The role of mutant p53 in human cancer. J Pathol 223, 
116-126. 
Gohler, T., Jager, S., Warnecke, G., Yasuda, H., Kim, E., and Deppert, W. (2005). Mutant p53 proteins 
bind DNA in a DNA structure-selective mode. Nucleic Acids Res 33, 1087-1100. 
Grozio, A., Catassi, A., Cavalieri, Z., Paleari, L., Cesario, A., and Russo, P. (2007). Nicotine, lung and 
cancer. Anticancer Agents Med Chem 7, 461-466. 
Grunert, S., Jechlinger, M., and Beug, H. (2003). Diverse cellular and molecular mechanisms 
contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4, 657-665. 
Gualberto, A., Aldape, K., Kozakiewicz, K., and Tlsty, T.D. (1998). An oncogenic form of p53 confers 
a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U 
S A 95, 5166-5171. 
Gupta, S.C., Sundaram, C., Reuter, S., and Aggarwal, B.B. (2010). Inhibiting NF-kappaB activation by 
small molecules as a therapeutic strategy. Biochim Biophys Acta 1799, 775-787. 
Haghnegahdar, H., Du, J., Wang, D., Strieter, R.M., Burdick, M.D., Nanney, L.B., Cardwell, N., Luan, 
J., Shattuck-Brandt, R., and Richmond, A. (2000). The tumorigenic and angiogenic effects of 
MGSA/GRO proteins in melanoma. J Leukoc Biol 67, 53-62. 
Han, J., Lee, J.D., Bibbs, L., and Ulevitch, R.J. (1994). A MAP kinase targeted by endotoxin and 
hyperosmolarity in mammalian cells. Science 265, 808-811. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. 
Haupt, S., di Agostino, S., Mizrahi, I., Alsheich-Bartok, O., Voorhoeve, M., Damalas, A., Blandino, 
G., and Haupt, Y. (2009). Promyelocytic leukemia protein is required for gain of function by mutant 
p53. Cancer Res 69, 4818-4826. 
Heinlein, C., Krepulat, F., Lohler, J., Speidel, D., Deppert, W., and Tolstonog, G.V. (2008). Mutant 
p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary 
carcinogenesis. Int J Cancer 122, 1701-1709. 
Helbig, G., Christopherson, K.W., 2nd, Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K.D., 
Broxmeyer, H.E., and Nakshatri, H. (2003). NF-kappaB promotes breast cancer cell migration and 
metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278, 21631-
21638. 
  117 
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., 
Chang, S., and Tuveson, D.A. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal 
instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483. 
Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991). p53 mutations in human cancers. 
Science 253, 49-53. 
Homayouni, R., Magdaleno, S., Keshvara, L., Rice, D.S., and Curran, T. (2003). Interaction of 
Disabled-1 and the GTPase activating protein Dab2IP in mouse brain. Brain Res Mol Brain Res 115, 
121-129. 
Hussain, S.P., Hofseth, L.J., and Harris, C.C. (2003). Radical causes of cancer. Nat Rev Cancer 3, 276-
285. 
Iacopetta, B. (2003). TP53 mutation in colorectal cancer. Hum Mutat 21, 271-276. 
Ingley, E., and Hemmings, B.A. (1994). Pleckstrin homology (PH) domains in signal transduction. J 
Cell Biochem 56, 436-443. 
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., 
Honma, Y., and Hayashi, J. (2008). ROS-generating mitochondrial DNA mutations can regulate tumor 
cell metastasis. Science 320, 661-664. 
Isono, K., Nemoto, K., Li, Y., Takada, Y., Suzuki, R., Katsuki, M., Nakagawara, A., and Koseki, H. 
(2006). Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the 
mediation of cell growth in response to morphogenetic and genotoxic signals. Mol Cell Biol 26, 2758-
2771. 
Iwamoto, K.S., Mizuno, T., Ito, T., Tsuyama, N., Kyoizumi, S., and Seyama, T. (1996). Gain-of-
function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently 
of the cell cycle and cell survival. Cancer Res 56, 3862-3865. 
Jackson, E.L., Olive, K.P., Tuveson, D.A., Bronson, R., Crowley, D., Brown, M., and Jacks, T. (2005). 
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65, 10280-
10288. 
Jin, D.Y., Teramoto, H., Giam, C.Z., Chun, R.F., Gutkind, J.S., and Jeang, K.T. (1997). A human 
suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor alpha. J Biol Chem 272, 
25816-25823. 
Juo, P., Kuo, C.J., Reynolds, S.E., Konz, R.F., Raingeaud, J., Davis, R.J., Biemann, H.P., and Blenis, J. 
(1997). Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires 
ICE/CED-3 family proteases. Mol Cell Biol 17, 24-35. 
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz, L.C., and Burrows, F.J. (2003). A 
high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-
410. 
Karin, M. (1999). The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol 
Chem 274, 27339-27342. 
Karin, M., Liu, Z., and Zandi, E. (1997). AP-1 function and regulation. Curr Opin Cell Biol 9, 240-246. 
Kato, S., Han, S.Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., and Ishioka, C. (2003). 
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor 
protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100, 8424-8429. 
  118 
Kim, E., and Deppert, W. (2004). Transcriptional activities of mutant p53: when mutations are more 
than a loss. J Cell Biochem 93, 878-886. 
Kitamura, T., Fukuyo, Y., Inoue, M., Horikoshi, N.T., Shindoh, M., Rogers, B.E., Usheva, A., and 
Horikoshi, N. (2009). Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-
dependent stabilization of Daxx. Cancer Res 69, 7681-7688. 
Kleer, C.G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S.A., Ghosh, D., Sewalt, R.G., Otte, 
A.P., Hayes, D.F., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic 
transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100, 11606-11611. 
Kogan-Sakin, I., Tabach, Y., Buganim, Y., Molchadsky, A., Solomon, H., Madar, S., Kamer, I., 
Stambolsky, P., Shelly, A., Goldfinger, N., et al. (2011). Mutant p53(R175H) upregulates Twist1 
expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death 
Differ 18, 271-281. 
Kojima, M., Morisaki, T., Sasaki, N., Nakano, K., Mibu, R., Tanaka, M., and Katano, M. (2004). 
Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor 
progression. Anticancer Res 24, 675-681. 
Kollmar, O., Rupertus, K., Scheuer, C., Junker, B., Tilton, B., Schilling, M.K., and Menger, M.D. 
(2007). Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal 
metastasis. Neoplasia 9, 862-870. 
Kong, Z., Xie, D., Boike, T., Raghavan, P., Burma, S., Chen, D.J., Habib, A.A., Chakraborty, A., 
Hsieh, J.T., and Saha, D. (2010). Downregulation of human DAB2IP gene expression in prostate 
cancer cells results in resistance to ionizing radiation. Cancer Res 70, 2829-2839. 
Kress, M., May, E., Cassingena, R., and May, P. (1979). Simian virus 40-transformed cells express 
new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31, 472-483. 
Kunze, E., Von Bonin, F., Werner, C., Wendt, M., and Schlott, T. (2006). Transitional cell carcinomas 
and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the 
caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med 
17, 3-13. 
Kyriakis, J.M., and Avruch, J. (2001). Mammalian mitogen-activated protein kinase signal transduction 
pathways activated by stress and inflammation. Physiol Rev 81, 807-869. 
Lane, D.P., and Crawford, L.V. (1979). T antigen is bound to a host protein in SV40-transformed cells. 
Nature 278, 261-263. 
Lang, G.A., Iwakuma, T., Suh, Y.A., Liu, G., Rao, V.A., Parant, J.M., Valentin-Vega, Y.A., Terzian, 
T., Caldwell, L.C., Strong, L.C., et al. (2004). Gain of function of a p53 hot spot mutation in a mouse 
model of Li-Fraumeni syndrome. Cell 119, 861-872. 
Lee, E.G., Boone, D.L., Chai, S., Libby, S.L., Chien, M., Lodolce, J.P., and Ma, A. (2000). Failure to 
regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289, 2350-
2354. 
Lee, K.C., Goh, W.L., Xu, M., Kua, N., Lunny, D., Wong, J.S., Coomber, D., Vojtesek, B., Lane, E.B., 
and Lane, D.P. (2008). Detection of the p53 response in zebrafish embryos using new monoclonal 
antibodies. Oncogene 27, 629-640. 
Leist, M., and Jaattela, M. (2001). Four deaths and a funeral: from caspases to alternative mechanisms. 
Nat Rev Mol Cell Biol 2, 589-598. 
  119 
Levine, A.J., Hu, W., and Feng, Z. (2006). The P53 pathway: what questions remain to be explored? 
Cell Death Differ 13, 1027-1036. 
Levine, A.J., and Oren, M. (2009). The first 30 years of p53: growing ever more complex. Nat Rev 
Cancer 9, 749-758. 
Levy, D., Adamovich, Y., Reuven, N., and Shaul, Y. (2007). The Yes-associated protein 1 stabilizes 
p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ 14, 743-751. 
Li, R., Sutphin, P.D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., 
Prokocimer, M., and Rotter, V. (1998). Mutant p53 protein expression interferes with p53-independent 
apoptotic pathways. Oncogene 16, 3269-3277. 
Li, X., Luo, Y., Yu, L., Lin, Y., Luo, D., Zhang, H., He, Y., Kim, Y.O., Kim, Y., Tang, S., et al. 
(2008). SENP1 mediates TNF-induced desumoylation and cytoplasmic translocation of HIPK1 to 
enhance ASK1-dependent apoptosis. Cell Death Differ 15, 739-750. 
Li, Y., and Prives, C. (2007). Are interactions with p63 and p73 involved in mutant p53 gain of 
oncogenic function? Oncogene 26, 2220-2225. 
Liao, X., Siu, M.K., Chan, K.Y., Wong, E.S., Ngan, H.Y., Chan, Q.K., Li, A.S., Khoo, U.S., and 
Cheung, A.N. (2008). Hypermethylation of RAS effector related genes and DNA methyltransferase 1 
expression in endometrial carcinogenesis. Int J Cancer 123, 296-302. 
Lin, Y.L., Sengupta, S., Gurdziel, K., Bell, G.W., Jacks, T., and Flores, E.R. (2009). p63 and p73 
transcriptionally regulate genes involved in DNA repair. PLoS Genet 5, e1000680. 
Linzer, D.I., and Levine, A.J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen 
present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52. 
Locksley, R.M., Killeen, N., and Lenardo, M.J. (2001). The TNF and TNF receptor superfamilies: 
integrating mammalian biology. Cell 104, 487-501. 
Lotem, J., and Sachs, L. (1995). A mutant p53 antagonizes the deregulated c-myc-mediated 
enhancement of apoptosis and decrease in leukemogenicity. Proc Natl Acad Sci U S A 92, 9672-9676. 
Lu, C., and El-Deiry, W.S. (2009). Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 
14, 597-606. 
Lu, W.J., Amatruda, J.F., and Abrams, J.M. (2009). p53 ancestry: gazing through an evolutionary lens. 
Nat Rev Cancer 9, 758-762. 
Lukashchuk, N., and Vousden, K.H. (2007). Ubiquitination and degradation of mutant p53. Mol Cell 
Biol 27, 8284-8295. 
Lunardi, A., Di Minin, G., Provero, P., Dal Ferro, M., Carotti, M., Del Sal, G., and Collavin, L. (2010). 
A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human 
p53 network. Proc Natl Acad Sci U S A 107, 6322-6327. 
Luo, D., He, Y., Zhang, H., Yu, L., Chen, H., Xu, Z., Tang, S., Urano, F., and Min, W. (2008). AIP1 is 
critical in transducing IRE1-mediated endoplasmic reticulum stress response. J Biol Chem 283, 11905-
11912. 
Maiuri, M.C., Malik, S.A., Morselli, E., Kepp, O., Criollo, A., Mouchel, P.L., Carnuccio, R., and 
Kroemer, G. (2009). Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 8, 1571-
1576. 
  120 
Malinin, N.L., Boldin, M.P., Kovalenko, A.V., and Wallach, D. (1997). MAP3K-related kinase 
involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 385, 540-544. 
Maniatis, T. (1997). Catalysis by a multiprotein IkappaB kinase complex. Science 278, 818-819. 
Mantovani, A. (2009). Cancer: Inflaming metastasis. Nature 457, 36-37. 
Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Nature 
454, 436-444. 
Mantovani, A., Marchesi, F., Porta, C., Sica, A., and Allavena, P. (2007). Inflammation and cancer: 
breast cancer as a prototype. Breast 16 Suppl 2, S27-33. 
Mantovani, A., and Pierotti, M.A. (2008). Cancer and inflammation: a complex relationship. Cancer 
Lett 267, 180-181. 
Mantovani, F., Piazza, S., Gostissa, M., Strano, S., Zacchi, P., Mantovani, R., Blandino, G., and Del 
Sal, G. (2004). Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 14, 625-
636. 
Marian, C.O., Yang, L., Zou, Y.S., Gore, C., Pong, R.C., Shay, J.W., Kabbani, W., Hsieh, J.T., and 
Raj, G.V. (2011). Evidence of epithelial to mesenchymal transition associated with increased 
tumorigenic potential in an immortalized normal prostate epithelial cell line. Prostate 71, 626-636. 
Marin, M.C., Jost, C.A., Brooks, L.A., Irwin, M.S., O'Nions, J., Tidy, J.A., James, N., McGregor, J.M., 
Harwood, C.A., Yulug, I.G., et al. (2000). A common polymorphism acts as an intragenic modifier of 
mutant p53 behaviour. Nat Genet 25, 47-54. 
Martin-Padura, I., Mortarini, R., Lauri, D., Bernasconi, S., Sanchez-Madrid, F., Parmiani, G., 
Mantovani, A., Anichini, A., and Dejana, E. (1991). Heterogeneity in human melanoma cell adhesion 
to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Res 51, 2239-2241. 
Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., and 
Rotter, V. (2001). Integrity of the N-terminal transcription domain of p53 is required for mutant p53 
interference with drug-induced apoptosis. EMBO J 20, 4163-4172. 
Matsukawa, J., Matsuzawa, A., Takeda, K., and Ichijo, H. (2004). The ASK1-MAP kinase cascades in 
mammalian stress response. J Biochem 136, 261-265. 
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 454, 428-435. 
Miller, L.D., Smeds, J., George, J., Vega, V.B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., 
Liu, E.T., et al. (2005). An expression signature for p53 status in human breast cancer predicts 
mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102, 13550-
13555. 
Mills, A.A. (2005). p53: link to the past, bridge to the future. Genes Dev 19, 2091-2099. 
Mills, A.A., Zheng, B., Wang, X.J., Vogel, H., Roop, D.R., and Bradley, A. (1999). p63 is a p53 
homologue required for limb and epidermal morphogenesis. Nature 398, 708-713. 
Milner, J., and Medcalf, E.A. (1991). Cotranslation of activated mutant p53 with wild type drives the 
wild-type p53 protein into the mutant conformation. Cell 65, 765-774. 
Milner, J., Medcalf, E.A., and Cook, A.C. (1991). Tumor suppressor p53: analysis of wild-type and 
mutant p53 complexes. Mol Cell Biol 11, 12-19. 
  121 
Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S.K., Reczek, E.E., De Raedt, T., Guney, I., Strochlic, 
D.E., Macconaill, L.E., Beroukhim, R., et al. (2010). An oncogene-tumor suppressor cascade drives 
metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16, 286-
294. 
Min, W., Lin, Y., Tang, S., Yu, L., Zhang, H., Wan, T., Luhn, T., Fu, H., and Chen, H. (2008). AIP1 
recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced ASK1-JNK activation. Circ Res 
102, 840-848. 
Mocellin, S., Rossi, C.R., Pilati, P., and Nitti, D. (2005). Tumor necrosis factor, cancer and anticancer 
therapy. Cytokine Growth Factor Rev 16, 35-53. 
Moll, U.M., Riou, G., and Levine, A.J. (1992). Two distinct mechanisms alter p53 in breast cancer: 
mutation and nuclear exclusion. Proc Natl Acad Sci U S A 89, 7262-7266. 
Moll, U.M., Wolff, S., Speidel, D., and Deppert, W. (2005). Transcription-independent pro-apoptotic 
functions of p53. Curr Opin Cell Biol 17, 631-636. 
Montesano, R., Soulie, P., Eble, J.A., and Carrozzino, F. (2005). Tumour necrosis factor alpha confers 
an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 118, 3487-3500. 
Moreno, E., Yan, M., and Basler, K. (2002). Evolution of TNF signaling mechanisms: JNK-dependent 
apoptosis triggered by Eiger, the Drosophila homolog of the TNF superfamily. Curr Biol 12, 1263-
1268. 
Morselli, E., Tasdemir, E., Maiuri, M.C., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J.M., Soussi, T., 
and Kroemer, G. (2008). Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 
7, 3056-3061. 
Morton, J.P., Timpson, P., Karim, S.A., Ridgway, R.A., Athineos, D., Doyle, B., Jamieson, N.B., Oien, 
K.A., Lowy, A.M., Brunton, V.G., et al. (2010). Mutant p53 drives metastasis and overcomes growth 
arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107, 246-251. 
Moustakas, A., Pardali, K., Gaal, A., and Heldin, C.H. (2002). Mechanisms of TGF-beta signaling in 
regulation of cell growth and differentiation. Immunol Lett 82, 85-91. 
Mukhopadhyay, T., Roth, J.A., and Maxwell, S.A. (1995). Altered expression of the p50 subunit of the 
NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11, 999-1003. 
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., 
Yuan, W., Wagner, S.N., et al. (2001). Involvement of chemokine receptors in breast cancer 
metastasis. Nature 410, 50-56. 
Muller, P.A., Caswell, P.T., Doyle, B., Iwanicki, M.P., Tan, E.H., Karim, S., Lukashchuk, N., 
Gillespie, D.A., Ludwig, R.L., Gosselin, P., et al. (2009). Mutant p53 drives invasion by promoting 
integrin recycling. Cell 139, 1327-1341. 
Murphy, K.L., Dennis, A.P., and Rosen, J.M. (2000). A gain of function p53 mutant promotes both 
genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J 14, 
2291-2302. 
Nakayama, H., Ikebe, T., Beppu, M., and Shirasuna, K. (2001). High expression levels of nuclear 
factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. 
Cancer 92, 3037-3044. 
Nalefski, E.A., and Falke, J.J. (1996). The C2 domain calcium-binding motif: structural and functional 
diversity. Protein Sci 5, 2375-2390. 
  122 
Nishitoh, H., Saitoh, M., Mochida, Y., Takeda, K., Nakano, H., Rothe, M., Miyazono, K., and Ichijo, 
H. (1998). ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 2, 389-395. 
Novak, U., Cocks, B.G., and Hamilton, J.A. (1991). A labile repressor acts through the NFkB-like 
binding sites of the human urokinase gene. Nucleic Acids Res 19, 3389-3393. 
Offer, H., Wolkowicz, R., Matas, D., Blumenstein, S., Livneh, Z., and Rotter, V. (1999). Direct 
involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Lett 450, 
197-204. 
Oh, J., Sohn, D.H., Ko, M., Chung, H., Jeon, S.H., and Seong, R.H. (2008). BAF60a interacts with p53 
to recruit the SWI/SNF complex. J Biol Chem 283, 11924-11934. 
Olive, K.P., Tuveson, D.A., Ruhe, Z.C., Yin, B., Willis, N.A., Bronson, R.T., Crowley, D., and Jacks, 
T. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-
860. 
Oloumi, A., McPhee, T., and Dedhar, S. (2004). Regulation of E-cadherin expression and beta-
catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta 1691, 1-15. 
Opdenakker, G., and Van Damme, J. (1992). Chemotactic factors, passive invasion and metastasis of 
cancer cells. Immunol Today 13, 463-464. 
Oren, M., and Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect 
Biol 2, a001107. 
Orlowski, R.Z., and Baldwin, A.S., Jr. (2002). NF-kappaB as a therapeutic target in cancer. Trends Mol 
Med 8, 385-389. 
Orosz, P., Echtenacher, B., Falk, W., Ruschoff, J., Weber, D., and Mannel, D.N. (1993). Enhancement 
of experimental metastasis by tumor necrosis factor. J Exp Med 177, 1391-1398. 
Pahl, H.L. (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 
6853-6866. 
Papandreou, C.N., and Logothetis, C.J. (2004). Bortezomib as a potential treatment for prostate cancer. 
Cancer Res 64, 5036-5043. 
Paradiso, A., Tommasi, S., Brandi, M., Marzullo, F., Simone, G., Lorusso, V., Mangia, A., and De 
Lena, M. (1989). Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. 
Comparison with locally advanced disease. Cancer 64, 1922-1927. 
Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Chang, Y., Vogelman, J.H., Orentreich, N., and 
Sibley, R.K. (1991). Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325, 
1127-1131. 
Peller, S., Frenkel, J., Lapidot, T., Kahn, J., Rahimi-Levene, N., Yona, R., Nissim, L., Goldfinger, N., 
Sherman, D.J., and Rotter, V. (2003). The onset of p53-dependent apoptosis plays a role in terminal 
differentiation of human normoblasts. Oncogene 22, 4648-4655. 
Perregaux, D.G., Dean, D., Cronan, M., Connelly, P., and Gabel, C.A. (1995). Inhibition of interleukin-
1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system 
dependence. Mol Pharmacol 48, 433-442. 
Petitjean, A., Achatz, M.I., Borresen-Dale, A.L., Hainaut, P., and Olivier, M. (2007). TP53 mutations 
in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 
2157-2165. 
  123 
Qiu, G.H., Xie, H., Wheelhouse, N., Harrison, D., Chen, G.G., Salto-Tellez, M., Lai, P., Ross, J.A., and 
Hooi, S.C. (2007). Differential expression of hDAB2IPA and hDAB2IPB in normal tissues and 
promoter methylation of hDAB2IPA in hepatocellular carcinoma. J Hepatol 46, 655-663. 
Restle, A., Farber, M., Baumann, C., Bohringer, M., Scheidtmann, K.H., Muller-Tidow, C., and 
Wiesmuller, L. (2008). Dissecting the role of p53 phosphorylation in homologous recombination 
provides new clues for gain-of-function mutants. Nucleic Acids Res 36, 5362-5375. 
Richardson, P., Hideshima, T., and Anderson, K. (2002). Thalidomide: emerging role in cancer 
medicine. Annu Rev Med 53, 629-657. 
Rossi, M., De Laurenzi, V., Munarriz, E., Green, D.R., Liu, Y.C., Vousden, K.H., Cesareni, G., and 
Melino, G. (2005). The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24, 836-848. 
Rubin, G.M., Hong, L., Brokstein, P., Evans-Holm, M., Frise, E., Stapleton, M., and Harvey, D.A. 
(2000). A Drosophila complementary DNA resource. Science 287, 2222-2224. 
Sampath, J., Sun, D., Kidd, V.J., Grenet, J., Gandhi, A., Shapiro, L.H., Wang, Q., Zambetti, G.P., and 
Schuetz, J.D. (2001). Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not 
MRP1. J Biol Chem 276, 39359-39367. 
Sauer, L., Gitenay, D., Vo, C., and Baron, V.T. (2010). Mutant p53 initiates a feedback loop that 
involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene 29, 2628-2637. 
Schmiegel, W., Roeder, C., Schmielau, J., Rodeck, U., and Kalthoff, H. (1993). Tumor necrosis factor 
alpha induces the expression of transforming growth factor alpha and the epidermal growth factor 
receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A 90, 863-867. 
Schneider, G., Henrich, A., Greiner, G., Wolf, V., Lovas, A., Wieczorek, M., Wagner, T., Reichardt, 
S., von Werder, A., Schmid, R.M., et al. (2010). Cross talk between stimulated NF-kappaB and the 
tumor suppressor p53. Oncogene 29, 2795-2806. 
Schuijer, M., and Berns, E.M. (2003). TP53 and ovarian cancer. Hum Mutat 21, 285-291. 
Schwahn, D.J., and Medina, D. (1998). p96, a MAPK-related protein, is consistently downregulated 
during mouse mammary carcinogenesis. Oncogene 17, 1173-1178. 
Scian, M.J., Stagliano, K.E., Anderson, M.A., Hassan, S., Bowman, M., Miles, M.F., Deb, S.P., and 
Deb, S. (2005). Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25, 
10097-10110. 
Senftleben, U., Cao, Y., Xiao, G., Greten, F.R., Krahn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., 
Sun, S.C., et al. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B 
signaling pathway. Science 293, 1495-1499. 
Senoo, M., Pinto, F., Crum, C.P., and McKeon, F. (2007). p63 Is essential for the proliferative potential 
of stem cells in stratified epithelia. Cell 129, 523-536. 
Sepehrnia, B., Paz, I.B., Dasgupta, G., and Momand, J. (1996). Heat shock protein 84 forms a complex 
with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J Biol Chem 
271, 15084-15090. 
Sethi, G., Sung, B., and Aggarwal, B.B. (2008). Nuclear factor-kappaB activation: from bench to 
bedside. Exp Biol Med (Maywood) 233, 21-31. 
Sidhu, R.S., and Bollon, A.P. (1993). Tumor necrosis factor activities and cancer therapy--a 
perspective. Pharmacol Ther 57, 79-128. 
  124 
Siebenlist, U., Franzoso, G., and Brown, K. (1994). Structure, regulation and function of NF-kappa B. 
Annu Rev Cell Biol 10, 405-455. 
Simon, J.A., and Lange, C.A. (2008). Roles of the EZH2 histone methyltransferase in cancer 
epigenetics. Mutat Res 647, 21-29. 
Solit, D.B., and Rosen, N. (2006). Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6, 
1205-1214. 
Solomon, H., Madar, S., and Rotter, V. (2011). Mutant p53 gain of function is interwoven into the 
hallmarks of cancer. J Pathol 225, 475-478. 
Song, H., Hollstein, M., and Xu, Y. (2007). p53 gain-of-function cancer mutants induce genetic 
instability by inactivating ATM. Nat Cell Biol 9, 573-580. 
Song, H., and Xu, Y. (2007). Gain of function of p53 cancer mutants in disrupting critical DNA 
damage response pathways. Cell Cycle 6, 1570-1573. 
Soussi, T., and Beroud, C. (2001). Assessing TP53 status in human tumours to evaluate clinical 
outcome. Nat Rev Cancer 1, 233-240. 
Sovak, M.A., Bellas, R.E., Kim, D.W., Zanieski, G.J., Rogers, A.E., Traish, A.M., and Sonenshein, 
G.E. (1997). Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J 
Clin Invest 100, 2952-2960. 
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Siegfried, Z., Shiff, I., Kogan, 
I., Shay, M., Kalo, E., et al. (2010). Modulation of the vitamin D3 response by cancer-associated 
mutant p53. Cancer Cell 17, 273-285. 
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., and Blandino, G. (2007). Mutant 
p53: an oncogenic transcription factor. Oncogene 26, 2212-2219. 
Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M.G., Monti, O., Baccarini, A., Del Sal, G., Levrero, 
M., Sacchi, A., Oren, M., et al. (2002). Physical interaction with human tumor-derived p53 mutants 
inhibits p63 activities. J Biol Chem 277, 18817-18826. 
Su, X., Paris, M., Gi, Y.J., Tsai, K.Y., Cho, M.S., Lin, Y.L., Biernaskie, J.A., Sinha, S., Prives, C., 
Pevny, L.H., et al. (2009). TAp63 prevents premature aging by promoting adult stem cell maintenance. 
Cell Stem Cell 5, 64-75. 
Suh, J., Payvandi, F., Edelstein, L.C., Amenta, P.S., Zong, W.X., Gelinas, C., and Rabson, A.B. (2002). 
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52, 183-
200. 
Sun-Kong, K. (2008). Molecular and cellular characterization of disable-2-interacting protein and 
investigation of its role in brain development. PhD thesis of University of Tennessee Health Science 
Center. 
Sutcliffe, J.E., and Brehm, A. (2004). Of flies and men; p53, a tumour suppressor. FEBS Lett 567, 86-
91. 
Szlosarek, P.W., and Balkwill, F.R. (2003). Tumour necrosis factor alpha: a potential target for the 
therapy of solid tumours. Lancet Oncol 4, 565-573. 
Takeda, K., Noguchi, T., Naguro, I., and Ichijo, H. (2008). Apoptosis signal-regulating kinase 1 in 
stress and immune response. Annu Rev Pharmacol Toxicol 48, 199-225. 
  125 
Tang, G., Minemoto, Y., Dibling, B., Purcell, N.H., Li, Z., Karin, M., and Lin, A. (2001). Inhibition of 
JNK activation through NF-kappaB target genes. Nature 414, 313-317. 
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in 
development and disease. Cell 139, 871-890. 
Tricot, G. (2000). New insights into role of microenvironment in multiple myeloma. Lancet 355, 248-
250. 
Tsang, D.P., and Cheng, A.S. (2011). Epigenetic regulation of signaling pathways in cancer: role of the 
histone methyltransferase EZH2. J Gastroenterol Hepatol 26, 19-27. 
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., 
Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993). Risk factors for hepatocellular carcinoma among 
patients with chronic liver disease. N Engl J Med 328, 1797-1801. 
Turini, M.E., and DuBois, R.N. (2002). Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53, 35-
57. 
van de Stolpe, A., Caldenhoven, E., Stade, B.G., Koenderman, L., Raaijmakers, J.A., Johnson, J.P., and 
van der Saag, P.T. (1994). 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-
mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional 
analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 269, 6185-6192. 
Van der Auwera, I., Van Laere, S.J., Van den Eynden, G.G., Benoy, I., van Dam, P., Colpaert, C.G., 
Fox, S.B., Turley, H., Harris, A.L., Van Marck, E.A., et al. (2004). Increased angiogenesis and 
lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse 
transcriptase-PCR gene expression quantification. Clin Cancer Res 10, 7965-7971. 
Van Laere, S., Van der Auwera, I., Van den Eynden, G., Van Hummelen, P., van Dam, P., Van Marck, 
E., Vermeulen, P.B., and Dirix, L. (2007). Distinct molecular phenotype of inflammatory breast cancer 
compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression 
analysis. Br J Cancer 97, 1165-1174. 
Van Laere, S.J., Van der Auwera, I., Van den Eynden, G.G., Elst, H.J., Weyler, J., Harris, A.L., van 
Dam, P., Van Marck, E.A., Vermeulen, P.B., and Dirix, L.Y. (2006). Nuclear factor-kappaB signature 
of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse 
transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding. Clin Cancer Res 
12, 3249-3256. 
Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, 
D., Pienta, K.J., Sewalt, R.G., Otte, A.P., et al. (2002). The polycomb group protein EZH2 is involved 
in progression of prostate cancer. Nature 419, 624-629. 
Varfolomeev, E.E., and Ashkenazi, A. (2004). Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 
491-497. 
Varley, J.M. (2003). Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21, 313-320. 
Verhoef, C., de Wilt, J.H., Grunhagen, D.J., van Geel, A.N., ten Hagen, T.L., and Eggermont, A.M. 
(2007). Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. 
Curr Treat Options Oncol 8, 417-427. 
Virchow (1863). Aetiologie der neoplastischen Geschulpte/Pathogenie der neoplastischen 
Geschwulste. Die Krankhaften Geschwülste-Berlin. 
  126 
Vivanco, I., and Sawyers, C.L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human 
cancer. Nat Rev Cancer 2, 489-501. 
von Bergh, A.R., Wijers, P.M., Groot, A.J., van Zelderen-Bhola, S., Falkenburg, J.H., Kluin, P.M., and 
Schuuring, E. (2004). Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 
9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes 
Cancer 39, 324-334. 
Voorzanger, N., Touitou, R., Garcia, E., Delecluse, H.J., Rousset, F., Joab, I., Favrot, M.C., and Blay, 
J.Y. (1996). Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and 
act as cooperative growth factors. Cancer Res 56, 5499-5505. 
Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003). Tumor necrosis factor signaling. Cell Death 
Differ 10, 45-65. 
Wang, C.Y., Cusack, J.C., Jr., Liu, R., and Baldwin, A.S., Jr. (1999a). Control of inducible 
chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-
kappaB. Nat Med 5, 412-417. 
Wang, S.P., Wang, W.L., Chang, Y.L., Wu, C.T., Chao, Y.C., Kao, S.H., Yuan, A., Lin, C.W., Yang, 
S.C., Chan, W.K., et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated 
degradation of Slug. Nat Cell Biol 11, 694-704. 
Wang, W., Abbruzzese, J.L., Evans, D.B., and Chiao, P.J. (1999b). Overexpression of urokinase-type 
plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. 
Oncogene 18, 4554-4563. 
Wang, X., and Lin, Y. (2008). Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin 
29, 1275-1288. 
Wang, Z., Tseng, C.P., Pong, R.C., Chen, H., McConnell, J.D., Navone, N., and Hsieh, J.T. (2002). 
The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a 
novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 
277, 12622-12631. 
Weidner, N., Semple, J.P., Welch, W.R., and Folkman, J. (1991). Tumor angiogenesis and metastasis--
correlation in invasive breast carcinoma. N Engl J Med 324, 1-8. 
Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., Kalis, M., 
Levrero, M., Strano, S., Gorgoulis, V.G., et al. (2007a). Mutant p53 enhances nuclear factor kappaB 
activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67, 2396-2401. 
Weisz, L., Oren, M., and Rotter, V. (2007b). Transcription regulation by mutant p53. Oncogene 26, 
2202-2211. 
Wertz, I.E., O'Rourke, K.M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., 
Baker, R., Boone, D.L., et al. (2004). De-ubiquitination and ubiquitin ligase domains of A20 
downregulate NF-kappaB signalling. Nature 430, 694-699. 
Whitmarsh, A.J., and Davis, R.J. (1996). Transcription factor AP-1 regulation by mitogen-activated 
protein kinase signal transduction pathways. J Mol Med (Berl) 74, 589-607. 
Wink, D.A., Ridnour, L.A., Hussain, S.P., and Harris, C.C. (2008). The reemergence of nitric oxide 
and cancer. Nitric Oxide 19, 65-67. 
  127 
Wong, R.P., Tsang, W.P., Chau, P.Y., Co, N.N., Tsang, T.Y., and Kwok, T.T. (2007). p53-R273H 
gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol 
Cancer Ther 6, 1054-1061. 
Wu, S., Boyer, C.M., Whitaker, R.S., Berchuck, A., Wiener, J.R., Weinberg, J.B., and Bast, R.C., Jr. 
(1993). Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: 
monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 
53, 1939-1944. 
Wu, Y., Deng, J., Rychahou, P.G., Qiu, S., Evers, B.M., and Zhou, B.P. (2009). Stabilization of snail 
by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15, 416-
428. 
Wu, Y., and Zhou, B.P. (2010). TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and 
invasion. Br J Cancer 102, 639-644. 
Xie, D., Gore, C., Liu, J., Pong, R.C., Mason, R., Hao, G., Long, M., Kabbani, W., Yu, L., Zhang, H., 
et al. (2010). Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer 
metastasis. Proc Natl Acad Sci U S A 107, 2485-2490. 
Xie, D., Gore, C., Zhou, J., Pong, R.C., Zhang, H., Yu, L., Vessella, R.L., Min, W., and Hsieh, J.T. 
(2009). DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc 
Natl Acad Sci U S A 106, 19878-19883. 
Xu, X.X., Yi, T., Tang, B., and Lambeth, J.D. (1998). Disabled-2 (Dab2) is an SH3 domain-binding 
partner of Grb2. Oncogene 16, 1561-1569. 
Yang, A., Kaghad, M., Caput, D., and McKeon, F. (2002). On the shoulders of giants: p63, p73 and the 
rise of p53. Trends Genet 18, 90-95. 
Yang, A., and McKeon, F. (2000). P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell 
Biol 1, 199-207. 
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R.T., Tabin, C., Sharpe, A., 
Caput, D., Crum, C., et al. (1999). p63 is essential for regenerative proliferation in limb, craniofacial 
and epithelial development. Nature 398, 714-718. 
Yang, L., Li, Y., Ling, X., Liu, L., Liu, B., Xu, K., Bin, X., Ji, W., and Lu, J. (2011). A common 
genetic variant (97906C>A) of DAB2IP/AIP1 is associated with an increased risk and early onset of 
lung cancer in Chinese males. PLoS One 6, e26944. 
Yano, M., Toyooka, S., Tsukuda, K., Dote, H., Ouchida, M., Hanabata, T., Aoe, M., Date, H., Gazdar, 
A.F., and Shimizu, N. (2005). Aberrant promoter methylation of human DAB2 interactive protein 
(hDAB2IP) gene in lung cancers. Int J Cancer 113, 59-66. 
Yook, J.I., Li, X.Y., Ota, I., Fearon, E.R., and Weiss, S.J. (2005). Wnt-dependent regulation of the E-
cadherin repressor snail. J Biol Chem 280, 11740-11748. 
Yoshida, H. (2007). ER stress and diseases. FEBS J 274, 630-658. 
Zacchi, P., Gostissa, M., Uchida, T., Salvagno, C., Avolio, F., Volinia, S., Ronai, Z., Blandino, G., 
Schneider, C., and Del Sal, G. (2002). The prolyl isomerase Pin1 reveals a mechanism to control p53 
functions after genotoxic insults. Nature 419, 853-857. 
Zarubin, T., and Han, J. (2005). Activation and signaling of the p38 MAP kinase pathway. Cell Res 15, 
11-18. 
  128 
Zhang, H., He, Y., Dai, S., Xu, Z., Luo, Y., Wan, T., Luo, D., Jones, D., Tang, S., Chen, H., et al. 
(2008). AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and inflammatory 
angiogenesis in mice. J Clin Invest 118, 3904-3916. 
Zhang, H., Lin, Y., Li, J., Pober, J.S., and Min, W. (2007). RIP1-mediated AIP1 phosphorylation at a 
14-3-3-binding site is critical for tumor necrosis factor-induced ASK1-JNK/p38 activation. J Biol 
Chem 282, 14788-14796. 
Zhang, H., Zhang, R., Luo, Y., D'Alessio, A., Pober, J.S., and Min, W. (2004). AIP1/DAB2IP, a novel 
member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem 279, 
44955-44965. 
Zhang, R., He, X., Liu, W., Lu, M., Hsieh, J.T., and Min, W. (2003). AIP1 mediates TNF-alpha-
induced ASK1 activation by facilitating dissociation of ASK1 from its inhibitor 14-3-3. J Clin Invest 
111, 1933-1943. 
Zhang, X., Li, N., Li, X., Zhao, W., Qiao, Y., Liang, L., and Ding, Y. (2011). Low expression of 
DAB2IP contributes to malignant development and poor prognosis in hepatocellular carcinoma. J 
Gastroenterol Hepatol. 
Zhou, J., and Hsieh, J.T. (2001). The inhibitory role of DOC-2/DAB2 in growth factor receptor-
mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to 
Grb2. J Biol Chem 276, 27793-27798. 
 
 
